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Chapter 1 
INTRODUCTION 
Prostate cancer in man has long been considered an inevitable malignant disease of old 
age. Dramatic initial response to endocrine treatment has moreover retarded the 
development of other treatment modalities for a long time. The lack of reliable animal 
models, Ίη vitro' models, and models for xenografting has also contributed to the lack 
of knowledge about the complex prostatic carcinoma. 
Overall life expectancy is, however, increasing in the Western world. The life 
expectancy for males in the Netherlands is currently 76 years (CBS 1975). As a 
consequence, more men will live long enough to 'develop' a prostate tumor or otherwise 
live long enough with this tumor to die of it (Whitmore 1984). Thirty per cent of all 
men over 50 may have histologic prostatic carcinoma, and this figure increases to 50% 
after the age of 70 (Franks 1973). Prostate cancer is now the third leading tumor in 
Germany (Faul 1982) and in the Netherlands (Silverberg 1980). 
Prostate cancer is the second most common tumor in the U.S.A. in males over 75 years 
of age (Hutchison 1981). 
Prostate cancer is usually considered a slow progressive disease, initially responding to 
hormonal therapy. A cure with this standard therapy is essentially non existent, as being 
originally proposed as a palliative one (Huggins and Hodges 1941). 
An inevitable relapse due to hormone-insensitive cell overgrowth will occur sooner or 
later (Sandberg 1981, deKernion and Lindner 1984). 
It was the VACURG study (Byar 1973) that made us think about the rationale of 
endocrine therapy in most cases of prostatic cancer. Survival did not really seem to be 
dependent on this hormonal treatment. 
Furthermore, a 'new look' at prostate cancer was provided when both more reliable 
animal models (Dunning 1963, Noble 1977, Pollard 1973) and Ίη vitro' models 
(Kaighn 1980) were developed in the early seventies. Non-hormonal drugs were more 
and more tested in randomized trials after 1973 (Javadpour 1982, Gibbons 1981, 
deKernion and Lindner 1984). 
Cells unresponsive to hormonal treatment as well as metastasizing cells are responsible 
for the death of a cancer patient. Therefore, a study of these responsible cells is of 
utmost importance. Wc have to identify those patients who have tumors with real 
malignant potential (Byar and Corle 1981). 
From a series of clinical staging studies we know that approximately 10-15% of the 
initially diagnosed prostatic tumors are poorly or fully undifferentiated tumors (Dhom 
and Hohbach 1982, Heany et al. 1977, Murphy et al. 1982) while 40% are moderately 
diffentiated (Heany et al. 1977). Furthermore, 40 to 45% of the patients are in stage С 
or D (Murphy et al. 1982, Whitmore 1973), which account for higher-grade metastases 
in lymph nodes and bones in a high percentage of cases. Survival in this group of patients 
is relatively poor, i.e. a ten-year survival of approximately 25% (Heany et al. 1977, 
Murphy et al.l982). 
Higher stage, larger size, and poor histologic differentiation are associated with a 
significantly higher probability of pelvic lymph node and bone metastases. Growth rate 
is also generally related to the grade of the lesions (Whitmore 1973). 
Even in silent tumors 25%-35% lymph node metastases are found (McLaughlin et 
al. 1976, Donohue et al. 1981). In undifferentiated tumors 70% lymph node metastases 
are observed. 
The various treatments available for prostatic cancer, including hormones, surgery, 
radiotherapy, and non-hormonal treatment in various combinations, reflect the dilemma 
of the managing urologists. 
Malignant potential of a tumor on the one hand and response to specific therapy on the 
other hand depend on tumor biology (Whitmore 1984). In spite of criticism on animal 
models in prostate cancer (Handelsman 1977), we agree with the statement of 
Sandberg (1981) that the development of an ideal system takes time and, therefore, we 
have to avail ourselves of the most reliable models presently available. 
It was the objective of this thesis to develop a model system in which both standard and 
new therapeutics could be tested in hormone-unresponsive prostate cancer and to study 
biology with standard and new techniques. 
Solid tumors are the end-result of progressive selection of genetically unstable cells, 
providing cell clones that could be different in diverse hosts (Nowell 1976). If this 
hypothesis holds, a specific therapy has to be found for a specific tumor. 
Hybrids provide an efficient number of animals to transplant tumors, all with the same 
features. The Dunning system comprises a tumor model with different types of prostate 
tumors as described in chapter 2. Hormone-dependent sensitive tumor (R3327H), 
hormone-independent sensitive tumor (R3327G), hormone independent-insensitive 
tumor (R3327AT) all represent the different tumor types in humans. We chose for 
our studies a recently developed prostatic anaplastic tumor in the rat, the MATLyLu. 
This tumor had additional metastatic potential, an inevitable event in humans with 
prostate cancer. 
The following concepts were studied: 
1. Morphology of the anaplastic tumor, heterogeneity (LM, EM, FCM and cell 
sorting), new techniques to characterize an anaplastic tumor (immunohistochemical), 
karyotypic changes, metastatic patterns. 
2. Development of a test system Ίη v/vo' for standard and new cytotoxic agents. 
Additional investigations into residual growth of the treated tumor in the bilayer soft 
agar culture. 
3. Evaluation of a two-parameter study of cultured cells in soft agar by way of the 
automated colony counter (OMNICON). 
4. Comparing cell biology Ίη vivo' and Ίη vitro1 (LM,EM,FCM, karyotyping). 
We hope that new characterizing techniques and techniques for therapeutic evaluation 
will ultimately be appropriate for clinical purposes. We too are aware that even more 
questions on prostatic cancer will arise than when we started. But it is better to go ahead 
with questions than to sit down and treat even elderly patients with a reasonable life 
expectancy and prostatic tumors with irrational therapy. 
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Chapter 2 
M O D E L S Y S T E M S IN P R O S T A T E C A N C E R 
2.1. Introduction 
Man is the only species in which adenocarcinoma of the prostate has been demonstrated 
to occur spontaneously and with significant frequency. However, obtaining basic 
information on many aspects of prostate cancer in man is difficult. 
Ethical reasons, time-consuming and expensive clinical trials restrict the use of all 
available drugs that can play a role in controlling prostate cancer. Animal models can 
be an aid in selecting one or more drugs from among many for clinical trials (Sandberg 
and Gaunt 1976). 
Tumor biologic research in humans is also hampered, mostly through practical causes. 
Despite limitations in extrapolating results from experimental animals (Handelsman 
1977) to the human situation, animal models have been very useful. 
Most of our basic knowledge of tumor biochemistry, physiology, endocrinology and cell 
biology has resulted from animal models (Coffey and Isaacs 1980, Isaacs and Coffey 
1983). The clinical knowledge of relapsing prostatic tumor after hormonal treatment 
or castration was 'visualized' in the Dunning R3327 model system (Coffey and Isaacs 
1980). In fact, a well differentiated prostatic tumor initially has two clones of cells, a 
hormone-sensitive and a hormone-insensitive population of cells. Hormonal treatment 
elicits an initial response of the hormone-sensitive cells, but the outgrowth of insensitive 
cells leads to advancing prostate cancer with fatal outcome for the patient. 
Prostate cancer is characterized by considerable variability in histologic appearance, 
biochemical indices, metastatic spread, sensitivity to hormones and rate of growth. 
More than one tumor model system has to be developed to investigate all of these 
different aspects of prostatic tumors. 
Subject to variabilities, there are groups of tumors with approximately the same 
features of growth rate, hormone sensitivity and metastatic potential. Proper matching 
of appropiate types of tumors in different species may lead to the development of useful 
concepts in prostate cancer (Coffey and Isaacs 1980). 
This involves comprehensive characterization of each animal model appropriate for a 
certain group of human tumors, or for certain aspects of prostatic tumors in man. 
Ideal properties for an animal model are described by Isaacs and Coffey (1983). 
1. Spontaneous tumors development in aged animals. 
Except in dogs and older rats (Leav and Ling 1968, Dunning 1963, Pollard 1973, 
Shain et al. 1975 ), spontaneous development of prostatic tumors in animals is rare. 
This is probably due partly to a lower life expectancy of animals in captivity and 
partly to laboratory animals being sacrificed before tumors can develop. 
2. Proved tumor origin from prostatic tissue. 
Besides anatomic differences between the species especially in transplanted and 
anaplastic tumors, the origin has to be proven with advanced biochemical and 
immunohistochemical methods. Details of the comparative anatomy of the prostate 
are found in a study by Price (1963). 
The five embryologie lobes of the prostate in man form a more or less organic entity 
in later life. The posterior 'dorsal' lobe of man is homologous with the dorsal lobe of 
the rat and mouse and possibly with the dorsal lobe of the dog prostate. 
The middle 'lobe' of the human prostate is homologous with the cranial lobe of the 
monkey and the coagulating glands of rats and mice. 
The lateral lobes in man, the caudal lobe of the monkey and the lateral lobes of the 
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rat and the mouse appear to be homologous. The ventral prostatic lobe of man does 
not seem to be homologous with the ventral lobes of the rat and the mouse (Price 
1963). 
3. Biochemical profiles similar to prostate tissue. 
The prostatic origin of transplanted or cultured tumors requires further proof of 
biochemical and immunohistochemical investigations. 
-Alkaline phosphatase and prostatic acid phosphatase. Patterns of acid phosphatase 
elevation in serum and in prostatic tissue are very variable in the different animal 
models. 
This is partly due to the low relative acid phosphatase acitivity in rodents as 
compared to that in man (man 1,200, rat 1.0, mouse 0.20). 
-Small molecules. High ratio of dihydrotestosterone/testosterone, patterns of steroid 
conjugate, zinc, cadmium, spermine and spermidine citric acid. 
-Receptors for estrogen, androgens in cytoplasm and nucleus, dihydrotestosterone 
(DHT), estradiol-17ß, nuclear uptake of DHT. 
-Tissue-specific and secretory proteins, tissue Polyacrylamide gel electrophoresis. 
In strongly dedifferentiated tumors (e.g. Pollard tumors and anaplastic Dunning 
sublines: R3327AT, MATLyLu and MATLu), it is often very difficult to establish 
the prostatic origin of the tumor. 
We shall describe a histochemical method for confirming the epithelial nature 
(adenocarcinoma) of the tumor (chapter 3). The search for specific monoclonals 
against prostatic tumor cells (cell surface and nuclear targets) is a relatively new but 
fast developing technique to identify tumors (Moon et al. 1983). 
4. Growth pattern and cell kinetics. 
Most human tumors are initially slow-growing tumors. A small fraction of cells 
divides. That makes them probably relatively insensitive to cytotoxic agents against 
fast-growing cells. 
Also, cytogenetic research is often hampered by a relatively low mitotic index. The 
only relatively slow-growing rat tumor is the Dunning R3327H, having a doubling 
time of 20 days (versus man approximately one month)(Isaacs et al. 1978). 
5. Hormonal responsiveness. 
6. Metastatic pattern. 
Essential basic knowledge about metastases in oncology is poor. 
Prostatic cancer is a potentially metastatic tumor spreading via the lymph nodes and 
hematogenously to the bones. In man pulmonary metastases in prostatic cancer occur 
in relatively low incidence. Only in spontaneous tumors in dogs (Leav and Ling 1968) 
and in carcinogenically induced tumors in rats (Dunning et al. 1946) have metastases 
been found in the bones. Moreover, metastases are mostly found in the lymph nodes 
and the lungs. Whether this is a consequence of subcutaneous implantation, of 
inadequate search in the bones for a difference in hemodynamics, or of a difference 
in the tumor itself has not been adequately investigated. 
7. Tumor model stability 
It is essential that a full characterization of every tumor be done Ίη vivo' or '/и vitro' 
both initially and thereafter according to a defined time table. Growth rate, hormone 
sensitivity and biochemical markers, light and electron microscopy and frequent 
karyotyping have to be done. Biologic drift in a tumor model system, especially in 
fast growing tumors, is not a rare occurrence. In transplanted tumors one always has 
to transplant the least fast growing tumor of a subline. Sudden growth rate 
alterations in a series should be noted. A new subline may arise. 
It is very easy to store a tissue sample or a sample of cell suspension of the subline at 
different periods for the sake of comparison. 
Loss of a subline may thus be avoided. In our laboratory the MATLyLu tumor was 
stored in liquid nitrogen for 18 months. 
Thawed tumors grow after inoculation in rats. Even cell suspensions could be made 
to grow in soft agar and monolayer. 
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2.1.1. Model systems in prostate cancer 
In accounting for the choice of a model system for our research purposes, we shall first 
give an overview of the spontaneously occurring tumors, the spontaneously 
transplantable tumors, the inducible tumors (chemically, hormonally) and the 
xenografts. Further more a short review of 'm vitro' systems dealing with prostatic tumor 
cells will be given. 
2.2. Spontaneous adenocarcinomas of the prostate in animals 
2.2.1 Non-human primates 
The only neoplasm ever found in non-human primates is an adenocarcinoma in an old 
rhesus monkey (Macaca mulatta) (Engle and Stout 1940). In the posterior third of the 
prostate gland, a small tumor was observed to grow above and lateral to the prostatic 
urethra with a small satellite tumor. This rather infrequent finding is possibly based on 
the lower life expectancy of non-human primates in laboratories and zoos, and does 
not estimate to the true incidence of prostate cancer in these animals (Engle and Stout 
1940). 
2.2.2. Dogs 
As in humans, adenocarcinomas of the prostate in dogs are age-related (Leav and Ling 
1968). In an 11-year period they found 20 cases of prostatic cancer in a group of 761 
dogs (clinical and autopsy material). 
Seven of the 20 dogs (35%) had bony metastases. 
2.2.3. Mastomys natalensis (female rattus) 
Snell and Stewart (1965) described an adenocarcinoma of the prostate gland in one 
mastomys. In a group of 55 untreated virgin females, four others developed proliferative 
hyperplasia. The female rodent prostate is homologous with the ventral prostate in the 
male rat and perhaps with the female human Skene's glands that serve to lubricate the 
distal urethra (Holland 1970). This author describes the response of the female 
prostate to androgens. Marked increase in prostate size and hyperplasia were seen. 
Increasing age leads to histologic changes of intraacinar adenocarcinoma. Those 
animals had tumors in many other organs. Due to development of many other animal 
models of prostate cancer, that model has lost it significance. 
2.2.4. Hamster (Syrian golden hamster) 
Fortner et al.(1963) described the first transplantable spontaneous prostatic carcinoma 
in animals. In two out of 94 untreated hamsters aged 9.5-35 months a prostate 
carcinoma was found. One of the two tumors was mentioned. The tumor was large and 
occupied the area of the prostate gland. No description of the lobe of origin could be 
given. The tumor was hormone-insensitive, growing equally well in male and in female 
animals. The tumor must have a fast doubling time as ulceration of the tumor was 
obvious on day 7, and death of the host occurred about two weeks after transplantation. 
The Fortner tumor was also mentioned by Webber et al.(1968). 
The tumor was described by these authors as highly anaplastic. Karyotypically, the 
tumor consisted of a heterogenous cell population. Selection pressure was suggested in 
the treatment of this kind of tumor with cytotoxic agents or hormones. Outgrowth of a 
resistant cell type occurred. The conclusion of the author that the Fortner tumor was 
not suitable for studying human prostatic carcinoma therefore does not agree with 
current knowledge that selection pressure probably takes place in treated human 
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prostatic cancers tending towards complete therapeutic resistance. 
Unfortunately this tumor was lost. 
2.2.5. Rats 
It is generally agreed that prostate cancer does not develop spontaneously in rodents in 
sufficient numbers to establish a model. 
An extensive study on the occurrence of tumors in wild rats of the species Mus 
norvegius was done at the beginning of this century (McCoy 1909). 
In 100,000 rats, 103 tumors were found in the subcutaneous tissue, the liver and the 
kidneys, but no prostatic tumor was found. Nothing was mentioned about the age of 
the rats. Probably the group investigated rats related to a rather young population. 
Until the early sixties, only one incidental case of prostatic tumor in rats had been 
reported (Guérin 1954). 
In 1961 Dunning observed a spontaneous adenocarcinoma of the prostate in a 
22-month-old Copenhagen breeder rat. The tumor was well differentiated, 
slow-growing and successfully maintained by serial transplantation. Initially, the lobe 
of origin could not be well identified because of extensive tumor growth. However, the 
tumor turned out to be of dorsal lobe origin, as confirmed by biochemical investigations 
(Smolevetal.l977a). 
Keeping rats in germ-free conditions for extended periods of time makes it possible to 
extend their lifespan. 
Pollard (1973) observed pelvic tumors in three out of 31 male GF (germ- free) Lobund 
Wistar rats at 32-40 months of age, and in one rat of 22 months. 
A population of retired breeders was concerned. They had been kept under germ-free 
conditions lifelong. Histologically, the developed tumors appeared to be extensively 
growing, rather anaplastic with metastatic lesions in lungs, spleen, liver, pancreas and 
intestines. 
Serum acid phosphatase in these animals was slightly higher than in the controls. In 
later years these tumors were successfully transplanted. 
The initial lobe of origin again was not identified. Three tumor sublines were developed 
(PA I - III) through passage in Lobund Wistar rats (Pollard and Luckert 1975) and 'in 
vitro1 propagation of cell monolayers (Chang and Pollard 1977). 
After inoculation of tumor cells, a tumor was palpable after approximately ten days. 
At 20 days the tumor ulcerated through the skin. 
In early stages, tumor growth and metastases can be prevented by cyclophosphamide 
(Pollard and Luckert 1976, Pollard 1980). 
The three different types of tumors are basically hormone-independent and grow 
rapidly with a doubling time of 18-20 hours 'ш vitro1. The PA I - PA III tumors do not 
differ in histology, growth rate or potential to metastasize to lymphatic system and 
lungs. The PA II is an undifferentiated tumor also with hematogenous metastases to 
visceral organs. The PA II and PA III contain distinct binding sites for androgens. The 
PA II cells have additional estrogen receptors (Pollard 1980). 
Prejcan et al.(1973) found a rather high spontaneous tumor incidence of 45% in 360 
Sprague-Dawley rats and 26% in Swiss SPF (specific pathogen free) mice. Most tumors 
in the former group were found in the endocrine system (pituitary, adrenal) while only 
one adenocarcinoma of the prostate was found. This tumor was not described in more 
detail. In the Swiss mice, no prostatic tumors were found. The age of most animals was 
18 months. 
Noble (1977a) examined 1,185 male control Nb rats in a period of five years and found 
two prostatic carcinomas. The two tumors occurred in a 13- and a 14-month-old rat 
respectively out of a group of 409 rats over 13 months of age. All rats were over nine 
months of age. Tumor incidence was 0.48%. These tumors were successfully 
transplanted and showed metastases. 
Shain et al.(1975) reported an incidence of microscopically detected prostate carcinoma 
up to 70% (20/23) in ACI rats 30-46 months of age. 
Ward et al.(1980) examined 201 male ACI rats in which early lesions (24 months) 
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progressed to invasive carcinomas (33 months). No rats died of carcinoma. This tumor 
was transplanted in syngeneic hosts and is appropriate for studying the dormant form 
of prostatic cancer. 
2.3. Experimentally induced primary prostate carcinomas 
2.3.1. Chemical carcinogens 
As a rule benzpyrene or methylcholanthrene have been used to induce prostate cancers 
in rodents. Unfortunately, in most cases a squamous cell carcinoma developed, a tumor 
not frequently seen in man. 
Moore and Melchionna (1937) were the first who produced a prostate carcinoma of 
the anterior lobe in the rat by introducing 1,2- benzpyrene in lard. 
They did not report metastases. 
Dunning et al. (1946) implanted compressed methylcholanthrene crystals in the 
prostate of A χ С male rats and Fischer male rats. 
In 59% and 17% respectively, squamous cell carcinoma of the prostate developed after 
an average duration of 329 days. The finding of a high percentage of skeletal metastases 
was remarkable. Tumors were successfully transplanted and they grew equally well in 
males and females. 
It is interesting to note that as far back as 1946, Dunning, in discussing metastasizing, 
suggested 'that something inherent in the cells of the primary tumor rather than its 
location or morphology determined the propensity of neoplasms for skeletal metastases'. 
This agreed with the observations made by Fidler (1978) and others that coded 
information due to genetically determined carcinogenic mutations directs a cell to home 
for a specific site of metastasis. In this connection, the difference in incidence of 
metastases to the bone between human and rodents is noteworthy. Franks (1953) 
suggested that the venous vertebral plexus plays an important role in carrying 
metastases from the blood to the bones. 
Other investigators believed in a route via the vena cava and subsequently to the 
systemic circulation and to the bone. After ligation of the inferior vena cava, the 
intraabdominal anastomoses were visualized, revealing both the vertebral plexus and 
the anastomoses via the vena cava. Both are possible routes for tumor emboli from the 
local tumor. 
Increasing intraabdominal pressure can stimulate the spread of metastases via the 
vertebral plexus to the bones. 
Horning (1946) induced squamous cell carcinomas or sarcomas following inoculation 
of methylcholanthrene in the prostate of rats or mice. This investigator developed a 
method of wrapping small strips of prostatic epithelium (rather young epithelium of 
the anterior, ventral or dorsal prostate lobes) for subcutaneous implantation in 
syngeneic Strong A/J mice. After 10 to 11 months approximately 80% of these mice 
developed carcinomas, usually adenocarcinomas. A remarkable finding was that cells 
with minimal or no functional capacity were most susceptible to carcinogens. 
The evoked tumors of the glandular type were hormone-sensitive and were readily 
transplanted (Horning 1949). 
Mirand and Staubitz (1956) induced three types of prostatic tumor by implanting 
20-methylcholanthrene in the ventral prostate of inbred Wistar rats. In 2% an 
adenocarcinoma developed after 180 days, in 30% a squamous cell carcinoma developed 
after 118 days, and in 3% a leiomyosarcoma developed after 301 days. The squamous 
cell carcinomas and the adenocarcinomas metastasized to the lungs, the lymph nodes 
and the ribs. 
The prostate carcinoma designated 11095-A was first observed by Segaloff (1963). He 
implanted 3-methylcholanthrene crystals in the ventral prostate of Fischer (F344) rats. 
The evoked tumors were squamous cell carcinomas. 
In later years this tumor model was used in an effort to demonstrate tumor-specific 
antigens (Lande et al. 1978). 
The study by Fingerhut and Veenema (1977) is an interesting one. Male Fischer/Fürth 
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rats, male Strong A/J mice and a group of golden hamsters were first conditioned by 
castration causing an atrophic prostate, subsequently 
9,10-dimethyl-l,2-benzanthracene (DMBA) was administered intravenously three 
times over three months. After three to four months all surviving animals developed 
prostate cancer, some having metastases in the lung. 
Histologically, the tumors appeared to be adenocarcinomas. 
2.3.2. Hormone-induced prostate tumors in animals 
As described under the heading spontaneously developing tumors, Noble (1977a,b) 
observed approximately 0.5% prostatic tumors in the Nb rats. However, with 
subcutaneous implantation of pellets containing 90% estrone and 10% cholesterol or 
90% testosterone propionate and 10% cholesterol (10 mg of steroid) carcinomas could 
also be evoked. 
Following insertion of three pellets containing testosterone propionate carcinoma of the 
prostate developed in 20% (11 /55) of Nb rats after an average of 64 weeks. The 
carcinomas were located in the base of the dorsal lobe or the coagulating glands. Four 
of these animals developed metastases in the lungs. Transplantable established sublines 
were observed in eight cases. 
The combination of one estrone and three testosterone pellets reduced the mean 
duration of tumor development to 46 weeks. The incidence of prostate carcinoma was 
17.7%. Rats were treated for at least six months and the testosterone pellets were 
replaced at least four times. 
Testosterone seems to dissolve more rapidly than estrone. All transplanted tumors were 
autonomous except for one adenocarcinoma. This tumor was observed at autopsy at 13 
months in a rat treated for six months with estrone alone. The transplantable lines were 
estrone- dependent. 
Noble also found brown pigmentations in the ventral lobe of treated animals, suggesting 
Ίη situ' changes of prostatic cancer. However, no outgrowth in the ventral lobe was 
observed. The same histologic appearance was found by Shain et al (1975,1977) in A 
χ С rats at an older age. 
In later years several transplantable sublines were established in Nb rats. Manipulation 
with the estrogen/testosterone balance produced autonomous, estrogen-dependent and 
androgen-dependent tumors. The available tumor lines are: androgen-dependent lines: 
2Pr-128, 2Pr-125 and 2Pr-129: estrogen-dependent lines: 52Pr-16, 52Prl-B, 114Pr-l, 
and several autonomous tumors; 13Pr-12,102Pr-22, 18Pr and Pr 90 (Drago et 
al.l979a'b'c,1980a'b'c. Noble and Hoover 1975). Androgen-insensitive tumors were noted 
by Drago and Worgul (1981). The nomenclature Nb Pr A.I.-II and Pr A.I.-III is 
confusing. 
Note that Drago et al.( 1980a) did not use pellets for release of steroids in the Nb rats 
but subcutaneous silastic implants, probably providing a more regular release of the 
steroids. Tumors were induced in 18-36 weeks. This is considerably shorter than Noble 
and Hoover reported earlier (1975). 
The doubling time of the three tumor types does not vary much, e.g. 
androgen-dependent tumor 2Pr - 129 : 7.5 days, autonomous tumor 102 Pr : 6.0 days, 
estrogen-dependent tumor 114 Pr : 7.3 days (Drago et al. 1980а'Ь). 
The androgen-dependent tumors contain more nuclear and cytoplasmic androgen 
receptors than the autonomous tumors (Rennie et al. 1977). The same statement holds 
good for the acid phosphatase tissue concentration (Drago 1980a'b). 
In this tumor model system a wide variation in tumors can be produced by changing 
the duration of hormonal treatment, the steroids used, or the dose of the steroid. 
However, it remains a not really 'spontaneous' tumor. All tumors have a similar growth 
rate despite the striking dependency on hormones (doubling time 4.3-8.5 days). This 
tumor system is valuable in studying hormone imbalance as a possible factor in the 
initial originating prostate tumor. 
It is worthwhile to use other parameters in the evaluation of this induced tumor in its 
early state (e.g cytogenetics, flowcytometry and electron microscopy). Investigations 
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of for instance changes in diploid-aneuploid patterns in progressive hormone-insensitive 
prostate tumors can be related to the presence of various subpopulations of cells as 
indicated by cell sorting procedures. With electronmicroscopy these cells can be 
characterized on a subcellular basis. Cytogenetic changes,such as translocations and 
specific marker chromosomes, can be studied in the same phases of tumor growth. 
2.4. DUNNING TUMORS 
2.4.1. Description of the various sublines 
During her studies on the carcinogen-induced prostate tumors in rats, Dunning observed 
a spontaneous tumor of the prostate at autopsy of a 22-month-old Copenhagen male 
rat from the 54th brother χ sister generation of line 2331. 
The lobe of origin could not be detected because of an extensively growing tumor in the 
lower abdominal cavity. The tumor was classified as a papillary adenocarcinoma and 
no metastases were found. Tumor grafts were implanted in four Copenhagen rats of 
the same inbred line as the host of the primary tumor, as well as in six Fl hybrids from 
a male Copenhagen χ Fischer cross. The tumors were slow-growing and became 
palpable after two months. 
Histologically, a tumor of the 245th day showed glandular formation with cellular 
material, suggesting the dorsal lobe as origin. Evidence for this dorsal lobe origin was 
provided by the electrophoretic patterns, the positive periodic acid Schiff stain and the 
dithizone stain (Dunning 1963). No acid phosphatase was discovered in serum. 
Over the years, several sublines have been derived from the parent tumor to study the 
response to estrogen therapy, the androgen dependence, the response to chemotherapy, 
and the biochemical profiles to identify immunologic characteristics. 
In recent years, the heterogeneity of the different sublines has been studied by means 
of fluorocytometric analysis and 'in vitro" culturing (Pollack et al. 1981, Claflin et 
al. 1982, Benson et al. 1984). 
After 11 years, Voigt and Dunning (1974) reported on the hormone sensitivity of the 
R3327 tumor. The tumor grew well in intact male animals, moderately well in females 
but did not grow in castrates. The tumor is androgen-sensitive via the 5a-reductase 
pathway. At that time the R3327 tumor was in the fourteenth passage (Voigt and 
Dunning 1974). 
After the fifth transfer generation of the R3327 tumor, a spontaneously fast-growing 
tumor was selected.The new subline was designated R3327-A. The tumor grew equally 
well in males, females and castrates. The tumor was histologically characterized as a 
squamous cell carcinoma. After ten days a subcutaneous tumor of approximately 1 cm3 
had developed. The tumor showed no DHT receptors and was confirmed to be 
androgen-insensitive (Voigt and Dunning 1974). These authors were the first to discuss 
the observed progression to the squamous cell tumor. This is also the first report on the 
absence or presence of androgen receptors and the subsequent response to androgens 
(Voigt et al. 1975). 
In 1977 Claflin et al. reported on the isolation of eight distinct sublines (A through H) 
by Dunning. 
All tumors differed in morphology, growth rate, and androgen sensitivity. The tumor 
sublines B-D have never been described in the literature. 
The Η tumor was very similar to the parent R3327 tumor (Smolev ct al. 1977a). 
The G tumor also mentioned in various reports is a rapidly growing undifferentiated 
tumor composed of densely packed primitive cells (Claflin et al. 1977). The tumor 
produces acid phosphatase. 
However, the H tumor is the most elaborately characterized and probably also the 
most widely used tumor of the Dunning model system. 
In terms of light-microscopic morphology it is a moderately to well differentiated tumor, 
an adenocarcinoma with distinct and prominent acinar formation, cellular and nuclear 
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pleomorphism, and little interacinar stroma. It resembles the well differentiated 
adenocarcinoma of the prostate in man. 
The glandular acini are filled with PAS-positive secretions. Ultra-structurally the cells 
have epithelial characteristics. These acinar cells possess both microvilli and 
desmosomes. Biochemical and enzymatic profiles indicate the origin from the rat dorsal 
prostate. 
The heterogeneity of the R3327-H tumor was shown by comparing cell kinetic and 
growth determinations under different conditions. Androgen deprivation ( castration, 
antiandrogens, estrogens ) resulted in a significant inhibition of growth rate lasting 
approximately 60 days. After this period, renewed cell growth occurred with a tumor 
doubling time of 20 days (the same as that of the original Dunning tumor). It seems 
that 70-90% of the cells of the H tumor required androgens for their growth. But 
another cell population (10-30%) was capable of growing in the absence of androgens. 
This mimics the relapse phenomenon observed in hormone-treated human prostate 
cancer (Smolev et al. 1977a·15, Coffey et al. 1978, Isaacs et al. 1978,1979). 
Two other sublines were mentioned during serial transplantation of the Dunning 
R3327-H tumor. 
During the fourth generation of tumor transfer a rapidly growing tumor developed with 
a doubling time of two days. The tumor grew equally well in males, females and 
castrates. Histologically, the tumor showed no acini but only sheets of anaplastic cells. 
The tumor was designated R3327-AT (Smolev et al. 1977a). The nomenclature used in 
the different laboratories is confusing. The established R3327-G tumor reported by 
(Claflin et al. 1977) also originated spontaneously during serial transplantation of the 
parent R3327 tumor, but its morphology is only slightly different from that of the 
R3327-AT tumor originally described by Isaacs et al. 1978 and maintained in the Johns 
Hopkins laboratory. However, histochemically and cell-biologically the G and the AT 
tumor show significant differences, as will be discussed later. 
Another subline of the R3327-H tumor was selectively induced through implantation 
of the H tumor in castrates. A tumor developed with a doubling time of approximately 
25 days. Histologically, the tumor showed smaller acini with fewer secretions. The 
tumor is hormone- insensitive and was designated R3327-HI (Isaacs et al. 1978). 
Two observations should be made concerning the type of host animals used for tumor 
implantation and concerning the location of tumor inoculation. As the original R3327 
tumor was observed in the Copenhagen rat, the tumor was maintained by transplanting 
in either inbred Copenhagen rats or Fl hybrids of the male Copenhagen χ female 
Fischer rats ( Fig. 2.1. Α-B). The Fischer rat is a better breeder. The Copenhagen rat 
is somewhat difficult to breed in terms of production on much more than replacement 
breeder basis (Claflin et al.1977). Some authors felt the use of Fl hybrids to be an 
unnecessary variable (Dibner and Nakeff 1983). Concerning this point, there is only 
one publication describing differences between the R3327H and the so-called 
R3327-C(openhagen)- F(ischer) tumor (Seman et al. 1978). The R3327 C-F tumor 
was characterized by a better developed stromal component and was less differentiated. 
The presence of these large abnormal fibroblasts in the stroma of R3327 C-F tumors 
suggests that the tumors may not have been pure adenocarcinomas but 
carcinosarcomas. Adding to this confusion is the paper by Markland et al.(1978) giving 
a characterization of steroid hormone receptors in prostatic adenocarcinoma of the 
Dunning R3327 rat. Tumors obtained from different laboratories were described. A 
moderately differentiated adenocarcinoma, a carcinosarcoma and a fibrosarcoma were 
described. Again this underlines the need for monitoring the histology, growth rate, 
hormone sensitivity, biochemical markers and frequent karyotyping. These tumor 
characteristics should be reported in every publication (Isaacs and Coffey 1983). 
12 
% % 
® 
'^•z 
® 
Fig.2.1.A-B 
A. Female Fischer (F344) rat (Zentral Institut für Versuchstiere, Hanover, West Germany), 12 weeks' old, 
200 grams. 
B. Male Copenhagen rat (OLAC 1976 Ltd. England), 12 weeks' old, 225 grams. 
The Fl hybrids of the Copenhagen χ Fischer cross were used in our chemotherapeutic experiments. 
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As most investigators inoculate the cell suspension or tumor grafts subcutaneously in 
the flank, it is worth knowing that only Lubaroff et al ( 1977,1978a b) introduced a cell 
suspension (1-4 χ 107 cells) into the prostate of rats. This mimics the human situation. 
It is remarkable that metastatic lesions developed in the draining lumbar and paraaortic 
lymph nodes as well as in the lungs. Furthermore, metastatic lesions were sometimes 
found in the liver, diaphragm, xiphoid, intercostal muscles and mediastinal nodes. The 
lesions were found in rats having tumors for seven weeks or longer (Lubaroff et 
al. 1977). Cultured cells of the R3327 tumor transplanted subcutaneously produced 
tumors within five weeks ( 1 x 1 0 cells). At 9-11 weeks all tumor-bearing animals had 
metastatic lesions. This is in disagreement with the finding that the original R3327 
tumor produced tumors of 1-2 cm3 after about 14 weeks (106 - 107 cells inoculated) 
(Smolev et al. 1977a). Metastatic lesions were found only in < 1% of the inoculated 
animals. This discrepancy may be variously accounted for, e.g by the difference in 
tumor behavior between the intraprostatic and subcutaneous site. 
The more aggressive behavior of tumor cells in case of inoculation of cultured cells may 
well be due to selective growth of dedifferentiated cells Ίη vitro1. Characterization of these 
cultured cells was not mentioned in that paper (Lubaroff et al. 1977). 
Lubaroff also mentioned metastatic lesions in long-standing subcutaneous, growing 
R3327 tumors. 
During continuous serial transplantation of the R3327 AT tumor, two highly metastatic 
sublines were created. The R3327 MATLyLu tumor occurred after the 60th passage 
of the AT tumor and produced over 75% of animals with lesions metastasizing to lymph 
nodes and subsequently to the lungs. Death of the animals ensued around 25-30 days 
after inoculation. 
The doubling time of the tumor was 1.5 ± 0.1 day (R3327 AT : 2.2 ± 0.2 days). 
Selective transplantation of lymph node material and lung metastases material could 
not support the belief that there are two separate clones of metastatic cells which have 
a differential preference for the lung or the lymph nodes (Isaacs and Coffey 1981). 
However, another subline from the AT tumor was developed by the St. Louis group 
and designated R3327 MATLu, an anaplastic tumor with a doubling time of 2.7 ± 0.3 
days and in 100% of the cases primarily metastasizing to the lungs. These results were 
obtained through Ίη vivó1 selection. 
In approximately 30%, retroperitoneal and mediastinal lymph node metastases were 
also found (Kadmon et al. 1982, Lazan et al. 1981 ). 
Further cell biologie characterization of both these sublines has to be undertaken. 
Recently, several sublines have been observed upon passage of the R3327 Η tumor. 
Within one single passage of the R3327 AT-2, a fast-growing anaplastic tumor 
developed. An additional moderately fast-growing tumor (doubling time 5.4 ± 2 days) 
was observed after slow progression of the Η tumor. The tumor was moderately 
differentiated and designated R3327 Η-F. Four more sublines were produced after slow 
progression and serial passage of the Η tumor in castrated male rats. The first line has 
already been mentioned, namely the R3327 HI-S tumor. This tumor is well 
differentiated and completely androgen-insensitive. 
The next line comprises the R3327 HI-M tumor, moderately differentiated (doubling 
time 10 ± 2 days) and androgen-insensitive, and the subsequently developed R3327 
HI-F, moderately differentiated and androgen-insensitive (doubling time 3.6 ± 0.5 
days). Upon passage of the latter tumor a completely anaplastic tumor, R3327 AT-3, 
developed with a doubling time of 2.4 ± 0 . 5 days. All these tumors referred to have 
not yet been extensively characterized. 
The emergence of sublines lends support to the subsequently discussed progressive 
dedifferentiating of tumors in this model system due to probably genetic instability from 
the well differentiated tumor to the completely autonomous fast-growing tumors. 
These variants provide an opportunity to compare the different features of a special 
animal tumor with those of a specific category of human prostate tumors (Isaacs and 
Coffey 1983). 
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2.4.2. Hormone sensitivity of the sublines 
The first report about hormone sensitivity and hormone receptors in the R3327 tumor 
was made by Voigt and Dunning(1974). They demonstrated that a 5-a-reductive 
pathway was present in the R3327 tumor. The R3327 A squamous cell carcinoma 
lacked both 5-a-reductase and DHT cytoplasmic receptor proteins (Voigt et al. 1975). 
The R3327 tumors grown in females contain fewer receptor proteins than tumors grown 
in males. Later a new item was added, when it was shown that the Dunning tumors 
contain both androgen and estrogen cytoplasmic receptors (Markland et al. 1978, 
Markland and Lee 1979). The insensitive R3327 HI tumor showed a 68% reduction in 
the cytoplasmic androgen binding protein, but the level of estrogen receptors is the same 
in the R3327 H and in the R3327 HI tumor (Heston et al. 1979). 
Additionally, small levels of progesterone receptors were found in hormone-insensitive 
lines and relapsing H tumors (Heston et al. 1979, Markland et al. 1978). This enzymatic 
shift from the H via the HI to the completely insensitive AT tumor (decreasing 
5-a-reductase and androgen receptors and increasing estrogen receptors) in addition 
to the decrease of other enzymes, such as alkaline phosphatase activity, implicates 
instability at the level of the genes involved, i.e. DNA or chromosomal structural 
changes. An alternative hypothesis would implicate cellular heritable posttranslational 
modifications in the gene product(s) (Markland et al. 1978, Isaacs et al. 1979). 
The initial clinical response to androgen ablation therapy is often highly variable both 
in extent and in duration of response (Humphries and Isaacs 1982) and has been the 
subject of studies on the Dunning tumor model system. 
Even less well differentiated human prostatic tumors often show a brief response to 
androgen ablation. 
This variation in response to androgen ablation is probably due to the heterogeneity of 
the initial growing prostatic tumor. Varying sensitivity of cancer cells comprising that 
tumor is suggested. 
The Dunning H tumor responds to androgen ablation (surgical or pharmacologic) with 
significant growth inhibition. After approximately 60 days the tumor progresses like 
an androgen-insensitive tumor (Isaacs and Coffey 1981). This appears to be due to the 
heterogeneity of the H tumor. At least two cell clones are present, e.g. an androgen-
dependent and an androgen-independent clone (Isaacs et al. 1981). Androgen 
deprivation ensures a highly selective growth advantage for the insensitive cells (Isaacs 
and Coffey 1981, Isaacs 1984). Sestili et al.(1983) undertook an interesting study. They 
isolated and characterized a cell line cloned from the R3327 H tumor. This line, R3327 
H-G8- Al, had epithelial characteristics in light and electron microscopy. Karyotyping 
showed a modal number of 70 (hyperdiploidy) with several structural chromosomal 
changes and numerous marker chromosomes. These cells developed completely 
androgen-insensitive tumors when inoculated in Fl rats. However, the cells possessed 
high-affinity testosterone binding sites, showed 5-a-reductase acitivity and even 
retained acid phosphatase (Sestili et al. 1982,1983). This could be a further expression 
of progressive dedifferentiation of the well differentiated cells to an androgen-insensitive 
state. Genetic changes could be the origin of uncoded or wrongly coded enzymes. 
The R3327 G tumor, too, has at least two different subpopulations of cells as shown by 
flow-cytometric analysis (Benson et al. 1984). Antiandrogen therapy induces a 1.8 - fold 
decrease in subsequent growth rate of the tumor, and a 78% increase in survival (Isaacs 
1982). 
During antiandrogen therapy, the tumor showed a consistent decrease in the aneuploid 
cell population. Relapse of tumor growth after approximately 50 days was predicted by 
an increase in aneuploidy as indicated in flow cytometry (Collins et al. 1981). G-tumor 
cells do not contain DHT (H-tumor) but testosterone as the major androgen in the 
nucleus. Furthermore α-reductase activity is obviously decreased. The tumor as a whole 
is not dependent on androgens but is still sensitive probably due to direct affinity of 
testosterone to the nuclear receptors (Humphries and Isaacs 1982, Collins et al. 1981). 
This is again an intermediate situation and probably a phenotypic expression of 
underlying progressive chromosomal alterations. 
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This leads us to the significance of the presence of receptors in correlation with 
subsequent positive or negative response of individual prostate cancer patients to 
hormonal therapy. In any case, R3327 H tumors relapsing after hormonal therapy 
mimic the human situation. Likewise, the substantial number of patients still 
progressing under antiandrogen therapy despite androgen-positive receptors can be 
accounted for by an androgen-independent but androgen-sensitive status as occurs in 
the G tumor. Terms such as complete, partial or stable disease are probably due to the 
heterogeneity of cells within an individual tumor (Ekman et al. 1979). 
The inhibition of highly anaplastic, fast-growing tumors, e.g. MATLu and AT tumors, 
by high doses of DES (diethylstilbestrol) (Heston et al. 1981, Lazan et al. 1982) 
eventually mimics the often dramatic initial response to hormones of advanced prostate 
cancer in man. The cause of these reactions to hormonal therapy in the face of 
appreciable cytosolic receptors for androgens and estrogens remains to be clarified. A 
cytotoxic effect of DES, as described by Schenken et al.(1943), should nevertheless be 
considered. 
2.4.3. Immunology 
Immunology undoubtedly plays a role in the equilibrium between host and tumor 
(Eccles and Alexander 1975). 
Why a prostatic tumor that has been in a dormant state for years starts growing is not 
clear. 
The sudden crossing by the growing tumor of the capsule of the prostate as well as the 
metastatic potential may be due at least in part to a major break-down of the host's 
immunologic system (Catalona 1980). 
Splenomegaly, increased responses to non-specific mitogens in lymphocyte 
transformation assay, and increased levels of killer cell action were demonstrated 
(Lopez and Voigt 1977). 
Purified plasma membrane preparations can induce a specific cytotoxic population of 
lymphocytes. Surface glycoproteins play an important role in a malignant process (Gold 
and Freedman 1965, van Beek et al. 1975). 
The cell membrane, together with these antigens, is the phenotypic expression of 
intracellular or intranuclear (chromosomal) alterations in the development of a tumor. 
It is not inconceivable that there is a strong correlation between the immunologic 
recognition system in the host and the changed phenotype of the tumor cell due to 
chromosomal alterations. 
The development of monoclonal antibodies against cell surface antigens or to nuclear 
oncogens is a recent and very interesting field to explore (Moon et al. 1983). 
Much immunologic research on the Dunning tumors still has to be done. Lubaroff 
(1978ab) studied the effect of cryosurgery on intraprostatic inoculated Dunning R3327 
H tumors. It has been clinically documented that after cryosurgery of the local growing 
prostate tumor the metastases present will shrink or disappear due to immunologic 
activation (Soanes et al. 1970, Gursel et al. 1972, Yantorno et al. 1967, Milleman et 
al. 1980). 
2.4.4. Flow cytometry 
Flow-cytometric cell analysis has been used in the Dunning R3327 model system for 
quantitative evaluation of tumor response to endocrine manipulation (Pollack et 
al. 1981,1982). Furthermore, the patterns of cells growing 'in vivo1 and 'in vitro1 have 
been compared (Claflin et al. 1982). In close relation to these differences '/л v/vo' and 
'in vitro', multiparameter flow cytometry (FCM) is an excellent tool to study the 
heterogeneity of Dunning tumors and to differentiate histologically identical tumors 
(Benson et al. 1984). 
FCM analyses show that the H tumor consists of two different cell populations, one 
diploid and the other hyperploid (aneuploid). In the G tumor, the percentage of 
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aneuploid cells is significantly higher. There is evidence that 7л vitro'' only diploid 
DNA-containing cells survive in culture after approximately four to five cultures. 
The H tumor shows the same feature except for the aneuploid population being lost 
more rapidly (1-2 subcultures) (Claflin et al. 1982). Inoculation of these cells into 
animals will produce a tumor of diploid and aneuploid cells. 
2.4.5. Therapeutic studies in the Dunning R3327 tumor model system 
The Dunning rat prostate adenocarcinoma system has been used to evaluate hormonal 
and non-hormonal drugs. 
Because of the major role of androgen ablation in human prostate cancer, Dunning 
tumors were the subject of hormonal treatment. Most of the work was done in 
connection with studies on the available receptors. This has been discussed under 
'Hormone sensitivity' above. 
Additionally, estramustine phosphate (EstracytR) was used in the treatment of the R3327 
H tumor in one study (Miintzing et al. 1977). Estramustine phosphate had a markedly 
inhibitory effect on the growth of the tumor. Enhancement of estramustine phosphate 
activity was seen when androgens were administered to orchiectomized animals. This 
is thought to be an autophagic mechanism in prostate tumor cells as seen in 
androgen-induced growth of prostate tumor cells (Bruchovsky et al. 1975). However, 
it also means activation of tumor cell turnover related to a probably increased 
susceptibility to estramustine. 
A combination of surgical (hypophysectomy, adrenalectomy, orchiectomy) and 
pharmacologic hormone manipulation was used by Shessel et al.(1980). 
They showed that hypophysectomy, alone or in combination with hormones, and 
orchiectomy plus stilbestrol were the most effective means of inhibition of the R3327 
G tumor. 
Estrogen therapy and radiation therapy were tested in the R3327 G tumor (Camuzzi 
et al. 1980). A single dose of 2,000 rads produced significant inhibition of the growth of 
the G tumor. The tumor doubling time increased from 10.25 to 36.44 days. Estrogens 
in various combinations with radiotherapy did not show an synergistic effect. DES alone 
increased the doubling time to 26.44 days. 
Radiation therapy and combinations of various chemotherapeutics were used in the 
R3327 H tumor (Mador et al. 1982). 
2,500 rads completely inhibited tumor growth for four to six months. However, zones 
of viable adenocarcinoma remained evident. The authors suggested evaluation of these 
residual cells 'in vitro'. The finding of histologically viable tumor cells after an one-year 
period is in agreement with the human situation (Cox 1977, Herman et al. 1983). As 
to the cytotoxic drugs used in Mador's study(1982) cisplatin 20 mg/m2 
intraperitoneally resulted in an optimal effect on tumor growth compared to vincristine 
2 mg/m2 and VP-16 150 mg/m2. 
In another study an alkylating agent (ICRF-159) was used in the MATLu tumor. The 
drug had almost the same effect on tumor growth inhibition as DES, but concomitantly 
a marked reductive effect of the ICRF-159 on the metastatic potential was seen. The 
same effects were seen in the AT and MATLyLu tumors (Heston et al. 1981, Lazan et 
al. 1982). 
Chemotherapy of Dunning tumors is mentioned by Block et al.(1977). He treated Fl 
rats bearing an implanted R3327 G tumor. 
Therapy was started when rats had palpable tumors. Cyclophosphamide 200 mg/kg 
i.p., and especially cyclophosphamide and DES 1.25 mg/kg, had a significant influence 
on the survival of the animals. On multiple-drug therapy (cisplatin, adriamycin, 
cyclophosphamide and 5-FU) fewer animals survived because of drug toxicity. 
Two reports about the combination of surgery and chemotherapy are known (Kadmon 
et al. 1981,1982). The best results in the MATLyLu tumor model were achieved when 
radical surgery (local tumor excision and lymphadenectomy) was combined with 
adjuvant chemotherapy. In experiments with the MATLu tumor (Kadmon et al. 1982) 
surgery and cyclophosphamide 150 mg/kg cured five out of twelve animals. When the 
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tumor was left 'ι/ι situ' and cyclophosphamide was given, the tumor continued to seed 
the lung with metastases. This mimics the clinical situation where, at an early 
metastatic stage, either chemotherapy or surgery failed. With the use of both treatment 
modalities in succession a substantial cure rate will probably be achieved. 
2.5. 'In vitro' models of prostate cancer 
A review of prostate cancer models would not be complete without a short survey of Ίη 
vitro1 model systems in prostate cancer. 
Nearly 70 years ago Burrows et al.(1917) described a culture method for bladder and 
prostate tumors in the first issue of the Journal of Urology. They used the 'hanging 
drop' technique with different types of medium: plasma of patients from whom the 
tumor had been derived, plasma of normal individuals, a medium consisting of agar 
0.25% dissolved in isotonic sodium chloride, or isotonic sodium chloride and ascitic 
fluid. Cellular activity in those culture media was minimal, and only one of the prostate 
tumor fragments showed 'slight evidence' of growth. Despite this relatively unsuccessful 
investigation, Burrows mentioned that 'The energy producing substance for the growth 
of cells in culture has not been shown to come from the medium'. As we will see from 
this brief review, the problem of the medium contents for cells in culture has not yet 
been solved. The nutrient and physiologic requirements in culture media for the 
complex prostate cell still require a lot of research (Merchant 1976, Kaighn and 
Babcock 1975, Clarke and Merchant 1980, Ham 1974). 
As with the animal models for prostate cancer, no significant work on 'in vitro' models 
had been published until 1970. 
In vitro models of prostate cancer include 'organ' culture, expiant cultures (migration 
of cells out of tumor fragments in monolayer), and cell culture after mechanical or 
enzymatic disaggregation of the tumor. AH of these are primary cultures directly 
originating from the prostatic tumor. These primary cell cultures can lead to the 
establishment of a cell line, after several passages. 
'Organ culture' had better be renamed tissue culture, because only part of an organ is 
usually cultured in a specific medium (Franks 1977). This tissue culture system 
provides the maintenance for normal cell interaction (epithelium/stroma), but the tissue 
is free of the systemic host-tumor relation (Merchant 1976, Franks 1977). Carcinogenic 
changes, endocrine interactions and effects of chemotherapeutics can be investigated 
in this system. Organ culture has been widely studied in animal systems. Lasnitzky et 
al.(1966,1972) and Franks and Barton (1960) extensively studied the effects of 
carcinogens or hormones on normal and malignant tumors of mouse and rat prostates 
in culture. 
A major disadvantage of the 'organ' culture is the limited time of culture (3-4 weeks). 
In the expiant technique, cells are allowed to migrate from the parent tissue in contrast 
to 'organ' culture (Webber et al. 1974, Webber 1980). This technique has been used by 
many investigators in animals (Chopra and Wilkoff 1977, Edwards et al. 1976) and in 
human normal and carcinomatous prostate (Stonington and Hemmingsen 1971, 
Stonington et al. 1975, Röhl 1959, Schroeder et al. 1971, Okada and Schroeder 1974, 
Brehmeretal.1972). 
The behavior of individual cells, the interactions with hormones, the development of an 
assay for potentially cytotoxic drugs, the demonstration of specific cell receptors, specific 
tumor antigens, and the process of carcinogenesis can be evaluated in cell culture 
(Merchant 1976). 
Cell cultures can also be obtained by mechanical or enzymatic disaggregation of tumor 
material (Waymouth 1974, Sato 1975, Brehmer et al. 1972, Stone et al. 1976). Despite 
a diversity of attempts many difficulties are met with in culturing prostatic cells. As 
already noted, the prostate cell is very complex, being a specialized cell controlled by 
various hormones (Webber 1980). Combined with the difficulties in finding the specific 
media, this leads to the awareness that prostatic tissue is one of the most difficult to 
grow'in vitro' (Franks 1977). 
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Moreover, even our understanding of the basic physiologic principles of normal prostatic 
tissue is hampered (Webber 1980) for two reasons: (1) normal prostatic tissue is 
difficult to obtain and (2) it is even more difficult to grow 'in vitro1 than tumorous 
prostatic material (Clarke and Merchant 1980). Hyperplastic tissue is not normal 
tissue! (Franks 1977). In 1980 Kaighn described the development of epithelial cell lines 
from normal neonatal prostate. A neonatal cell line NP2 was developed (Lechner et 
al. 1978) in order to provide a system for investigation of normal prostatic cells. 
For prostatic tumor culture systems, too, prostatic samples are rather scarce: biopsies 
provide small amounts of tissue, prostatic chips (obtained by transurethral resection) 
are often damaged by fulguration, while samples from metastases or from radical 
prostatectomy specimens are ideal but rare. We should realize that only a small 
percentage of the samples provides tissue or viable cells fit for culturing, and even then 
only a small percentage of these cells is growing (Merchant 1976, Franks 1977). 
Prostatic tissue consists mainly of epithelial and stromal components. Fibroblasts from 
the stroma often have a higher growth rate and soon dominate the culture (Webber et 
al. 1974, Kaighn 1980). This usually occurs after the second or the third passage. The 
problem of overgrowth has been the subject of many investigations. 
One has tried to isolate homogeneous cell lines by plating them enzymatically; if single 
cell suspensions form discrete colonies, subculturing can be done to avoid the 
overgrowth of fibroblasts (Kaighn and Babcock 1975). 
A final problem we have to discuss is the identity of prostatic tumor cells 'in vitro'. The 
characterization of cells originating from prostatic epithelium is often difficult (Kaighn 
1980). Methods described are morphology and ultrastructural analyses (Brehmer et 
al. 1973), karyotyping (HeLa markers!), tumorigenicity (e.g. nude mouse) (Williams 
1980), growth in soft agar (Kaighn 1980), and biochemistry (prostatic acid 
phosphatase, 5-a reductase) (Kaighn 1975, Coffey et al. 1979). In later years 
flow-cytomctry was used both in animal models (Benson et al. 1984) and in human cell 
lines (Hoehn et al. 1984, Webber et al. 1977). Specific monoclonal antibodies against 
cell skeleton fractions have been suggested for use to differentiate between epithelial 
and mesenchymal tumor cells (Ramaekers et al. 1981). In this thesis the latter method 
is described in chapter 5. 
One of the main limitations is that subclones often develop in culture. These subclones 
are selected from the optimal growth based on the particular culture conditions 
(Merchant 1976, Webber 1980, Kaighn et al. 1979). Environmental pressure and 
genetic instability of the cells in culture can lead to selection of more virulent clones. 
Established prostatic cell lines can be developed from primary cultures. These cell lines 
can be maintained in culture indefinitely. The characterization of these permanent 
cultures is even more important. As we will see, some of the scarce cell lines of prostatic 
tumor are contaminated with HeLa. These lines are not appropriate for prostate cancer 
research, although they are seldom discontinued (Kaighn 1980, Williams 1980). An 
overview of cell lines is given by Murphy (1980). 
In short, six cell lines have been described in more or less detail. The first cell line was 
developed by Fraley et al. in 1970 . It was a possibly spontaneous transformation 'in 
vitro' from a human prostate adenoma. The line was denoted MA 160. 
In later years, HeLa contamination was demonstrated (Nelson-Reed and Flandermeyer 
1976, Webber et al. 1977). 
In 1974 Okada and Schroeder described the EB 33, a cell line derived from a 
moderately differentiated adenocarcinoma of the prostate. The tumor was obtained 
during a radical perineal prostatectomy. This cell line was also found to be 
contaminated with HeLa (Kaighn et al. 1978). 
Four uncontaminated cell lines remain. The PC-3 cell line (Kaighn et al. 1978) was 
derived from a rib metastasis. It is a hormone-unresponsive cell line. 
Stone et al. (1978) reported the DU-145, a cell line that arose from a brain metastasis 
in a prostatic cancer patient.This is also a hormone- insensitive cell line. 
In 1977, Lubaroff described the HPC-36 cell line, derived from a primary prostatic 
tumor. 
The LNCaP cell line was developed by Horoszewicz in 1980, and derived from a 
metastatic lesion of a supraclavicular node. 
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2.6. Nude mouse 
In 1966 a hairless mutant was found in an inbred stock of albino mice by Dr. N.R. Grist 
of the virus laboratory at Ruchill Hospital in Glasgow. 
The mutant mouse was investigated by Flanagan (1966). 
Pantelouris (1968) found that the nude mouse was congenitally athymic and therefore 
immunologically deficient. Early attempts were made to use the nude mouse as a model 
for xenografting. Human skin grafts were transplanted onto nude mice without the use 
of immunosuppressive agents (Reed and Manning 1973). Povlsen and Rygaard (1971) 
transplanted human adenocarcinomas of the colon and the rectum into nude mice, thus 
proving that this model could be used as an inert environment for growing human 
tumors. 
In later years it became evident that the initial enthousiasm about the nude mouse 
model had to be restrained. 
It became apparent that the nude mouse is immunologically not as inert as was 
originally thought (Gittes 1980). Besides, the nude mouse must be kept under special 
conditions not always available in the laboratories (germ-free or at least a laminar flow 
sterile cage, temperature controlled at 25 °C). Tumor takes are furthermore infrequent 
and slow. The nude mouse usually does not survive for six months. Often, hundreds of 
nude mice are necessary to establish a take in approximately 25% of various tumors 
(Shimosato et al. 1976). This author mentioned a rather low tumor take in case of breast 
carcinoma, a tumor similar to prostatic tumor. 
In case of prostatic carcinoma, many attempts have been made for heterotransplantation, 
while almost unsurmountable problems were encountered in transplantation from 
well differentiated to moderately differentiated tumors in spite of androgen 
stimulation (Schroeder and Jellinghaus 1978, Gittes 1980, Okada et al. 1981, 
Reid and Shin 1978, Sato et al. 1975). 
Apart from the 25% take, often no carcinomatous tissue remained, or squamous 
metaplasia and interstitial fibrosis were seen in persistent benign prostatic tissue (Gittes 
1980). 
Human cell lines provide a better take as with the EB 33 (Okada et al. 1981), the 
DU-145 (Mickey et al. 1977), PC-82 (Hoehn et al. 1980) and PC EW (Hoehn et 
al.1984). 
Metastatic lesions are never found in nude mouse with a xenograft. 
A peculiar observation was made by Graham et al.(1978), who found liver metastases 
occurring after subcutaneous inoculation of T-cells in xenografted nude mice. Most 
mouse and rat tumors will be accepted by the nude mouse (Gittes 1980). Drago et 
al.(1979a,b) successfully transplanted various Nb rat prostatic tumors into nude mice. 
The tumors retained their normal hormonal dependency patterns. 
Various chemotherapeutic agents were evaluated in this model system. 
However, the ultimate goal of developing an indifferent inert environment for the 
growth of serially transplanted human tumors has not been reached at this moment. 
The hope that a biologic drift, as is often seen in animal and human cell lines in culture, 
would not occur in the xenografts in the nude mouse, was dashed by the lack of real 
immunologic inertness of the model itself. 
Natural killer lymphocytes are found in all mice. These probably cytotoxic cells could 
prevent tumor take (Herberman et al. 1975). 
More research on this nude mouse model has to be done to provide a promising model 
for testing endocrine dependency and chemotherapeutic susceptibility of human 
prostate cancer. 
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Chapter 3 
CHARACTERIZATION OF THE DUNNING R3327 MATLYLU 
PROSTATIC ADENOCARCINOMA IN VIVO AND IN VITRQ 
A MULTIPARAMETER STUDY. 
ORIGIN AND STABILITY 
3.1. Introduction 
Since Huggins et al.(1941) reported about the efficacy of androgen ablation by means 
of castration or estrogen therapy in prostate cancer, no real progress has been made in 
the treatment of this tumor, which is usually considered a relatively benign tumor of old 
age. 
Comprehensive work has been done in the field of steroid hormone receptors and 
prostate cancer (Sandberg and Karr 1983) and the relevant consequences for therapy 
have been evaluated. 
In contrast, therapy of anaplastic or disseminated prostate cancer is still relatively 
ineffective, as no effective non-hormonal drugs are available. Hormone-insensitive 
prostate cancer cells are more or less primarily present in every malignant prostate 
(Byar 1973). Subsequent to hormonal therapy an almost universally observed relapse 
occurs, and sooner or later the patient will die due to the overgrowth of hormone 
insensitive cells. 
Progress has been further retarded by the lack of reliable animal models to study the 
control of hormone-insensitive cells and therapy modalities to treat them. 
Despite the many disadvantages inherent in the use of animal models (Handelsman 
1977, Merchant 1977, Sandberg and Gaunt 1976), it should be recognized that our 
recent progress in biologic and medical science has been made largely through animal 
studies (Isaacs and Coffey 1983). The phenomenon of preexisting hormone-insensitive 
cells in prostate cancer was confirmed by animal studies (Smolev et al. 1977, Isaacs 
1984). 
Spontaneous prostate tumors in animals do not usually occur with sufficient frequency 
to serve as a model system. Prostate tumors were observed in an aged monkey (Engle 
and Stout 1940), an aged female African rodent (Snell and Stewart 1965, Holland 
1970), dogs over eight years old (Leav and Ling 1968) and an aged Syrian golden 
hamster (Fortner et al 1963). Since 1961, interest has focused on prostatic 
adenocarcinomas in rats. Transplantable models derived both from spontaneous tumors 
(Dunning 1963, Pollard 1973) in rats and from induced tumors (Noble and Hoover 
1975) were developed. 
The Dunning R3327 model system has been extensively studied. 
Dunning (1963) observed a spontaneous tumor of the prostate at autopsy of a 
22-month-old retired Copenhagen breeder rat. The tumor appeared to involve the dorsal 
prostate gland and was classified as a papillary adenocarcinoma. No metastases were 
found. The hormone sensitivity of the well differentiated tumor with a doubling time of 
approximately 20 days was reported by Voigt and Dunning (1974). 
During serial transplantation, several sublines were derived from the parent R3327 
tumor named A-H. 
The R3327H tumor is the most extensively characterized tumor of the series (Smolev 
et al. 1977). The tumor is well differentiated, slow-growing, and androgen-dependent 
and has low metastatic potential (1%). The Dunning R3327 G tumor, maintained in 
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Claflin's laboratory of the University of Miami, Florida,U.S.Α., is an undifferentiated, 
androgen-sensitive, rapidly growing prostatic adenocarcinoma (Pollack et al. 1982, 
Claflin et al. 1982, Collins et al. 1981). 
During serial transplantation of the R3327 H tumor in the Brady laboratories at Johns 
Hopkins University, several sublines were derived, partially through selected growth 
(castration): R3327HI; partially through spontaneous mutation: R3327 AT 1-3 (Isaacs 
and Coffey 1983). 
The R3327HI-S tumor is androgen-insensitive, slow-growing, and well differentiated. 
The R3327AT tumors are fast-growing, anaplastic, and hormone-insensitive. 
Because all of these derivatives rarely metastasize, comparison with the human situation 
is difficult. Human prostatic anaplastic cancers have a high rate of both local invasion 
and metastases. 
In 1981 Isaacs et al. reported on a highly metastatic tumor observed during serial 
transplantation of the ATI tumor. It appeared to be a fast-growing anaplastic tumor 
(doubling time 1.5 days) with an almost 100% capacity for metastasizing to lymph nodes 
and lungs. This tumor was named R3327 MATLyLu. Another metastatic subline 
produced only lung metastases: R3327 MATLu (Lazan et al. 1982, Fig.3.1). 
We have studied the R3327 MATLyLu prostatic tumor as a model for therapy-resistent 
anaplastic carcinoma of the prostate in man. The marked dedifferentiation of the 
MATLyLu tumor convinced us of the need for further characterization of the prostatic 
origin of this tumor. 
Furthermore, the stability of this tumor during serial transplantation was assessed. 
In addition to the conventional histology and growth rate determinations 'ія vivó' and 
'/« vitro1, we studied additional tumor characteristics. 
Immunohistochemical, flowcytometric DNA histogram analysis, chromosomal and 
ultrastructural features of the MATLyLu tumor Ί'/ι vivo\ and tumor cells Ίη vitro' were 
considered. Especially the intermediate filamental studies presented here provide 
relevant information on the nature and origin of this anaplastic tumor. 
R-3327-H tumor Castration (induced selection) 
Γ 
AT-2 
R-3327 AT-1 t 
H-F 
MATLyLu- MATLu 
r 
ι 
I 
HIS 
ι 
I 
I 
I 
I 
HI-M 
ι 
I 
HI-F 
I 
AT-3 
N. Wake, J. Isaacs and A. Sandberg, Cancer Res. 42, 4131-4142 1982. 
Fig.3.1 Overview of sublines derived from the Dunning R3327-H prostatic adenocarcinoma in the rat. Partially 
the sublines were induced by selection (castration), partially spontaneous mutation provided a new subline. 
progression of tumor which required multiple serial passages 
progression of tumor within a single passage 
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3.2. M A T E R I A L S A N D M E T H O D S 
3.2.1 Animals 
Experiments were carried out in the first generation (Fl) of male Copenhagen χ Fischer 
(F344) cross. 
Male Copenhagen rats for breeding were obtained from OLAC 1976 Ltd. England and 
the female Fischer rats were obtained from the 'Zentral Institut für Versuchstiere' in 
Hanover (West Germany). 
The animals were housed in cages containing four animals. One male serviced three 
females. 
Once good breeding mothers had been selected, almost 100% survival of the litters (Fl) 
was obtained. 
3.2.2. Tumor 
The R3327 MATLyLu tumor was obtained in September 1982 from Dr. J.T. Isaacs 
and Dr. D.S. Coffey (Brady Urological Institute, Johns Hopkins Hospital, Baltimore, 
Maryland, U.S.A.). 
The tumor has been maintained for several generations in our laboratory and was in its 
fifteenth passage in January 1984. 
The tumor was maintained by subcutaneous inoculation of viable cell suspensions made 
from the parent tumor as described in the next paragraph. For characterization 
procedures tumors of the first and the fifteenth passage were studied. 
3.2.3. Preparation of monodispersed cell suspension 
Rats bearing the parent tumor were sacrificed through ether inhalation. 
The tumor measured approximately 20 cm3 after 15 days. 
The tumor was surgically removed under sterile conditions. After specimens had been 
collected for histology, histochemistry/immunohistochemistry, and ultrastructural 
analyses, the solid tumor was finely minced with scissors for 15 minutes through a metal 
sieve with 60 holes per inch into McCoy's 5A medium (GIBCO, Europe). 
The dispersed pieces of tissue were centrifuged at 450 G for 10 minutes. After removal 
of the supernatant, the tumor mince was incubated with 5 ml of type II collagenase (LS 
0004176 1168 U/ml Worthington, Amstelstad B.V., The Netherlands) in McCoy's 
wash medium for one hour at 37 °C, pC02 6%, humidity 97%. The tumor mince was 
passed through a metal sieve to remove large clumps of cells, and the filtrate was 
centrifuged for seven minutes at 450 G. The supernatant was discarded and the pelleted 
cells were washed with 10 ml of McCoy's medium to eliminate the collagenase. After 
final centrifugation, the pelleted cells were resuspended in 20 ml of McCoy's wash and 
manually passed through an 0.50-mm needle. Trypan blue dye exclusion was determined 
by means of an 0.1-ml cell suspension and 0.1 ml of trypan blue. 
The cell concentration of large nucleated cells was adjusted to 2.4 χ IO6 trypan 
blue-excluding cells per ml of McCoy's wash. 
With this technique, a tumor of approximately 20 cm3 produced 20 χ IO7 trypan 
blue-excluding cells. 
3.2.4. Growth rate determinations 
Following subcutaneous injection of 1.2 χ IO6 cells into the right flank of Fl rats, tumors 
became palpable after 8-10 days and were measured three times a week. Tumors were 
measured with microcalipers and tumor volumes were calculated according to the 
formula L χ W χ Η χ 0.5236 as described by Janik et al.(1978). 
The change in tumor volume with time was analyzed semilogarithmically to determine 
whether these tumors grew exponentially, and, if so, with what doubling time. At the 
time of death or sacrifice, complete autopsies were performed. 
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3.2.5. Light microscopie (LM) determinations 
Biopsies of both the primary tumor and metastatic lesions were routinely fixed in 
buffered formaldehyde 4%. After embedding in paraffin, separate sections were stained 
with hematoxylin eosin (H.E.), periodic acid Schiff (P.A.S.), pretreatment with amylase 
(A.P.A.S.), silver staining according to Laguesse or Movat, Papanicolaou (PAP). Acid 
phosphatase, and tartrate-sensitive acid phosphatase were performed histochemically. 
Lymphatic tissue in axillary, inguinal and paralumbar regions and mediastinum was 
removed and submitted for evaluation of tumor metastases. 
The lungs with intact trachea were inflated with Jores I (formaldehyde 40% 50 ml, 
Carlsbad salt 50 mg, and a saturated solution of chloral hydrate 50 ml) and stored in 
the same solution. 
The lungs were dissected and evaluated for peripheral (pleural) and central (hilar) 
metastases. 
Other organs including kidneys, peritoneum, diaphragm, liver and costal bone were 
stored in formaldehyde 4% for investigation in a later phase. 
3.2.6. Growth rate determination Ίη v/rro' 
Growth rate of the R3327 MATLyLu tumor was determined as described before 
(Kirkels et al. 1983). 
An aliquot of cell suspension from the primary tumor was used for culturing in bilayer 
soft agar. The cell suspension was adjusted to a concentration of 3 χ IO4 cells/ml and 
suspended in 5.2 ml of double enriched CMRL-1066 tissue culture medium with 0.8 ml 
of agar (Salmon et al. 1978). This suspension was plated in six petri dishes (diameter 35 
mm) over an 0.5% agar layer containing enriched McCoy's medium. Five thousand cells 
per culture dish resulted in complete overgrowth of colonies after eight to ten days, after 
which it was impossible to measure number and diameter of the colonies. 
After the cells had been plated, the cultures were incubated at 30 °C in a humidified 
pCOj incubator. Two culture dishes were removed the first day for control purposes and 
after one week and two weeks for automatic colony counting and colony size 
measurements. Culture dishes were fixed in carbowax and counted by the OMNICON 
automated colony counter (Bausch and Lomb Inc., Rochester, N.Y., U.S.A.) to 
determine colony growth pattern (Herman et al. 1983b). According to their diameter, 
colonies were counted in the following classes: 60-72 μτη; 72-86 /tm; 86-104μπι; 
104-124μπι; 124-149дт and > 149дт. On a log scale these classes have the same width 
(multiplication factor 1.2). By fitting a log normal distribution (after substracting 60 
from the class limits) to these grouped observations, a median colony diameter could be 
calculated per culture plate. 
3.2.7. Flow-cytometric analysis (FCM) 
-cell suspension 
The remainder of the cell suspension, not used for soft agar culture was fixed in ethanol 
70% at -20 °C prior to FCM. Flow-cytometric DNA distributions of tumor cells were 
done with the aid of techniques described elsewhere (Alabaster et al. 1978, Hamilton et 
al. 1980, Tannenbaum et al. 1978). 
For staining DNA, mithramycin (SERVA Feinbiochemica, Heidelberg, West Germany) 
was used with chicken erythrocytes as an internal control for each specimen as 
previously described (Tannenbaum et al. 1978). The ethanol was removed by 
centrifugation and the cells were resuspended at a concentration of 3 χ 10б cells per ml 
of staining solution (0.1 mg of mithramycin per ml of 0.85% NaCl, 15 mM MgCl2). 
After 30 minutes staining in the dark at room temperature, the cells were analyzed while 
still suspended in staining solution. 
The analysis was performed with an Ortho System 50H (Ortho Instruments, 
Wcstwood, Mass., U.S.A.) and a PDP 11/34 computer (Digital Equipment Corp., 
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Maynard, Mass., U.S.A.) for process control and data storage and analysis. The amount 
of fluorescence per cell was displayed as a DNA histogram. 
-monolayer 
Flow-cytometric analysis of MATLyLu cells from monolayers was also performed on 
3-7 χ 106 cells. For this purpose, cells from the first, second, third, fourth and tenth 
passages were stored in liquid nitrogen in 10% DMSO (dimethylsulfoxide) and 20% 
normal calf serum and defrosted simultaneously. Cells were washed once with 10 ml of 
MEM (minimal essential medium) and fixed in 70% ethanol at -20 °C, concentration 
3 χ 106 cells/ml. 
-soft agar cultured cells 
The agar colonies were visualized with the aid of a dissection microscope and aspirated 
from the agar one by one with a pasteur pipet. The cells were then suspended in 
McCoy's medium and processed according to the abovementioned methods. 
3.2.8. Immunohistochemistry of intermediate filament proteins 
For the detection of intermediate filament protein types, small pieces of tumor tissue, 
dissected from ten rats, were immediately frozen in liquid nitrogen and stored until use. 
Five to seven microns of thick frozen sections of the tumor tissue were cut in a cryostat, 
air-dried and processed for the indirect immunofluorescence technique as described 
before (Ramaekers 1983a). 
Cells in culture were grown on cover-slips and after one or two days washed with 
phosphate buffered saline (PBS), fixed in methanol (-20 °C, five minutes) and acetone 
(dipping at room temperature) and also incubated for the indirect immunofluorescence 
procedure. 
The following antibody preparations were used (Ramaekers et al. 1981,1983 a-d): 
a. An antiserum raised in a rabbit and directed against human callus keratins. 
b. A rabbit antiserum against calf lens vimentin. 
c. A rabbit antiserum directed against chicken gizzard desmin 
d. A rabbit antiserum directed against human glial filament acidic protein 
e. A monoclonal mouse antibody to cytokeratin 18 (RGE 53) specific for cytokeratins 
in glandular and columnar epithelial tissues as well as adenocarcinomas 
f. A monoclonal mouse antibody to human skin keratins (RKSE 60) known to react 
exclusively with keratinizing stratified epithelia and keratinizing cells in squamous 
cell carcinomas 
As second antibody preparations FITC (fluorescein isothiocyanate)- conjugated 
goat-anti-rabbit IgG or rat-anti-mouse IgG was used (obtained from Nordic Tilburg, 
The Netherlands). 
For double lable studies Rhodamine-conjugated goat-anti-rabbit IgG and 
FITC-conjugated goat-anti-mouse IgG (Nordic) were used as second antibodies. 
Sections were viewed under a Leitz Dialux 20EB microscope equipped with appropriate 
filters for fluorescein fluorescence, using epifluorescent illumination. 
Pictures were taken with a Tri-X film (Kodak) in an automatic camera with an ASA 
setting of 400 or 800. 
3.2.9. Ultrastructural analysis of MATLyLu tumor cells 'in VÌVO' and Ίη vitro1 
All tumor tissues were cut into small pieces and fixed by immersion in either 2.5% 
glutaraldehyde or a mixture of 2% glutaraldehyde and 2% paraformaldehyde in 0,1 M 
cacodylate buffer for 2-3 hours at 4 °C. They were rinsed in buffer, and then post-fixed 
in a similarly buffered 1% osmium-tetroxide. Dehydration was performed in an 
ascending series of aqueous ethanols, and the tissues were transferred via a mixture of 
propylene oxide and Epon (1:1) to pure Epon 812 as an embedding medium. Semi-thin 
sections (0.5-1 μια) were examined after staining with 2.5% toluidine blue in 2.5% borax 
solution to select the areas. Ultrathin sections were cut with glass or diamond knives on 
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a Reichert Om U3 ultramicrotome and picked up on formvar-coated copper grids, 
double- contrasted with 3% aqueous uranyl acetate and saturated lead citrate. The grey 
sections were examined in a Philips EM 300 or EM 301 electron microscope. 
3.2.10. Chromosomal analysis of MATLyLu tumor cells Ίη v/'vo' and 'in vitro' 
Cytogenetic analysis of tumor cells from tissues, ascites fluid cells and cultures 'in vitro' 
was done with Q-banding and G-banding techniques as described before (Caspersson 
et al. 1970, Scheres et al. 1972). 
Cells from agar colonies were harvested in the same way as described under FCM 
analysis. The cells were suspended in McCoy's wash, and chromosomal preparations 
were made (Scheres et al. 1972). 
3.3. R E S U L T S 
3.3.1. Growth pattern 'in vivo' 
The 'in vivo' growth pattern of the MATLyLu tumor did not change over a period of 
approximately one year (1st passage - 15th passage). After 24 days a tumor volume of 
40 cm3 is reached, when initially 1.2 χ IO6 tumor cells are inoculated (Fig.3.2). 
Med 
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о о MATLyLu 1st passage(n=13) 
. . MATLyLu- 15th passage(n=13) 
Fig.3.2 
MATLyLu tumor growth Ίη vivo'. Comparison of the median tumor volumes of the first and fifteenth 
passages of the tumor within approximately one year. No significant changes, after inoculation of 1.2 χ IO6 
viable tumor cells a tumor volume of 40 cm3 is reached within 24 days. This accounts for a doubling time of 
approximately 1.5 days (method of Smolev et al. 1977). 
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3.3.2. Histology 
Growth pattern 'in vivo' (21 days) 
Tumor. 
The tumor was composed of compact epithelioid cells, some arranged in differentiated 
tubular structures, most growing as sheets and nests. Fine reticular fibers surrounded 
these cell strands. Large as well as smaller sized tumor cells were uniform in aspect. The 
granular nucleus demonstrated distinct, irregular nucleoli. The cytoplasm was finely 
granulated and slightly eosinophilic. Many mitotic figures were present. 
The tumor was well vascularized by small blood vessels, some of them demonstrating a 
few tumor cells in the lumen. Scattered necrotic areas of various sizes were prominent. 
Within these areas, the most resistant tumor cells were found at the circumference of 
the blood vessels. Fat cells lied scattered throughout the tumor; the peripheral part of 
the tumor mass was surrounded by loose connective tissue. In this demarcation zone, 
several distinct patent ducts were localized. The lining epithelial cells were slender and 
columnar with hyperchromatic nuclei. 
When an intracutaneous tumor expanded, infiltration of tumor cells into the neighboring 
skeletal muscles was observed. Several myofibers were invaded by groups of tumor cells, 
mostly in the direction of the peritoneum. In the abdominal cavity, cells were also seen 
to settle on the parietal peritoneum (figs.3.3 A-E, 3.4 A-D). 
Staining of various tumor sections revealed tartrate inhibitable prostate acid 
phosphatase granules (not shown). 
Lung: 
Surrounding the bronchi and bronchioli, large accumulations of lymphoid tissue were 
present. Few tumor cells were also demonstrated between the lymphocytes. Well defined 
metastases with the same uniform aspect as the primary tumor were localized within 
the alveolar space. 
Tumor cells were preferentially present in several lymph capillaries, none were seen in 
the blood vessels (Figs. 3.5 A-D) 
Lymph nodes: 
The nodes were enlarged and tightly packed with tumor cells, and a striking depletion 
of lymphocytes was obvious. The remaining lymphocytes were randomly scattered. 
There was hardly any recognizable basic reticular architecture, except for the widened 
marginal sinus, which was stuffed with tumor cells. Remnants of trabeculae were found 
in the tumor mass (Figs. 3.6 A-B). 
Growth pattern 'in vitro' 
On day 0, solitary tumor cells with cloudy cytoplasm and well defined borders were 
present. The hyperchromatic nuclei were mostly roundish or oval. An increase in cells, 
predominantly as small clusters, was evident on day 3. The nuclear/cytoplasmic ratio 
was high. High cellular activity was indicated by colonies of varying sizes on day 6. The 
eccentrically localized nuclei with granular chromatin were more hyperchromatic. 
Sometimes anisokaryosis could be observed. 
Hyperchromatic and polymorphic nuclei contained irregularly dispersed chromatin. The 
increase in cell sizes was distinct compared to those at earlier stages. 
In smaller colonies another larger cell type could be noticed. They showed a larger, 
hypochromatic nucleus with distinct nucleoli and less intensely stained cytoplasm. 
Many colonies, varying from small-sized to very large and bulky, were present on day 
8. Some cells contained larger nuclei than those in younger cultures. Distinct, but 
irregular nucleoli were observed. The increase in necrotic cells and the presence of cell 
debris were indicative of the later stages of culture (day 10, and severer on day 13). 
Some remaining vital tumor cells still contained large nuclei, and cytoplasmic 
vacuolizations (Figs.3.7 A-C, 3.8 A-F). 
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Fig.3.3 
A: Low magnification of compact, arranged epithelioid tumor cells. Few fat cells are found scattered around, 
χ 150 
B: Tumor cell nests are well defined by delicate reticular fibers (silver impregnation, Laguesse), χ 150 
С: The tumor cells with distinct nucleoli are uniform in aspect. Mitoses are frequently observed, χ 400 
D: In the peripheral part of the tumor, ductal structures with a columnar epithelium are present, χ 150 
E; Lumen of blood vessel in tumor demonstrating a single tumor cell (arrow), χ 250 
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Fig.3.4 
A: At the top; settling of tumor cells on the parietal peritoneum. Below the stromal compartment, χ 250 
В, С and D : Subperitoneal muscle fibers are dislocated by densely infiltrating tumor cells (Β, χ 250). Invaded 
tumor cells either solitary or as clusters are found within several myocytes (C,D| χ 400). 
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Fig.3.5 
A: Low magnification reveals clearly metastatic tumor nodules centrally as well as peripherally in the lung 
χ 4 
B: Peripheral localized metastasis (thin arrow) and a lymph follicle (thick arrow) χ 25 
С: Higher magnification of that follicle: tumor cells are not well discernable, χ 100 
D: At higher magnification, part of the tumor metastasis clearly shows presence of tumor cells in a lymphatic 
capillary (arrows) χ 250 
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Fig.3.6 
A: Peripheral part of a lymph node with metastasized tumor cells. The depletion of lymphoid tissue is evident, 
χ 75 
B: Higher magnification reveals tumor cells (left) and dispersed lymphocytes (right) χ 250 
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3.3.3. Utrastructural analysis 
The MATLyLu of the fifteenth passage was analyzed with an electron microscope. Both 
the central and the peripheral part of the tumor were considered. 
- peripheral part of the tumor (skin side area) 
Epithelioid conglomeration of the tumor cells of a so-called intermediate type (I-type) 
was seen; (chapter 4) evident with a tendency to glandular formation resembling lumina 
into which long irregular microvilli protrude. The greater part of the smooth cell 
membranes were in close contact, showing fascia adherens-like junctions at several 
places. Most tumor cells contained polysomes and a number of Golgi areas that were 
dilated. Accumulations of mitochondria as well as 10-nm filaments were present too 
(figs. 3.9 A-B). 
- central part of the tumor 
All tumor cells were arranged in an epithelioid fashion. Clusters were separated by 
threads of collagen fibers and amorphous electron-dense material. 
Most cells with electron-light to electron-grey cytoplasm contained prominent nucleoli. 
Judging from the organelles and their distribution pattern , the tumor cells appear to 
be rather of the intermediate type. In certain areas they interdigitated with long 
microvilli, but their smooth surfaces were generally in close contact. In other areas 
detachment of cells and incipient degeneration were observed. 
These studies were done on the MATLyLu tumor that had grown for three weeks 
(figs.3.10A-C). 
-colony 'in vitro' 
The colonies were regular cell balls with a distinct epithelial character. Towards the 
fluid compartment all cells were tightly junctioned, their outer membranes showing 
short microvilli. In the center of the conglomerate, the cells more or less interdigitated 
with longer microvilli. The aspect of the cytoplasm varied from electron- light to 
electron-dense. Monosomes, long rough endoplasmic reticulum profiles and few 
filaments were visible. Lysosomal structures and fat droplets were also present (Figs. 
3.11 A-D). 
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Fig.3.7 
A: Typical soft agar colony of the tumor (phase contrast ), χ 30 
В; Histological section of soft agar colony, day 8, χ 250 
С: Eccentrically localized, coarse granular nuclei with irregular macronucleoli. Some cells contain fine 
vacuoles in the cytoplasm, day 6, χ 1000 
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Fig.3.8 
Α-F: Growth pattern of soft agar colonies after histologic processing (days 0-13) 
A(0),x 60 D(8),x 60 
B(3),xl00 E (10) χ 100 
С (6), χ 100 F (13) χ 60 
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Fig. 3.9 
A: Epithelial arrangement in the peripheral part of the tumor mimicking glandular formations with free 
microvilli in lumen-like slits (arrows). 
Note aggregation of mitochondria (asterisk), χ 5000 
В; Two adjacent tumor cells with few small fascia adherence-like junctions (arrows) and well distributed 
various organelles in the cytoplasm; dilatations of the Golgi complexes are distinct, χ 9500 
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Fig.3.10 
A; Epithelial arrangement in the center of the tumor showing subdivision by long, thin bundles composed of 
collagen fibers and amorphous substance (arrows), χ 4300 
В: Epithelioid arrangement of tumor cells of various electron- densities, locally separated by bundles of 
collagen fibers. Generally the cells exhibit extended organelles-rich cytoplasms, χ 5000 
С: Higher magnification of the central part reveals a pseudoglandular arrangement with microvilli protruding 
into the slit-like lumina (arrows), χ 6400 
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Fig.3.11 
A; Cluster of tumor cells in soft agar (phase contrast), χ 400 
В: Detail of two tumor cells with well preserved organelles. Note 10-nm filaments (arrow) and lipid droplet 
(asterisk), χ 37000 
С: In the center of a colony the tumor cells are linked by interdigitations. Generally, cultured cells contain 
more lysosomal structures and lipid droplets, χ 14800 
D: Detail of edge of a colony. Small irregular microvilli are present at the apex with several junctions laterally, 
χ 14800 
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3.3.4. Chromosomal analysis of the MATLyLu tumor Ίη vivo' and 'in vitro' 
Fifty cells from an enzymatically prepared cell suspension of the MATLyLu tumor were 
considered for chromosomal analysis. The modal number of chromosomes was 64, with 
a range of 58-69 (conventional staining). Trypsin Q- and G-banding techniques revealed 
the presence of normal and structurally altered rat chromosomes. All cells had abnormal 
karyotypes. 
Several translocations were present, e.g.: t (4;7), 5p+ and t(2;l 1). Two further marker 
chromosomes were consistent. One was a large mesocentric chromosome with a banding 
pattern of an isochromosome i (4q), the other was interpreted as a l p + . 
Chromosomal analyses of cell populations grown in ascites and in soft agar showed all 
marker chromosomes to be identical to those described above. 
The results of the chromosome counts per cell from ascites, soft agar culture (tenth day) 
and from the two different sorted fractions are listed in table 3.1. The ascites cell 
population contained a high proportion (75%) of cells with a normal rat karyotype 
having 42 chromosomes per cell. The modal numbers and the count ranges differed 
slightly in the four samples (Figs. 3.12 A-B). 
Fig.3.12a,b 
Marker chromosomes characteristic of the MATLyLu tumor. 
A. The large mesocentric chromosome with the G-banding pattern of an isochromoome i (4q). 
B. The lp+ marker chromosome (m) compared with the two normal chromosomes No.l (G-banding on 
the left, Q-banding on the right). 
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TABLE 3.1 Chromosome counts in the various MATLyLu cell samples. 
chromosome numbers 
Total 
40 41 42 43 45t /m49 50 t/m 58 59 60 61 62 63 64 65 66 67 68 130 through 140 number 
of cells 
Ascites cells 
Cells from soft 
agar cultures 
1 2 18 1 
1 1 
2 1 2 
4 5 
27 
13 
Solid tumor cells 
fraction I (upper)** 1 1 1 4 2 4 1 1 20 
Solid tumor cells 
fraction II (lower)** 1 2 7 13 
Table 3.1. 
Chromosome counts in the various MATLyLu cell samples. 
Note that more than 75% of the ascitic cell population had a normal karyotype probably due to proliferation 
of reactive cells of the host in ascites. Cultured cells in soft agar tend to have an increasing number of 
chromosomes. 
( * 136 and + 130) 
(** Chapter 4) 
Fig.3.13 A-C 
Α. Indirect immunofluorescence of frozen sections from primary MATLyLu tumor incubated with the 
monoclonal antibody to cytokeratin 18 (RGE 53) ,150 x. 
B,C. Double label immunofluorescence of lymph node metastasis of MATLyLu tumor incubated with RGE 
53 (B) and the rabbit antiserum to vimentin (С), 150 χ . 
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3.3.5. Immunohistochemical detection of intermediate filament proteins 
The polyclonal and monoclonal antibodies to intermediate filaments were applied to 
frozen sections of normal rat prostate, MATLyLu tumor sections, and to cultures of 
MATLyLu cells in order to determine their nature. 
Incubation of normal rat prostate tissue with the antibodies produced a strong reaction 
in the epithelial ductal cells only with antibodies to keratin. In detail, the polyclonal 
rabbit antiserum to skin keratin recognized all epithelial cell layers (the innermost 
glandular cell layer and the myoepithelial cells) while the monoclonal antibody RGE 53 
stained only the inner layer of glandular cells. RKSE 60 and the other polyclonal 
antisera did not stain the epithelial cells. The antibody to vimentin stained only 
connective tissue fibroblasts, endothelial cells and some smooth muscle cells. The desmin 
antibody stained only smooth muscle cells (results not shown). 
When frozen sections from MATLyLu subcutaneous tumors as well as from lymph node 
metastases were examined for their intermediate filament types, the following results 
were obtained. Both 'primary' tumors and lymph node metastases were slightly positive 
with the polyclonal antikeratin antiserum. The tumor cells showed a moderate to strong 
reaction to the polyclonal antibody to vimentin (fig.3.13 C) and a strong reaction to the 
monoclonal antibody to glandular epithelium cytokeratin 18 (RGE 53) (Figs. 3.13 A,B). 
Using the double label immunofluorescence technique, we could clearly demonstrate 
that one and the same cell contained both cytokeratin and vimentin (Fig. 3.13 B,C). 
Fig. 3.14 A-B 
Indirect immunofluorescent pictures of cultured MATLyLu tumor cells incubated with the monoclonal 
antibody to cytokeratin 18 (RGE 53,A) and the rabbit antiserum to vimentin (В), 400 χ . 
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In the tumor cells, no reaction was seen with any of the other antisera. Stromal cells 
were strongly stained with the antibody to vimentin. 
Incubation of MATLyLu tumor cells cultured in monolayer and continued up to ten 
passages produced similar results as obtained for the tumor tissue. Again, the cells 
showed only a positive reaction to the polyclonal antibodies to keratin, mouse 
monoclonal antibody RGE 53 (Fig.3.14 A) and to vimentin (Fig.3.14 B). 
As can be seen from figure 3.14, the intermediate filaments formed typical supranuclear 
concentrations, while typical filamentous networks were hard to recognize in these cells 
with the three antibodies. 
When cultured cells were injected into nude mice, subcutaneous tumors were 
occasionally formed. Upon examination for their intermediate filament types, the cells 
of the nude mice MATLyLu tumors yielded the same results as described for the rat 
tumors and for the cultured cells (results not shown). 
3.3.6 Flow-cytometric analysis 
FCM analysis was performed on the first and the fifteenth passage of the MATLyLu 
tumor cells. The MATLyLu of the fifteenth passage was also used for FCM analysis of 
cells grown in soft agar culture. 
The MATLyLu first passage was cultured in monolayer and compared to the tenth 
passage in monolayer. 
Concerning the stability of the MATLyLu tumor in our laboratory for approximately 
one year, we can demonstrate that FCM analysis of the first and fifteenth passages did 
not show gross alterations (Figs. 3.15 A,B). The DNA index (Gl tumor/CRBC) of the 
first passage was 4.3 and of the fifteenth passage 4.5. 
Only hyperdiploid (aneuploid) cells were present throughout the first until the tenth 
passage in monolayer culture, showing DNA indices of 4.8 and 4.7 respectively (Fig.3.15 
C,D). Inoculation of monolayer cultured cells into Fl(Copenhagen χ Fischer) rats 
produced tumors with an aneuploid peak in flow-cytometric analysis (Fig.3.15 E). 
FCM performed on cells harvested from soft agar culture also showed an aneuploid 
peak only (fifteenth passage)(Fig.F). 
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Fig3 15 
Cellular DNA histograms of R3327 MATLyLu 
Chicken red blood cells are used as an internal standard in all samples as shown in Fig 4 2 A For illustrative 
reasons the internal standard is not shown in Fig 4 2 C-F 
Abscissa DNA quantity per cell in arbitrary fluorescent units 
Ordinate number of cells 
In A First passage of MATLyLu tumor 'in vivo' DNA index (Gl tumor, channel 65 / CRBC in channel 
2 5 = 4 3) 
In В Fifteenth passage of MATLyLu tumor,DNA index 4 5 
In С and D, distribution of MATLyLu tumor cells after one (C) and fifteen (D) passages in monolayer 
culture 
The diploid (Gl normal) peak as seen in channel 35 in В disappears to an undectectable level The aneuploid 
peaks are seen in channel 65 DNA index 4 8 and 4 7 respectively 
In E the distribution after inoculation of the second passage of monolayer cultured cells 'w vivo' 
In F the distribution of MATLyLu tumor cells in soft agar is shown 
Only an aneuploid peak is seen in both distributions in channel 65 
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3.4. DISCUSSION 
Multiparameter studies of the MATLyLu tumor showed a confirmation both of rat 
prostatic origin and of the stability of the tumor after approximately one year of 
subcutaneous serial transplantation. 
Morphologic histologic diagnosis reveals not only the anaplastic character of the 
MATLyLu tumor but also the primarily lymphogenic metastatic potential of tumor 
cells. 
Lung metastases invariably follow the lymphogenic pattern before local extension 
produces intrapulmonary lesions. 
This is in agreement with the findings of Isaacs et al.(1981), who proved that selective 
transplantation of lymph node metastases and lung metastases did not lead to increasing 
percentage of animals with either lung or lymph node metastases. 
Electron-microscopic analysis further clarifies the epithelial nature of the MATLyLu 
tumor. Even a tendency to glandular formation is present in the peripheral part of the 
growing tumor. 
The intermediate filament patterns of MATLyLu tumor tissue and MATLyLu cells in 
tissue culture, however, definitely prove the epithelial nature of the tumor cells. So far 
only epithelial cells have been shown to contain (cyto)keratins (Sun et al. 1979), and 
polyclonal antisera to skin keratins have proven to be excellent tools for 
immunohistochemical identification of epithelial cells (Franke et al. 1981). Moreover, 
the reactivity of the tumor cells to the monoclonal cytokeratin 18 antibody (RGE 53), 
which has been shown to react with human epithelial glandular tissues, for example 
human prostate ductal cells (Ramaekers et al. 1983e) and with rat prostatic ducts, may 
be used to subtype the MATLyLu tumor cells as glandular epithelial cells. 
The coexpression of cytokeratin and vimentin, the mesenchymal type of intermediate 
filament protein, in the tumor cells of solid tumors is surprising, but can be explained 
in view of recent findings with cultured cells (Franke et al. 1979). Most epithelial cell 
types in tissue cultures examined so far can be shown to contain both cytokeratins and 
vimentin. This is in complete agreement with our findings in the MATLyLu cell 
cultures. Apparently, MATLyLu cells maintained through subcutaneous inoculations 
of viable cell suspensions made from solid tumor, also develop the extra vimentin 
intermediate filament skeleton. This skeleton is retained in the cells of solid tumors, as 
seen in frozen sections of primary MATLyLu tumors, in their lymph node metastases 
as well as in the MATLyLu tumors induced in nude mice. 
However, the presence of cytokeratin in all of these cells undoubtedly confirms their 
epithelial nature. 
Cytogenetic studies were done to confirm the rat origin of the MATLyLu cells and to 
exclude contamination with human (HeLa) cells. As could be shown by karyotyping of 
the MATLyLu tumor, this tumor contains a high incidence of numerical and structural 
chromosomal abnormalities. Disparity between the chromosome numbers Ίη vivo' and 
'/и vitro' was obvious in the ascitic cell population. More than 75% of these cells had a 
normal karyotype (n= 42). 
These cells must be considered to originate from the host rat (reactive, normal cell 
proliferation in ascites). Chromosomal numbers of cultured cells in soft agar tended to 
differ slightly and showed an increasing number of chromosomes in soft agar cultured 
cells. Although the cells counted were too few to attach too much significance to these 
observations, we can imagine that selective influences of the culture condition played a 
role. 
As to the stability of the tumor, no marked differences in chromosomal counts and 
structural abnormalities were noted during twelve months of MATLyLu tumor 
passages. This again deals with a relatively stable tumor subline. 
Both numerical and structural chromosomal abnormalities are reflected in alterations 
of cellular DNA content as the primary substrate of chromosomes. 
Measurements of cellular DNA became possible with multiparameter microfluorometry 
(Horan and Wheeless 1977). Besides, FCM is not dependent on cell cycle phase as in 
chromosomal analysis. 
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Flowcytometric DNA histogram analysis also confirms the stability of the MATLyLu 
tumor. 
The DNA index is quite stable from the first until the 15th passage. Slight alterations 
are sometimes noticed due to differences in composition of the tumor sample (stromal 
element, endothelial cells, nucleated hematopoetic elements)(Benson et al. 1984). 
FCM of cells in monolayer or cells growing in soft agar culture reveals only a 
hyperdiploid (aneuploid) type of DNA histogram. This characteristic is retained in 
monolayer until the tenth passage. A tentative explanation will be discussed in the 
chapter on the heterogeneity of the MATLyLu tumor. 
Concluding, we may assume on the ground of multiparameter studies that the 
MATLyLu tumor is an epithelial tumor (adenocarcinoma) of rat origin with metastatic 
potential primarily via the lymphatics. As it is a subline of the R3327H rat prostatic 
adenocarcinoma, we have to consider its prostatic origin. 
Especially in the case of fast-growing tumors, it is essential to monitor histology, growth 
rate, chromosomal analysis, and FCM in order to standardize the subline used. 
Both filamental studies and chromosomal analysis are very helpful in tissue and species 
identification respectively. 
The MATLyLu tumor model can be used as a screening model for known and newly 
developed cytotoxic agents, either single or in combinations. 
Furthermore, different treatment modalities can be compared (e.g. surgery + adjuvant 
chemotherapy). Metastatic mechanisms can also be studied. The ultimate goal is to 
make progress in the treatment of anaplastic or relapsing carcinoma in man. 
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Chapter 4 
CHARACTERIZATION OF T H E D U N N I N G R 3327 MATLyLu 
PROSTATIC A D E N O C A R C I N O M A IN VIVO A N D IN VITRO: 
A MULTIPARAMETER S T U D Y . 
HETEROGENEITY 
4.1. Introduction 
Prostatic cancers often show both a variation of biologic behaviour (Whitmore 1973) 
and a variation in clinical response to therapy. Clinical evidence (Byar 1973) and results 
in the Dunning rat prostatic carcinoma model make it clear that prostatic tumors have 
a variable content of both hormone-sensitive and hormone-insensitive cells (Humphries 
and Isaacs 1981; Isaacs 1984; Smolev et al. 1977; Isaacs and Coffey 1981). 
The Dunning R3327 prostatic tumor model system has been extensively analyzed and 
described (Claflin et al. 1982, Isaacs and Coffey 1983, Benson et al. 1984). Multiple 
sublines have been derived from the parent R3327 tumor as discovered by Dunning 
(1963). 
Morphology, growth rate, hormone sensitivity and metastatic potential differ widely 
among the sublines. The Dunning H is a slow-growing, well differentiated, 
hormone-sensitive tumor, mainly (hypo-)diploid, without marked chromosomal changes. 
With serial transplantation even more aberrant tumors have been developed. 
In 1981 Isaacs et al. described the MATLyLu prostatic tumor as suitable for 
investigation of the heterogeneity of a fully developed solid tumor. Via a variety of 
sublines, the MATLyLu is perhaps the end result of tumor progression from a nearly 
diploid tumor (R3327 H) to a fully aneuploid metastasizing tumor. 
Tumor heterogeneity has been demonstrated in other non solid (Rowley 1980) and solid 
(Vindelev et al. 1980) human and animal tumors (Dexter et al. 1978). 
If we accept that tumor cells originate from normal cells possibly by activation of special 
genes (oncogenes) or other changes in DNA and/or nucleoproteins, it is clear that 
chromosomal changes are an integral part of tumor progression (Rowley 1980; 
Mitelman and Levan 1978; Wake et al. 1982). 
Due to genetic instability within a neoplastic population of cells, tumors progress 
(Nowell 1976). Clonal selection takes place under environmental pressure and results 
in the diverse composition of tumors. Each neoplasm has its own individual 
characteristics resulting in marked differences in clinical behavior and therapeutic 
response (Nowell 1976,1978). 
An important feature in the concept of treating the most pathologic cell type within a 
given neoplasm is that even the fast-growing MATLyLu tumor shows clonal selection. 
Morphologic studies alone are not capable of discovering these dynamically important 
additional tumor characteristics. 
Multiparameter studies, including ultrastructural, cytogenetic, and flow-cytometric 
analyses with cell sorting (Horan and Wheeless 1977), are necessary to solve basic 
problems of biologic tumor behavior. 
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4.2. MATERIALS AND METHODS 
For ultrastructural, flow-cytometric analysis, cytogenetic investigations and soft agar 
culture techniques, tumor material of the MATLyLu was used. Methods are described 
in chapter 3 (tumor origin and stability). 
4.2.1. Cell sorting 
An unfixed cell suspension of the MATLyLu tumor was evaluated flow- cytometrically 
(ORTHO 50 H cytofluorograph with cell sorting capacity). Sorting of cells was 
performed based on measurement of the following cell characteristics. Right angle light 
scatter (RAS) was measured with argon laser light at 488 nm wave length (Spectra 
Physics, Mountain View, Ca., U.S.A.). Axial light loss (AXL) of cells was measured 
with a helium-neon laser at 628 nm wave length. 
Sorted subpopulations of cells were fixed and stained with hematoxylin-eosin (HE) and 
Papanicolaou for morphologic identification after being collected in cups and 
rcsuspended in McCoy's medium. In addition approximately 105 cells of each 
subpopulation were inoculated in the right flank of Copenhagen χ Fischer FI male rats. 
These tumors were removed after two and three weeks and processed for light and 
electron-microscopic investigations. 
4.2.2. Cytospin preparations 
For light-microscopy, cytospin preparations of tumor cell suspensions were fixed and 
stained with May Griinwald-Giemsa. 
4.3. R E S U L T S 
4.3.1. Flow-cytometric analysis and cell sorting 
Two-parameter FCM analysis of the MATLyLu cell suspensions using RAS and AXL 
demonstrated two clearly distinguishable cell subpopulations (figs. 4.1. A-B, 4.2.D). 
One population (upper) had both higher axial light loss and higher right angle scatter 
than the second (lower) population. In addition, the FCM data showed some suggestion 
that the lower population could be subdivided into higher and lower RAS populations 
but this differentiation was too inconsistent for further evaluation in the present studies. 
AXL and RAS readings were made and plotted as points on the abscissa versus ordinate 
axes. The number of cells with the same scatter measurements was represented by the 
imaginary Z-axis. The plot of AXL and RAS showed a wide range in the morphology 
of the tumor cell population. There was marked heterogeneity with two distinct peaks 
and one less well marked population of cells (HeNe laser). 
FCM analysis of DNA content of the unsorted tumor cell population showed the 
presence of both diploid and aneuploid fractions with prominent S and G2M phases of 
the aneuploid fraction (fig. 4.2.A). 
Since cells stained for DNA analysis are fixed while viable cells can be analyzed for 
RAS and AXL, these parameters were correlated by means of sorting of cell 
sub-populations. With the aid of AXL and RAS, the upper cell fraction was sorted, 
stained for DNA and reanalyzed with FCM. This upper fraction was found to consist 
of over 95% aneuploid cells, including the aneuploid S and G2M phases (fig. 4.2.C). 
Conversely, the lower AXL/RAS population contained 50% diploid cells and the 
aneuploid S and G2M phases were virtually absent (fig. 4.2.B). 
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Fig.4.1.(A, В) 
MATLyLu tumor. Axial light loss (AXL) and right angle scatter (RAS) plotted as points on the abscissa 
and ordinate respectively (B). The number of cells with the same scatter measurements is plotted against the 
imaginary Z-axis. Marked heterogeneity is obvious, with at least two distinct peaks (A). 
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Cellular DNA histograms of subpopulations of the MATLyLu tumor 
In A the normal distribution of the MATLyLu sample used for the cell sorting procedure The Gl tumor 
(aneuploid) peak is shown in channel 65, and the diploid Gl normal cells in channel 35 The chicken red blood 
cells are used as an internal standard (channel 10) 
In В the distribution of the lower fraction (D) is seen 
Nearly 50% diploid (Gl normal) cells are present, the aneuploid S and G2M phases have disappeared 
In C, the distribution of the upper fraction (D) is shown with over 95% aneuploid cells The diploid peak is 
virtually absent (3% in channel 35) 
D shows the two-parameter FCM analysis of the MATLyLu cell suspension with the use of the HeNe laser 
(see Fig 4 1 and text) 
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4.3.2. Light-microscopic morphology 
(Morphology of cells sorted by AXL/RAS) 
4.3.2.1. Upper aneuploid fraction 
This fraction is particularly enriched with hyperchromatic small tumor cells. Numerous 
cells are found to be pyknotic. 
Sparsely distributed among these small-sized cells, damaged and hypochromatic nuclei 
of larger tumor cells are observed (fig. 4.3.A). 
4.3.2.2. Lower mixed diploid-aneuploid fraction 
Hypochromatic nuclei with prominent nucleoli of large tumor cells are mainly found. 
Contamination with very few hyperchromatic nuclei of small-sized tumor cells are 
present (fig. 4.3.B). 
4.3.2.3. Cell suspension of MATLyLu tumor after 13 and 21 days 'ш vivo' 
growth 
Light-microscopic observations did not reveal distinct differences between the two tumor 
cell suspensions. Generally, two types of tumor cells were distinguished in all the 
suspensions, contaminated with blood cells, macrophages and degenerated cells. 
A small population consisted of large star-shaped, polygonal or roundish cells, but most 
of the tumor cells varied from medium-sized to small cells. 
The large cells showed distinct large nuclei, which often appear folded or lobed with 
finely granular chromatin. 
The nucleoli were indicated as well-circumscript light patches. The cytoplasm was 
slightly granulated and at some times a cytocenter was noted. Undulations of the cell 
membrane might be present. 
Medium-sized tumor cells contained irregularly or horseshoe-shaped as well as bilobed 
nuclei. Nuclear fragmentations were recognizable. The cytocenter was frequently 
distinct within the finely granular cytoplasm. Bleb formations of the cytoplasm were 
also observable. Several cells showed a few, small clear vacuoles but in some instances 
extensive vacuolizations were evident as well. 
The small-sized tumor cells had hyperchromatic or hypochromatic nuclei of irregular 
form, but they were usually bean-shaped. Circumscipt cytocenters were distinctly 
present in many cells as were cytoplasmic bleb formations. Mitoses of different types of 
tumor cells were common (Figs. 4.4. A.B.). 
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Fig.4.3. 
A. Upper aneuploid fraction consisting of predominantly small hyperchromatic tumor cells.x 150. 
B. Lower mixed diploid-aneuploid fraction consisting of predominantly large hypochromatic tumor cells, 
χ 150. 
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4.3.3. Ultrastructural analysis 
4.3.3.1. Tumor cell suspensions (13 and 21-day-old tumors) 
In toluidine blue-stained semi-thin sections of both 13 and 21 days' old tumors, intact 
tumor cells with distinct, sometimes bilobed nuclei are present. Several nuclei were 
pycnotic or show signs of apoptosis. Contamination with cellular debris, blood cells and 
macrophages was evident (figs. 4.5 A, 4.6 A). 
Despite all of these events, it appeared that the tumor cells were present as light or 
dark-stained cells. Due to manipulation and preparation procedures, many cells showed 
small vacuoles or cleft formation as became evident in less optimal preservation of the 
tumor cells in ultra-thin sections. 
However, some characteristics were still observable in both the suspensions of the 13 
days' and the 21 days' old tumors (Figs. 4.5 B-C, 4.6 B-C). 
Cell suspension of 13-day-old tumor 
Judged by their cytoplasmic appearance, two types of cells were still recognizable. The 
electron-dense cells, mostly with many microvilli and numerous polysomes, measure 
about 8-10 дт . Most electronlight cells provided with microvilli, with the exception of 
a few bald ones, showed more rough endoplasmic reticulum (RER) profiles and 
measured about 12 д т or more. Generally, the nuclei showed margination of their 
chromatin, but the nucleoli are distinct and intact. The distribution of the cytoplasmic 
organelles was the same as that found in the tumor nodules 'in vivo\ described earlier 
(chapter 3). There was an increase in vacuoles, partly due to the preparation procedures, 
and indicated by several clefts in the cytoplasm (Fig. 4.5 B-C) 
Cell suspension of 21-day-old tumor 
Generally, the differences in electron densities of cytoplasm were not strongly marked, 
and cell characteristics parallel those in 13-day-old suspensions. Again, smaller sized 
and more densely stained tumor cells were present with a diameter of about 8-10 μίτι 
and contained fewer organelles than the larger, more lightly stained cells. 
The latter were composed of cells with a diameter of about 12-13 μτη and cells 
measuring 14-16 μτη. The larger the cells, the more organelles and even more lysosomal 
structures, fat droplets and filaments were observed (Fig. 4.6 B-D). 
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Fig.4.4. 
Cell suspensions of tumors 'in vivo' show small-sized.medium-sized and few large tumor cells 13 days (A) 
and 21 days (B) after inoculation respectively, χ 400. 
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Fig.4.5. Tumor cell suspension, 13 days after inoculation. 
A: Light and dark-stained cells are present, some of them contain many vacuoles (semi-thin 
blue), χ 250 
B,C: Electron-light (Β, χ 6800) and electron-dense (C, χ 8300) tumor cells in suspension. 
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Fig.4.6. Tumor cell suspension, 21 days after inoculation. 
A: Light and dark-stained cells are present, some of them contain dark granules (semi-thin section, toluidine 
blue) χ 250 
B,C,D: Tumor cells of various sizes; small- sized (Β, χ 8300) and larger ones (C, χ 6,800; D, χ 5,300) with 
distinctly more organelles. 
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Fig.4.7. 
A: Electron-dense tumor cell (S-type) packed with organelles and bearing numerous prominent long microvilli 
at the free edges of the cell, χ 7400. 
В: Detail of S-type tumor cells with microvilli. The presence of monosomes and thin bundles of 
intermediate-sized filaments (arrows) are evident, χ 23,000. 
69 
íi 
·-»*» , 
' 
'. 1 
I ¿ w crjkí; ƒ-·-: :; ^ 
• 
-
• > . - - · 
'у-Щь^ ( А 
Fig.4.8. 
A: L-type electron-light tumor cell with a larger cytoplasm. The increase of RER profiles and decrease of 
monosomes and polysomes are distinct, χ 7,400. 
В: Characteristic S-type tumor cell. 
There is a striking difference between this type of cell and the L- type in (A), χ 11,500. 
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4.3.3.2. Ultrastructural investigation of sorted fractions of the MATLyLu tumor 
grown 'ш v/vo' 
Tumors that originated after subcutaneous inoculation of sorted cells from the 'upper' 
and 'lower' fractions of the MATLyLu tumor were removed early (after two weeks) 
and late (after three weeks) and were investigated. 
As described in chapter 3, the ultrastructure of a three weeks' old MATLyLu tumor 
showed morphologically mainly one type of cell (intermediate type) (Figs. 3.9 and 3.10). 
Two weeks after inoculation with the lower fraction 
On the basis of the morphologic findings, the population of tumor cells appeared to be 
composed of three types (Figs. 4.7, 4.8, 4.9). 
1. Small-sized cells (S-type), with long microvilli which appeared to be electron-dense, 
they exhibited a high nucleo-cytoplasmic ratio and showed distinct nucleoli. The 
cytoplasm contained densely distributed polysomes, but rough endoplasmic reticulum 
(RER) was sparsely present. 
2. Larger cells (L-type), which were more electron-lucent. This cell type revealed 
randomly distributed stalks of RER and numerous Golgi areas but also moderate 
quantities of free polysomes. Some lysosomal structures and bundles of 
intermediate-sized filaments were present. Generally, a few short slender filopodia and 
some small fascia adherens-like junctions were demonstrated. 
3. The third type of cell was an intermediate form (I-type) between types S and L. This 
cell was more electron-grey but almost as large as type L. Numerous free polysomes 
and monosomes were shown and there was an increase in RER profiles while 
mitochondria tended to aggregate. Some lipid droplets and 10-nm filaments were also 
observed. 
Two weeks after inoculation with the upper fraction 
Most tumor cells were of the smaller type (S-type), the remaining ones resembled the 
intermediate-type cells (I-type). 
The presence of numerous, regular and long microvilli especially in the S-type cells was 
remarkable. Very close contact points were also observed. 
Three weeks after inoculation with the lower fraction 
Most cells present resembled the I-type of cells, as described above. Aggregation of 
mitochondria was more evident. Close contact of cell membranes over long distances 
was frequently found as well as an increased number of small fascia adherens-like 
junctions. However, cell contact through interdigitation of laterally localized microvilli 
was also observed. At bare sites of the cells, short filopodia were demonstrated. At some 
places, an amorphic electron-dense substance resembling condensed basal lamina-like 
material was found among the tumor cells. It appeared to be more frequently present 
between tumor cells and the true basal laminae of capillaries. 
Three weeks after inoculation with the upper fraction 
The amount of intermediate type cells increased. There were fewer long microvilli, and 
the cells tended to be arranged in an epithelioid fashion, showing more close contact 
points and even more small fascia adherens-like junctions. Dense amorphous basal 
lamina-like material was sometimes present between the tumor cells, and was more 
frequently observed to surround the capillaries. 
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Fig.4.9 
A: The I-type tumor cell contains more electron-grey cytoplasm. 10-nm filaments (arrow), lipid droplets and 
RER stalks are evident. Polysomes and monosomes are present in fewer quantities than in S- type cells, 
χ 9500. 
B: Compare the L-type tumor cell with more dispersed organelles and distinct intermediate-sized filaments 
with the l-type in (A), χ 11,500. 
С: Detail of two tumor cells showing a diversity of organelles. In most cases cell contacts between either 
I- or L-types are formed by these fascia adherens-like junctions, χ 18,800. 
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4.3.3.3. Ultrastructural observations of metastases in lymph node and lung (21 
days) 
Metastatic lesion in lymph node: 
Clustered large tumor cells were arranged epithelioidally. The nuclei were distinct and 
often bizarrely shaped. The cells contained abundant organelles and, judging from the 
amount of polysomes, RER, and aggregated mitochondria, they resembled the I-type 
of tumor cells as previously described. Extensive lateral interdigitations were present 
between the cells, but close contact of membranes over long distances of adjoining cells 
was frequently observed. Small fascia adherens-like junctions were present in these 
areas. The free cell surfaces were covered with numerous long microvilli, giving rise to 
lumina-like formations within several islets of tumor cells. These tumor cell islets were 
separated by collagen fibers and amorphous basal lamina- like material (fig. 4.10 A). 
Metastatic lesion in lung: 
Large tumor cells with irregularly shaped nuclei and distinct nucleoli were found to be 
aggregated. As is the case with lymph node metastases, these cells were again of the 
I-cell type. Most cells were interconnected by lateral interdigitations, and few 
demonstrated membrane- close contact formations. The free surfaces of the tumor cells 
did not show any particular membrane specialization (Fig. 4.10 B) 
4.4 DISCUSSION 
Evaluation of the R3327 H, the G, and the AT2 and the AT3 tumors showed increasing 
heterogeneity when multiparameter flowcytometry was used (Benson et al. 1984). These 
authors concluded that FCM analysis of cell and nuclear size and shape can be useful 
to predict tumor aggressiveness. 
FCM analysis of the Dunning R3327 H and the Dunning G tumors showed stable tumor 
cell population ratios, but in monolayer culture only the diploid DNA cells persisted 
through five passages (Claflin et al. 1982). In culturing the AT 2 tumor, Wake et 
al.(1982),however, found that only the aneuploid cells grew in monolayer culture. 
The first evidence of the heterogeneity of the MATLyLu tumor came from our FCM 
analysis. Multiparameter flowcytometry showed at least two different cell types, 
characterized by RAS and AXL. When the HeNe- laser was used, three types of cells 
could be distinguished. By means of cell sorting procedures an aneuploid upper fraction 
and a mixed aneuploid-diploid lower fraction could be investigated. Morphologic 
evaluation of these cells was more difficult because of cellular damage due to sorting 
procedures. But ultrastructurally the three cell types were undoubtedly tumor cells. The 
upper fraction showed small roundish cells with a dark-stained nucleus. These cells 
resembled type the S- type cells described with the aid of electron microscopy (EM) of 
the tumor fractions grown Un vivo\ The lower fraction showed a mixed population of 
cells the small dark-stained tumor cells and another fragile larger hyperchromatic cell 
(L type cells in the electron- microscope?). 
FCM analysis of cells of the MATLyLu tumor growing in monolayer or in soft agar 
consistently showed an aneuploid peak in the DNA histograms. Even after ten passages 
in monolayer culture, no changes in the DNA pattern of the cultured cells were seen. 
These findings were in contrast to the findings of Claflin et al. (1982) but were in 
agreement with the findings of Wake et al.(1982). 
Light-microscopic evaluation cannot discriminate between basic difference in cell 
behavior within a tumor. 
Other techniques, such as EM, multiparameter FCM, and chromosomal analysis in 
vivo and in vitro, could confirm real heterogeneity. 
Light-microscopic analysis of the MATLyLu tumor as described in chapter 3 only 
discriminate small or large cells. It appeared that Un vitro' in smaller colonies also of 
larger, less intensively stained cells were present. 
Ultrastructural analyses of the Dunning system are scarce. 
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A well documented study comparing normal Copenhagen rat prostate cells and the 
R3327 H prostatic tumor was done by Feuchter et al.(1980). In monolayer culture, 
tumor cells appeared as slightly rounded polygonal cells not flattening with age. These 
cells were electron-microscopically different from normal prostate cells in vitro in their 
cell surface characteristics. When inoculated subcutaneously into syngeneic rats, these 
monolayer passaged cells produced tumors within several weeks instead of several 
months. This indicated that a special clone of the R3327 H was growing in vitro for the 
R3327 H tumor is an extremely slowly growing tumor. 
This is in agreement with the findings of Sestili et al.(1983). She cultured a cell clone 
G8-A1 from the R3327 H tumor, which produced a purely aneuploid tumor in vivo. The 
electron-microscopic findings of these cells confirmed small secretory epithelial cells. 
Dibner and Nakeff (1983) described the H tumor cultured in agar. The cells were small 
and round (diameter 10 μτη) with a rather high ratio of nucleus to cytoplasm. Tumors 
were not produced after inoculation of the cultured cells into rats. 
Our EM studies suggested that the MATLyLu tumor was composed of three types of 
tumor cells. One small tumor cell (S-type) and two other types (I-type and L-type). The 
latter cell types were not always distinguishable and may be the same cells in a different 
functional state. However, a remarkable finding was that the I-type of cell initially 
occured in small numbers. In the final growth stage (approximately at 3.5 weeks), the 
I-type cell constituted the majority of the tumor cells. The I-type cell was also the most 
common cell growing in vitro. Sorted cell fractions from the MATLyLu tumor 
inoculated into male rats produced tumors with different quantities of these 
electron-microscopic characterized cell types in the initial and late stages of tumor 
growth. 
Ultimately, it was the I-type cells that usually remained in the tumor after three weeks 
(table 4.1.). 
These results not only confirmed the heterogeneity of the MATLyLu tumor, but also 
suggested that the end result of the tumor tended to be more homogeneous. Possibly the 
end result of a process of selection is influenced by environmental culture conditions or 
host-tumor interaction. 
If we consider that malignancies are of clonal origin (Nowell 1976,1978), then a minor 
chromosomal change in a single prostate cell produces a diploid tumor cell. This stem 
cell starts to proliferate, resulting in a clone of cells all of the same type. These tumor 
cells may be genetically unstable and environmental pressure can lead to the emergence 
of mutant cells with a subpopulation which show an increase in growth/survival 
potential. 
Cells are produced each with special biochemical and morphologic (cell surface) 
features. Basic chromosomal patterns are changed, and codes for enzyme systems 
disappear or are inadequate. In the Dunning system clonal selection may explain the 
various receptor patterns in cytoplasm and nucleus of prostate tumor cells (Humphries 
and Isaacs 1982, Collins et al. 1981, Sestili et al. 1982,1983, Heston et al. 1979, Markland 
et al. 1978). 
Selective alteration of a cell population in a tumor can be caused by cytotoxic drugs, 
radiation, O2 changes, or hormonal changes. Cultured cells in particular are dependent 
on a completely altered 'host' environment (Krishan et al. 1969). 
Chromosomal analysis showed an increasing number of chromosomes in soft-agar 
cultured cells, similar to increased aneuploid cells grown in culture, and these might be 
the most aggressive cells. Considering the Dunning R3327 system, it can be 
demonstrated that progressively selective growth occurs from a well differentiated 
hormone-sensitive (R3327 H) tumor to the highly metastatic fast growing anaplastic 
MATLyLu tumor. 
The H tumor is an initially heterogeneous tumor composed of 80% hormone-sensitive 
and 20% hormone-insensitive cells (Smolev et al. 1977, Coffey and Isaacs 1981, Isaacs 
1984). This heterogeneity was confirmed by flow-cytometric analysis (Benson et 
al. 1984) and through minor chromosomal abnormalities (Wake et al. 1982). 
Exogenous pressure through androgen ablation (castration or estrogens) enhances the 
selective growth of hormone-insensitive cells and is responsible for the relapse of tumor 
growth. Serial transplantation of the H-tumor into castrated male animals (changed 
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host environment) produced the HI tumor. This tumor is phenotypically still comparable 
with the parent H-tumor, but is androgen-insensitive and is characterized by increasing 
chromosomal alterations (loss of Y chromosomes, translocation t 4,7). 
After serial transplantation, an androgen insensitive tumor developed, the R3327 H-F, 
with a doubling time of approximately five days, moderately well differentiated, and 
with marked chromosomal changes again including 14,7. Further mutations sometimes 
occurred within a single passage of the Η-tumor, and subsequently the AT 1 and AT 2 
tumors developed. These tumors were characterized by further chromosomal 
aberrations, but still the consistent 14,7 was present (Wake et al. 1982). Multiparameter 
FCM of the AT tumors showed them to be markedly heterogeneous (Benson et al. 1984). 
As could be seen, chromosome 4 seemed to play an important role in the progression of 
the Dunning tumors compared with the role of chromosome 15 in mouse lymphoid 
tumors (Dofuku et al. 1975). 
Chromosomal analysis of the MATLyLu tumor showed nearly the same modal number 
of chromosomes as demonstrated by Wake et al.(1982): 64 and 66 respectively. 
Concerning the chromosomes alterations, we found three markers identical to 14,7, 
5p+, t 2,11. However, two of the marker chromosomes clearly differed from those 
described by Wake et al. (1982). The appearance of one extra marker: isochrome 4q 
was noteworthy. This was the same marker chromosome as found by Wake et al. (1982) 
after ten passages of the AT2 tumor in monolayer culture. Already one isochrome ( 17q) 
has been found in bone marrow metastasis of a human prostate cancer (Oshimura and 
Sandberg 1975). Is there any relationship between this marker chromosome and the 
metastatic potential of a prostatic tumor cell? 
Special attention has to be paid to the R3327 G tumor. This tumor is a relatively 
fast-growing tumor, poorly differentiated and androgen-sensitive (chapter 2). FCM 
showed marked heterogeneity with two sub populations and the G tumor is known to 
occupy an intermediate position in terms of hormone sensitivity between the R3327 H 
and the R3327 AT tumors (Benson et al. 1984, Pollack et al. 1981). 
Isolation and characterization of a cloned cell line of the R3327 H tumor, H-G8-A1, 
was carried out by Sestili et al.(1983) as mentioned earlier. In monolayer culture these 
cells retained a saturable high- affinity binding for testosterone, while they grew as an 
anaplastic, androgen-insensitive tumor in animals. 
This probably means a gradual dedifferentiation of the cell population in the H tumor 
towards totally hormone-insensitive cell populations in the AT tumors. It is worth while 
to investigate if the H-G8-A1 cell clone is probably part of the G tumor. The G tumor 
is perhaps an example of the existence of a mechanism of slow progression from a diploid 
(normal) prostate cell to a hormone dependent and sensitive (H) tumor towards an 
aneuploid hormone-dependent, androgen-insensitive tumor cell (G tumor) and further 
to the aneuploid hormone-insensitive, independent cells (AT tumors). The MATLyLu 
and MATLu may then form the end stage, fully independent, anaplastic and 
metastasizing tumors (Fig. 4.11). 
For the most part, metastatic potential of tumor cells is not yet understood. Metastases, 
not the primary tumor when excised, kill the host bearing that anaplastic prostatic 
tumor. There is some evidence that enzymatic and membrane expressions play a role in 
the metastatic potential of a cell. Lowe and Isaacs (1984) found higher elastase and 
chymotrypsin-like activity in highly metastatic prostate cancer. At the 'face' of the cell, 
the cell surface is probably changed indirectly due to chromosomal changes. As already 
mentioned, special marker chromosomes may be essential for the emerging metastatic 
potential of a tumor cell. 
Studies with malignant fibroblasts suggest that expression of the malignant phenotype 
is related to the adhesive properties of the membrane of the cell transformed 
(Willingham 1977). Coman (1944) mentioned long ago that release of metastatic cells 
from tumors is dependent upon their decreased adhesiveness. In experimental prostatic 
cancer, altered adhesive properties of R3327 H cell surfaces were reported (Feuchter 
et al. 1980). 
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Fig.4.10 
A: Lymph node metastasis shows I-type tumor cells with locally extensive lateral interdigitations. Small 
junctional complexes (not visible due to low magnification) are mainly localized in areas indicated by 
asterisks, χ 3,600. 
В: Detail of lung metastasis revealing a cluster of I-type tumor cells and interconnecting lateral 
interdigitations, χ 6,500. 
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TUMOR HETEROGENEITY BY GENETIC INSTABILITY AND 
CLONAL SELECTION 
in i t ia l 
oncogenic 
nuclear changes 
N 
norma 
prostate 
Fig.4.11 
Clonal selection in the Dunning system due to genetic instability of tumor cells. Sublines can emerge with 
various composition of subpopulations of cells (heterogeneity). Each sub-population of cells (clone) has its 
own biochemical and morphologic features as an expression of genetic nuclear content. 
In the normal prostate an initial oncogenic nuclear change occurs and results in a diploid tumor cell. While 
progressing, the R3327H contains Tl = hormone dependent sensitive cells and T2= hormone independent 
sensitive cells, the R3327G tumor has additional T3= hormone- independent insensitive cells, and the R3327 
AT tumors mostly consists of hormone-independent insensitive cells (T3) and only a small number of 
hormone-sensitive (independent) cells (see text). The R3327 MATLyLu tumor consists of 
hormone-independent insensitive cells and, due to further differentiation (end stage), metastasizing (T4) cells. 
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A speculative question meriting further investigation is which cell represents the real 
'stem' cell. The stem cell is the target cell for therapy 'ultimoprimo'. In fact, in the 
double layer soft agar only stem cells will form colonies. However, cells with a limited 
growth potential (transitional cells) will grow in soft agar and sometimes form abortive 
small colonies (Selby et al. 1983). Stem cells with a doubling time of more than a few 
weeks will never be recognized in short-term culture (Lieber and Kovach 1981 ). 
Multiparameter research to discover the most important (stem ?) cell population in a 
tumor mass has to be initiated. The existence of such a cell was also suggested by our 
study of the heterogeneity in the MATLyLu tumor. It was found that, in the final stage 
of tumor growth in vitro and in the metastases of the MATLyLu tumor, one type of cell 
dominated, the intermediate type cell (EM). 
It was not clear what the function of the larger cells (L) was. The DNA pattern seemed 
to be diploid. However, this type of cell was very fragile, and was possibly damaged by 
the disaggregation procedures prior to culturing (Herman et al. 1979). Light microscopic 
investigations of soft agar cultures indicated that in smaller colonies larger cells were 
also present. 
Tumor heterogeneity is a very intriguing phenomenon. A fully developed solid 
malignancy is proposed to be the end result of sequential selection of increasingly mutant 
sub-populations (Nowell 1978). Tumors are probably even heterogeneous also with 
regard to invasion and metastasis (Fidler 1978). Tumor cell heterogeneity is responsible 
for the varied clinical presentation of a certain cancer and probably for the failure of 
response to therapy of a variable percentage of otherwise sensitive tumor types (Owens 
1982). 
The heterogeneity of tumors clearly has consequences for therapy and calls for a more 
tumor-specific therapy compared to the conventional 'over-all' therapy. 
The Dunning tumor system - and especially the MATLyLu tumor - seems to be a 
reliable tumor model system for studying cell-biologic prostatic cancer in detail. 
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Chapter 5 
EFFECTS OF CHEMOTHERAPEUTIC T R E A T M E N T ON T H E 
R3327 MATLyLu PROSTATIC A D E N O C A R C I N O M A IN T H E 
C O P E N H A G E N χ FISCHER Fl RAT 
5.1. Introduction 
A great number of patients in whom a prostate carcinoma is diagnosed, already have 
lymph node and/or vascular (bony) metastases (Whitmore 1973). 
This disseminated disease is not suitable for strictly localized treatment, e.g. surgery or 
radiotherapy. A systemic treatment modality has been applied for over 30 years to 
patients with disseminated prostate cancer in the form of androgen ablation therapy 
(Hugginsand Hodges 1941, Hugginsetal.1941). 
Following initial response, an almost universal relapse occurs due to growth of 
androgen-insensitive cells (Menon and Walsh 1979). 
Hormonal therapy is not capable of curing prostate cancer. Survival time is not 
significantly influenced by hormones (Byar 1973). 
Systemic treatment by way of chemotherapy of metastatic or primary anaplastic 
prostate tumors has lagged behind chemotherapeutic treatment of other solid tumors. 
Several reasons have been responsible for this back-log, such as initial dramatic 
subjective response to hormonal manipulation, increasing toxicity of cytotoxic agents 
used in elderly men, and the lack of objective response parameters in prostate cancer. 
Above all, until recently neither an appropriate animal model nor a bioassay in which 
cytotoxic drugs could be tested had been available. 
The MATLyLu tumor has a high rate of both local invasion and metastases (Isaacs et 
al. 1981). The MATLyLu tumor was observed in 1981 by Dr. J.T. Isaacs during serial 
transplantation of the R3327 AT (anaplastic) tumor, a subline derived from the parent 
R3327 Dunning tumor (Dunning 1963). 
The objective of this study was to investigate if the MATLyLu prostatic adenocarcinoma 
is a reliable model system for testing cytotoxic drugs that could be used in the treatment 
of purely anaplastic or disseminated prostatic tumors in man. 
5.2. MATERIAL AND METHODS 
5.2.1. Tumor maintenance 
The transplantable R3327 MATLyLu prostatic tumor is an anaplastic carcinoma. The 
tumor was obtained in December 1982 from Dr. J.T. Isaacs and Dr. Coffey (Brady 
Urological Institute, Johns Hopkins, Baltimore, Maryland, U.S.A.). The tumor has been 
maintained in our laboratory by subcutaneous inoculation of cell suspensions into Fl 
male hybrids of the Copenhagen χ Fischer (F344) cross. The tumor has remained 
histologically and biologically stable for 18 months and is now in its eighteenth passage. 
Animals bearing a tumor of approximately 40 cm3 survive on average for 24 days. 
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5.2.2. Tumor inoculation for the experiments 
For the experiments, we prepared a single cell suspension of the MATLyLu tumor as 
described before. 
Each animal was inoculated subcutaneously in the right flank with 0.5 ml of fresh tumor 
cell suspension (2.4 χ IO6 trypan blue excluding cells per ml). 
5.2.3. Animals 
Male Copenhagen rats for breeding were obtained from OLAC 1976 Ltd., England, 
and the female Fischer rats were obtained from the "Zentral Institut für Versuchstiere" 
in Hanover (West Germany). 
5.2.4. Drugs 
Based on multiple dose toxicity studies in Fl rats, we chose the following drug doses 
(near LD10): 
cisdiamminedichloroplatinum (II) (PlatinolR, Bristol Myers Company, Syracuse, New 
York, U.S.A.) = CDDP 3 mg/kg of body weight and cyclophosphamide (EndoxanR, 
Asta Werke A.G., Bielefeld, West Germany) = CTX, 90 mg/kg of body weight were 
obtained as injectable intravenous preparations from the hospital pharmacy. 
Diamminemethylcyclohexanesulfate platinum (II); TNO-6, NSC-311056; 2 mg/kg of 
body weight was developed as a derivative of cisplatin and obtained as an injectable 
preparation from Bristol Myers Company International Division (Lenaz 1981). 
Placebo injections consisted of physiologic saline i.v. in doses of 1 ml/kg of body weight 
given on the same day as the chemotherapeutic injections. All injections were 
administered intravenously in the dorsal penile vein without previous hydration of the 
animals and under brief ether anesthesia. 
5.2.5. Follow-up of animals 
Tumors were measured with micro-calipers (fig.5.1.) and tumor volumes were calculated 
according to Janik's method: V = LxWxHxO.5236 (Janik et al. 1978). From the day of 
tumor inoculation, body weight was measured three times a week. 
Retrobulbar blood samples were obtained prior to drug administration and prior to 
autopsy. A complete autopsy was performed on all animals which had had full 
chemotherapeutic treatment, following sacrifice or death as a result of disease. 
5.2.6. Quantitation of lymph node and lung metastases 
All lymphatic tissue in bilateral axillary, inguinal and paralumbar regions and in the 
mediastinum was removed and submitted for histologic confirmation of presence or 
absence of metastases. No attempt was made to measure the total amount of metastatic 
tissue. 
The lungs and the trachea were inflated with Jores I (formaldehyde 40%, Carlsbad salt 
50 mg and a saturated solution of chloral hydrate 50 ml) and stored in the same solution, 
after gross counting for the presence of peripheral (pleural) and central (hilar) tumor 
metastases. 
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Fig.5.1. 
Tumor measurement with micro-calipers. Tumor volumes are calculated according to the 
formula: volume = length χ width χ height χ 0.5236 (Janik et al. 1978). 
5.2.7. Experimental design 
Eighty male Fl hybrids of the Copenhagen χ Fischer cross matched for age and weight 
(10-14 weeks old and weighing 200-250 g at the start of the experiment) were included 
in the study. Each animal was inoculated with R3327 MATLyLu tumor cells as outlined 
above and was randomly assigned to one of five treatment groups, as follows: 
GROUP 1:15* animals treated with placebo injections on days 5 and 19 after 
inoculation of tumor cell suspension. 
GROUP 2 : 1 6 animals treated with CDDP on days 5 and 12. 
GROUP 3 : 1 6 animals treated with TNO-6 on days 5 and 19. 
GROUP 4 : 1 6 animals treated with CTX on days 5 and 19. 
GROUP 5 : 1 6 animals treated with a combination of CTX + CDDP in full doses of 
each drug on days 5 and 19. 
To exclude any tumor catabolic effect without losing too many animals to cachexia, the 
animals were allowed to regain weight after the first dose of chemotherapy (figure 5.2). 
This regaining of weight occurred about seven days earlier in the CDDP treated animals. 
Therefore, the second CDDP dose was given to this group on day 12 rather than on day 
19 as in the other groups. 
Animals were sacrificed five to six days after the last chemotherapeutic treatment. 
5.2.8. Statistics 
The parameters studied include survival of animals in the different treatment groups, 
and tumor growth, both local and metastatic. 
Statistical analysis of the survival rate in the various groups was hampered because the 
exact dates when the individual rats died from tumor growth were not known. Not all 
rats were allowed to survive beyond the estimated final date of the experiments. 
The observation period of this study was shorter than the natural death of the 
tumor-bearing animal. This incomplete follow-up gave us censored data. The survival 
function in the five treatment groups dependent on the number of days post inoculation 
was estimated with the Kaplan-Meier method (Kaplan and Meier 1958). Besides, the 
survival function in the five treatment groups was compared by means of a conservative 
* One animal was withdrawn from the study prior to treatment. 
85 
approximation of the log rank test by Peto and Pike (1973). The same implications hold 
good for tumor growth information. 
Most statistical methods require complete growth information on each individual. 
Moreover, particular therapies may cause regression of tumor growth at a certain 
moment, and parametric data were not available. Therefore, analyses to detect 
differences in tumor growth between the five treatment groups in our study were based 
on a distribution- free test (Koziol et al. 1981). This test is appropriate for the detection 
of ordered alternatives of distribution. 
Statistical analysis of the metastases and blood values was done with the chi-square test, 
2 x 2 table tests, the Kruskal-Wallis test and Wilcoxon tests respectively. Statistical 
analyses of blood values were performed on the ratio of blood values obtained just before 
autopsy to the initial blood values prior to chemotherapy (ratio E/S, E = end value and 
S = start value). Initial blood levels were not significantly different (except for 
lymphocyte counts between the treatment groups). If the p-value of the statistical test 
is less than 0.05, the difference is accepted as significant. 
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Fig.5.2. 
Distribution of weight of animals in the different therapy groups and a saline control group. Minimal not 
significant changes are seen in all groups. The influence of cachexia on tumor volume could be practically 
eliminated. 
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5.3. RESULTS 
5.3.1. Survival 
There was no significant difference in survival of all rats (n = 79) between the five 
treatment groups (p=0.15). 
Comparison of rats with observed tumor take (n = 72) only indicated a significant 
difference (p=0.006) between the five treatment groups. Paired comparison showed 
that survival in the control group was poorer than in the other group (p<0.02) (fig.5.3). 
5.3.2. Tumor growth 
Tumor growth was analyzed in rats where a tumor take had occurred. 
Seventy-two rats were considered (three rats treated with CTX + CDDP, one rat 
treated with CTX, one rat treated with CDDP, and two rats treated with saline had 'no 
tumor take'). 
Tumor growth in the CDDP group was compared to tumor growth in the other 
treatment groups until day 17 in connection with the drug schedule. The saline, TNO-6, 
CTX and CTX + CDDP treated animals were compared up to day 24. 
Table 5.1 shows the median tumor volumes of primary tumors treated with the different 
cytotoxic drugs. The group receiving CTX, alone or in combination with CDDP, showed 
significantly (p < 0.002) smaller tumors than the saline control or CDDP or TNO-6 
treated animals. Tumor volume was not significantly smaller in rats treated with CTX 
+ CDDP compared to rats treated with CTX alone (p > 0.05). 
Except for one animal, the median tumor volumes in the combination group did not 
exceed 10 cm3. 
The same statements can be made for tumor volume growth curves until day 24 (only 
CDDP was not considered in this comparison). 
Eight of the CTX-treated animals (50%) showed decreasing tumor growth after initial 
growth (1/16 animals had no tumor growth at all). 
In the CTX + CDDP group, six rats (37.5%) showed decreasing tumor size after initial 
growth, while in two rats (12.5%) the tumor disappeared after initial growth. Tumor 
volume of these rats was 280 mm3 and 490 mm3 respectively. Four of the 16 animals 
(25%) had no tumor growth at all. This is probably related to the early inhibition of 
injected tumor cells. 
In the CDDP and TNO-6 group, each individual animal had only slightly decreasing 
tumor growth after initial growth. 
87 
SURVIVAL RATE (%) 
1.00 
0.80-
0.60-
0.Д0-
0.20- 1 = Saline (n = 15) 
2= Cisplatin(n = 16) 
3=TN0-6 (n = 16) 
U- Cyclophosphamide(n = 16) 
5= Cyclophosphamide+ Cisplatin (n = 16) 
8 
I I 
12 
-г-
16 20 2Д 
Implantation of 
1.2x106MATLyLu tumor cells 
28 
DAYS 
Fig.5.3. 
Survival rate of cytotoxic-treated animals compared with a saline · treated control group. There is no 
significant difference in survival in all treated animals (n= 79) : p= 0.15, but when only rats with observed 
tumor take are considered (n= 72) the survival in the saline group is poorer than in the cytostatic-treated 
animals (p< 0.02). 
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TABLE 5.1. MEDIAN TUMOR VOLUME IN CM3 FOLLOWING IMPLANTATION OF THE MATLyLu TUMOR IN RATS WHERE 
THE IMPLANTED TUMOR TOOK 
'in vivo' treatment day 8 day 10 day 12-13 day 15 day 17 day 19-20 day 22 day 24 
1. saline (N=13) 
2.CDDP(N=15) 
3.TNO-6(N = 16) 
4. CTX(N = 15) 
5. CTX + CDDP(N = = 13) 
DISTRIBUTION-FREE 
TEST 
2 x 2 table tests* 
(paired comparison) 
0.52 
0.10 
0.20 
0.00 
0.00 
2.09 
0.66 
1.25 
0.00 
0.00 
5.40 
2.67 
3.73 
0.03 
0.00 
12.43 
9.02 
11.74 
0.78 
0.35 
20.58 
14.96 
16.47 
2.92 
1.30 
Ρ < 0.0001 
1 2 3 4 5 
27.65 
26.62 
24.28 
4.26 
3.03 
34.65 
33.93 
30.91 
7.96 
4.02 
36.23 
— 
35.87 
7.78 
5.10 
Ρ < 0.0001 
1 3 4 5 
* Group numbers above the same bar are not signincantly different from each other and are ordered by 
increasing mean rank number. 
5.3.3. Metastases 
The percentages of lymph node and lung metastases in the different treatment groups 
are listed in tables 5.2 and 5.3. 
It is obvious that in the saline and the TNO-6- treated animals all autopsied animals 
had lymph node and lung metastases. 
Significantly fewer axillary metastases (right and left) were present in the CDDP, CTX 
and the CTX + CDDP treated animals compared to the saline and the TNO-6 group 
(right side ρ = 0.0002 and left side ρ = 0.002). 
Retroperitoneal, inguinal and mediastinal lymph node metastases were not statistically 
different in the treated groups versus the control animals. However, lesions in the 
animals treated with cytotoxic drugs were smaller compared to the saline group (except 
TNO-6), as estimated by visual inspection of macroscopic lesions and the histology. 
Inguinal lymph node metastases were mostly seen in the saline and TNO-6- treated 
animals as a result of local tumor extension. 
Lung metastases in the CTX + CDDP and CTX groups, were fewer than in other 
treatment modalities (p=0.003). Besides, lung lesions were smaller in these therapy 
groups. 
Histologically, primary lymphatic spread was noticed. 
In 11 cases lung metastases were present without mediastinal lymph node lesions, and 
in three cases mediastinal metastases were present without lung metastases (only in the 
CDDP, CTX + CDDP and CTX treated rats). 
5.3.4. Cure 
Cure was defined as absence of gross or histologic evidence of tumor at autopsy after 
initial tumor take. Only in the CDDP + CTX group were two animals completely cured 
of this anaplastic tumor with the drug schedules used. Both animals were sacrificed in 
good condition on day 26. 
5.3.5. Toxicity 
The presentation of extensive toxicity data is beyond the scope of this study. 
A severe decrease of leukocytes in terms of reduction of neutrophil and lymphocyte 
counts was seen in the CTX and CTX + CDDP treated animals (fig. 5.4). 
In the platinum drug groups (CDDP and TNO-6) less toxicity occurred. A relative 
leukocytosis was seen in these groups. The same feature occurred in the saline-treated 
animals and may be due to necrosis in a rapidly growing tumor. 
Hematologic changes, i.e, mild anemia, was observed in all treatment groups including 
the saline control group. A decrease of platelets was noted in the TNO-6 group. Organ 
toxicity was considered after evaluation of the histologic sections of the kidneys, in 
particular to detect any difference in damage between TNO-6 and CDDP. 
Normal signs of toxicity in the renal tubule cells (epithelial swelling, vacuolization of 
cytoplasm and nuclear atypia) were in both groups to the same extent (fig.5.5 A-C). 
5.4. DISCUSSION 
The objective of the study outlined above was to test several therapeutic agents in the 
MATLyLu prostatic adenocarcinoma as a model for primary anaplastic or relapsing 
disseminating prostate cancers in man. 
Drugs were selected for use in this tumor reductive experiments that had previously 
revealed some activity either against prostatic cancer in man (Javadpour 1982, Murphy 
1979, Merrin and Beckley 1979, Yagoda 1973) or in animal prostatic tumor models 
(Pollard and Luckert 1976, Block et al. 1977, Drago et а1.1980а'Ь, 1981, Kadmon et 
al.1981,1982). 
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TABLE 5.2 LYMPH NODE METASTASES 
Treatment group 
l.SALINE 
2.CDDP 
3.TNO-6 
4.CTX 
5.CTX + CDDP 
Chi-square test 
(overall comparison) 
2 x 2 table tests* 
(paired comparison) 
N 
7 
14 
14 
15 
10 
P= 
Axillary 
R L 
6 
8 
14 
4 
3 
0.0002 
4 
3 
10 
2 
1 
0.002 
1 2 ? 4 5 
Retroperito­
neal 
R L 
5 
7 
8 
2 
2 
0.024 
0 
2 
2 
0 
0 
0.30 
Inguinal 
R L 
1 
0 
3 
1 
0 
0.22 
0 
0 
1 
0 
0 
0.30 
Mediast. 
Metastases 
L negative 
5 
7 
5 
4 
2 
0.17 
0 = 0% 
4 = 29% 
0 = 0% 
10 = 67% 
5 = 50% 
'Refer to table 5.1 
TABLE 5.3 LUNG METASTASES 
Treatment group 
l.SALINE 
2. CDDP 
3. TNO-6 
4. CTX 
5. CTX + CDDP 
Chi-square test 
(overall comparison) 
2 x 2 table tests* 
(paired comparison) 
N 
6 
14 
13 
13 
9 
Macroscopic 
pleural 
6 
5 
10 
2 
0 
ρ < 0.001 
1 3 2 4 5 
Microscopic 
pleural 
6 
7 
11 
2 
3 
P = 0.0007 
Microscopic 
central 
5 
6 
9 
1 
0 
P = 0.003 
Metastases 
negative 
0 = 0% 
3 = 21% 
0 = 0% 
10 = 77% 
6 = 67% 
»Refer to table 5.1. 
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1 2 3 
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of W B C (Δχ) 
4 
MATLyLu 
Relative alteration — 
of lymphocytes (Δχ) 
2.0
Ί 
4 5 
3-
2-
1 — 
MATLyLu 
1 
-I' 
4 ri-
1 
Relative alteration 
of platelets (Δχ) 
1 = Saline 
2 = Cisplatin 
3 =TNO-6 
4 = Cyclophosphamide 
5 = Cyclophosphamide • 
Cisplatin 
Fig.5.4. 
Toxicity data on hematology parameters in cytotoxic-treated animals compared with a saline treated control 
group. 
1 = saline, 2= TNO-6, 3=CDDP, 4 = CTX, 5= CTX + CDDP(see also tables 6.2 and 6.3). 
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Fig. 5.5. Similar areas in kidneys (border between juxtamedullary cortex and outer medulla) 
A: control rat with normal straight descending limbs and thick ascending limbs, χ 400 
В: cisplatin-treated rat with aberrant thick ascending limbs (silver staining according to Movat), χ 250 
С: cisplatin-treated rat with swollen and partially ruptured epithelium of thick ascending limbs. 
Note distinct nuclear atypia, regularly found in almost all treated animals, χ 400. 
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In addition, a newly developed cytotoxic drug TNO-6 (NSC 311056), a derivative of 
CDDP, was used. Its LD50 was claimed to be 40-50% lower than that of CDDP. 
Therefore, its nephrotoxicity might be lower (Lenaz 1981). 
One major conclusion could be drawn from the cytotoxic experiments in this model. 
CTX alone was as efficacious in inhibiting tumor growth and in preventing massive 
metastases to lymph nodes and lungs, as was the combination therapy. 
Tumor growth was retarded by approximately five days. Five animals in the CTX 
containing chemotherapeutic regimens showed no tumor growth at all, possibly due to 
early tumor cell inhibition. As no tumor take took place in two saline-treated animals, 
we cannot fully endorse the above mentioned statement. 
As cytotoxic treatment was started before palpable tumor growth had occurred, it 
cannot be established whether tumor growth was initially inhibited by these agents. 
Evaluation is therefore only speculative, since there were two rats in the saline group 
without tumor growth (immunostimulation ?). 
Only in the CTX + CDDP group were two animals completely cured. CTX showed 
remarkable prevention of the appearance of hormone-independent transplantable 
prostatic rat tumors (Pollard and Luckert 1976). CTX alone or in combination produced 
reduction or regression of tumor volume in autonomous Pr 18 and Pr 19 Noble tumors. 
Metastatic lesions in the lungs were either prevented or inhibited (Drago 1980a, 1981). 
The effect of CTX was observed to diminish following metastasis in the lung (Karrer et 
al.1967). Reactivation of metastatic lesions in 'cured' animals after CTX treatment was 
noted (Pollard and Luckert 1976). 
It appears also from our study that prolonged survival studies are called for. Is the 
above-mentioned phenomenon caused by activation of dormant metastatic cells or is it 
due to selection of resistant cells (to CTX) in the local growing tumor?The latter 
hypothesis is supported by observations of Kadmon et al. (1982). He observed that a 
combination of early surgery and adjuvant CTX chemotherapy in the anaplastic 
MATLu tumor probably prevented seeding of tumor cells after recovery from cytotoxic 
treatment. 
The use of alkylating agents in combination with hormones (DES) in the R3327 
MATLyLu produced more tumor growth inhibition than treatment with an alkylating 
agent alone (Lazan et al. 1982). This was effectuated only in case of early tumor growth 
(within seven days of tumor inoculation). 
These important concepts have clinical implications. 
Early surgical treatment with adjuvant chemotherapy is beneficial in other tumors as 
well (Vugrin et al. 1979, Einhorn and Williams 1980) but is uncommon in prostate 
cancer. The findings that prostate cancers are primarily polyclonal and that 
hormone-insensitive cells will inevitably overgrow after single androgen ablation 
(Smolev et al. 1977, Coffey and Isaacs 1981, Isaacs 1984) have not yet been utilized in 
clinical prostate cancer. 
Combination of cytotoxic agents and DES as a rational therapy has hardly been used 
(Mukamel et al. 1980, Beckley et al. 1980). 
All the study drugs were administered intravenously, mimicking the clinical situation. 
Peritonitis developing after intraperitoneal administration of CTX alone or in 
combination could, therefore, have been prevented (Block et al. 1977, Kadmon et al. 
1982). 
The drug schedules in our study were aimed at the rats regaining weight after the first 
dose of chemotherapy. Severe cachexia and subsequent loss of animals were prevented 
while tumor-reductive effects of weight loss were almost balanced. 
In our experiments blood toxicity did not differ from experiences in other studies (Evans 
et al. 1980). Systemic drug toxicity is invariably associated with survival. This is a 
problem in the clinical setting too. The same problem was noted in our study. 
Duration of treatment, intervals between the doses and the total dose administered are 
important items to investigate (Goldin et al. 1975, Braunschweiger and Schiffer 1980, 
Tew and Taylor 1980). 
Even timing of chemotherapy according to the host's circadian rhythm is suggested 
(Schevingetal.1980). 
This leaves us with the final question: the extrapolation of results of chemotherapeutic 
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treatment in this animal model to man. 
These extrapolations have to be done with care (Handelsman 1977, Merchant 1977). 
First, there are the anatomic and physiologic differences between the animal prostate 
and the human prostate. The bioavailability of drugs in animals and humans could be 
basically different. 
Secondly, prostate tumors are not homogeneous as we learn from cell kinetic studies by 
Skipper (1975) so that, at the time of clinical detection of a 1 cm3 palpable prostatic 
cancer, it has already grown to two thirds of its size (approximately 30 doublings) 
(Weissmann et al. 1977, Devita et al. 1975). 
Due to Nowell's (1978) clonal selection theory a human solid malignancy is an end 
result of sequential selection of increasingly mutant subpopulations. From this point of 
view it is not surprising that a prostatic tumor is heterogeneous, when observed clinically. 
In this respect the parent Dunning R3327 tumor, too, was an advanced prostate tumor 
when observed in 1961. Probably only the dormant or very small silent prostatic tumors 
contain hormone dependent cells derived from a single hormone-sensitive stem cell. 
On the one hand, this concept stresses the need for finding cytotoxic agents against 
hormone-insensitive cells, but on the other hand early treatment with a combination of 
hormones and chemotherapy is probably indicated. 
Furthermore, the effectiveness of local tumor excision with adjuvant chemotherapy still 
remains to be proven in prostatic cancer. The development of chemotherapeutic 
treatment in prostate cancer is greatly aided by the availability of animal models. Drugs 
that are effective in these animals merit trials in humans, taking into consideration the 
abovementioned objectives. 
The MATLyLu anaplastic adenocarcinoma is a reproducible tumor model and will 
provide the best opportunity to test potentially active chemotherapeutic agents in human 
prostate cancer. 
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Chapter 6 
EVALUATION OF CHEMOTHERAPY IN THE MATLyLu RAT 
PROSTATIC TUMOR. AN 'IN VIVO' - 'IN VITRO' STUDY 
6.1. INTRODUCTION 
The Dunning R 3327 transplantable prostatic adenocarcinoma of the rat is an accepted 
model for human prostatic carcinoma (Smolev et al.l977a,b; Heston et al. 1979, Isaacs 
et al. 1978, Claflin et al. 1977, Isaacs et al. 1982). The tumor was observed in 1961 as a 
spontaneous adenocarcinoma originating in the dorsal lobe of the prostate of a syngeneic 
Copenhagen rat (Dunning 1963), and has since been maintained as a subcutaneous 
flank tumor. 
During serial transplantation, several sublines were derived from the original R 3327 
tumor, partially through selected growth (R3327HI) partially through spontaneous 
mutation (R3327AT). The several sublines differ in hormone sensitivity and in growth 
rate. The R3327HI is androge-insensitive, slow-growing, and well differentiated. The 
R3327AT is an anaplastic fast-growing, hormone-insensitive tumor (Coffey et al. 1979; 
Isaacs et al. 1978; Wake et al. 1982). 
Because all of these derivatives rarely metastasize, comparison with the clinical situation 
is lacking, since human anaplastic prostate cancer has a high rate of both local invasion 
and metastases. 
A variant of the R3327AT tumor has been found to metastasize regularly via the 
lymphatics with subsequent lung lesions (Isaacs et al. 1981). In our study we have used 
this R3327 MATLyLu tumor as a model for therapy- resistant anaplastic carcinoma of 
the prostate in man. 
Studies involving tumor response to cytotoxic drug manipulation have primarily used 
caliper measurements of tumor diameter 'in vivo' (Block et al. 1977; Drago et al. 1980; 
Drago et al. 1981; Kadmon et al. 1981). No further information can be obtained about 
inhibition of cell populations responsible for tumor growth nor can the number of viable 
cells left behind in the treated tumor be estimated. 
We have developed a tumor model system in which the effects of cytotoxic drugs on 
tumor growth 'in vivo' are compared with cell biologic behavior 'in vitro1, evaluating 
the growth potential of the residual tumor in soft agar culture (Herman et al. 1983a). 
The influence of cytotoxic manipulation on the 'in vivo' MATLyLu tumor has been 
further compared with the changing of cell cycle kinetic parameters within the treated 
tumor, determined by flow-cytometric (FCM) analysis. 
6.2. M A T E R I A L S A N D M E T H O D S 
6.2.1. Animals 
All the chemotherapeutic experiments were carried out in the first generation (Fl) of 
the male Copenhagen χ Fischer (F344) cross. Male Copenhagen rats for breeding were 
obtained from OLAC 1976 Ltd., England, and the female Fischer rats were obtained 
from the 'Zentralinstitut für Versuchstiere' in Hanover (West Germany). The FI male 
hybrids were 10-14 weeks' old and weighed 200-250 grams at the start of the 
experiments. 
6.2.2. Tumors 
The R 3327 MATLyLu tumor was obtained from Dr. John Isaacs and Dr. Donald 
Coffey (Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, 
U.S.A.) and has been maintained by subcutaneous inoculation of viable cell suspensions. 
The tumors became palpable after 8-10 days and reached approximately 25 cm after 
20 days. 
6.2.3. Preparation of monodispersed cell suspension 
Rats bearing a 20 cm3 tumor were sacrificed through ether inhalation. The tumor was 
surgically removed under sterile conditions. After a specimen had been collected for 
histology, the solid tumor was finely minced with scissors for 15 minutes through a metal 
sieve with 60 holes per inch into McCoy's 5A medium (GIBCO Europe). 
The dispersed pieces of tissue were centrifuged at 450 G for 10 minutes. After removal 
of the supernatant the tumor mince was incubated with 5 ml of type II collagenase (LS 
0004176 1168 U/ml Worthington, Amstelstad B.V., The Netherlands) in McCoy's 
wash medium for one hour at 37 °C, pCOj 6%, humidity 97%. The tumor mince was 
passed through a metal sieve to remove large clumps of cells, and the filtrate was 
centrifuged for seven minutes at 450 G. The supernatant was discarded and the pelleted 
cells were washed with 10 ml of McCoy's medium to eliminate the collagenase. After 
final centrifugation, the pelleted cells were resuspended in 20 ml of McCoy's wash and 
manually passed through an 0.50-mm needle. Trypan blue dye exclusion was determined 
by means of an 0.1 -ml cell suspension and 0.1 ml of trypan blue. 
The cell concentration of large nucleated cells was adjusted to 2.4 χ IO6 trypan blue 
excluding cells per ml of McCoy's wash. 
For each experiment, the animals were inoculated with cells derived from a single 
primary tumor. 
6.2.4. Clonogenic cell culture 
An aliquot of cell suspension prepared as described above was used for culturing in 
two-layer soft agar. The technique of culturing was previously described in detail 
(Herman et al. 1983a). The cell suspension was adjusted to a concentration of 3 χ IO4 
cells/ml and suspended in 5.2 ml of double enriched (CMRL-1066) tissue culture 
medium with 0.8 ml of agar (Salmon et al., 1978)). This suspension was plated in six 
petri dishes (diameter 35 mm) over an 0.5% agar layer containing enriched McCoy's 
medium (5,000 cells per plate). 
After the cells had been plated, the cultures were incubated at 37 °C in a humidified 
pCOj incubator. Two culture dishes were removed the first day for control purposes and 
after one week and two weeks for automatic colony counting and colony size 
measurements. Culture dishes were fixed in carbowax and counted by the OMNICON 
automated colony counter (Bausch and Lomb., Inc., Rochester, N.Y.,U.S.A.) to 
determine colony growth patterns (Herman et al. 1983b, Kirkels et al. 1983). According 
to their diameter, colonies were counted in the following classes: 60-70 μτη; 72-86 μτη; 
86-104 μτη; 104-124 μνη; 124-149 μπ\ and > 149 μτη. On a log scale, these classes have 
the same width (multiplication factor 1.2). By fitting a log normal distribution (after 
substracting 60 from the class limits) to these grouped observations, a median colony 
diameter could be calculated per culture plate. The results of soft agar cloning in the 
five treatment groups are compared with the Kruskal-Wallis test on day 8 and day 15 
for the two variables: 
1. the mean number of colonies per culture plate and per animal, 
2. the median colony diameter per culture plate and per animal. 
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6.2.5. Flow-cytometric analysis (FCM) 
The remainder of the cell suspension, not used for soft agar culturing, was fixed in 
ethanol 70% at -20 °C prior to FCM. Flow-cytometric DNA distributions of saline- and 
cytotoxic-treated tumors were compared, with the aid of techniques described elsewhere 
( Alabaster et al., 1978; Hamilton et al.,1980;Tannenbaum et al., 1978). For the staining 
of DNA, mithramycin (SERVA Feinbiochemica, Heidelberg, West Germany) was used 
with chicken erythrocytes as internal controls for each specimen as previously described 
(Tannenbaum et al., 1978). The ethanol was removed by centrifugation and the cells 
were resuspended at a concentration of 3 χ IO6 cells per ml of staining solution (0.1 mg 
of mithramycin per ml of 0.85% NaCl,15 mM MgClj). After 30 minutes' staining in 
the dark at room temperature, the cells were analyzed while still suspended in staining 
solution. 
The analysis was performed by means of an Ortho System 50H (Ortho Instruments, 
Westwood, Mass., U.S.A.) with a PDP 11/34 computer (Digital Equipment Corp., 
Maynard, Mass., U.S.A.) for process control and data storage and analysis. The amount 
of fluorescence per cell is displayed as a DNA histogram. 
6.2.6. Drugs 
Chemotherapeutic doses used in our experiments were approximately LD10 as 
determined from toxicity data in pilot studies. 
- cisdiamminedichloroplatinum (II) (PLATINOLR, Bristol Myers Company, Syracuse, 
New York, U.S.A.), CDDP 3 mg/kg of body weight; 
- cyclophosphamide (ENDOXA№\ Asta Werke A.G., Bielefeld, West Germany; 
CTX), 90 mg/kg of body weight; 
- diamminemethylcyclohexane sulfate platinum (II); TNO-6, (NSC-311056), 2 mg/kg 
of body weight. 
TNO-6 is a newly developed derivative of cisplatin and was obtained as an injectable 
preparation from Bristol Myers Company International Division (Lenaz 1981). All 
injections were administered intravenously in the dorsal penile vein without previous 
hydration of the animals and under brief ether anesthesia. 
6.2.7. Experimental design 
Eighty male Fl hybrids of the Copenhagen χ Fischer cross matched for age and weight 
were included in the study. Each animal was inoculated subcutaneously in the right 
flank with 0.5 ml of tumor cell suspension (1.2 χ IO6 trypan blue excluding cells per 
animal). 
The animals were randomly assigned to five treatment groups. 
GROUP 1:15* animals treated with placebo injections on days 5 and 19 after 
inoculation of tumor cell suspension. 
GROUP 2: 16 animals treated with CDDP on days 5 and 12. 
GROUP 3: 16 animals treated with TNO-6 on days 5 and 19. 
GROUP 4: 16 animals treated with CTX on days 5 and 19. 
GROUP 5: 16 animals treated with a combination of CTX + CDDP in full doses of 
each drug on days 5 and 19. 
Drug schedules were adapted to predictable weight loss of animals after cytotoxic 
treatment. To exclude tumor reductive effect of weight loss without losing too many 
animals to cachexia, the animals were allowed to regain weight after the first dose of 
chemotherapy. This regaining of weight occurred about seven days earlier in the 
CDDP-treated animals. Therefore, in this group the second drug dose was given on day 
12 rather than on day 19 as in the other groups. 
Retrobulbar blood samples were obtained prior to drug administration and prior to 
One animal was withdrawn from the study prior to treatment. 
autopsy. Hemoglobin, hematocrit, erythrocytes, platelets and white blood cells with 
differential blood count were determined. As from the day of tumor inoculation, body 
weight was measured three times a week. Tumors were measured with micro-calipers, 
and tumor volumes were calculated according to JANIK's method: V = L x W x H x 
0.5236 (Janik et al. 1978). 
A complete autopsy was performed on all animals which had completed 
chemotherapeutic treatment. The animals were sacrificed on average six days after the 
last dose or were found dead in their cages. All lymphatic tissue in axillary, inguinal and 
paralumbar regions bilaterally and in the mediastinum was removed and submitted for 
histologic confirmation of the presence or absence of metastases. 
No attempt was made to measure the total amount of metastatic tissue. The lungs and 
trachea were inflated with Jores I (formaldehyde 40% 50 ml, Carlsbad salt 50 mg, and 
a saturated solution of chloral hydrate 50 ml) and stored in the same solution. 
After macroscopically visible metastatic peripheral lung lesions had been counted, the 
left lung was dissected and evaluated histologically for the presence of peripheral 
(pleural) and central (hilar) tumor metastases. 
6.2.8. Statistics 
A description of the statistical distribution-free procedures used, is given under the 
appropriate headings in RESULTS. If the p-value of the statistical test is less than 0.05, 
the difference is accepted as significant. 
6.3. R E S U L T S 
6.3.1. Effect of cytotoxic treatment on survival of animals 
The survival function of the treated animals was estimated with the KAPLAN-MEIER 
method (Kaplan and Meier 1958), and the survival percentage for day 21 is given in 
table 6.1. The estimated survival functions do not differ significantly between the five 
treatment groups (log rank test: ρ = 0.15). 
6.3.2. Effect of cytotoxic treatment on tumor growth 'in vivó' 
The tumor volume curves in the five treatment groups are compared with a 
distribution-free test (Koziol et al. 1981) appropriate for the detection of ordered 
alternatives of distribution. Comparison with the CDDP-treated group, based on drug 
schedule, was made until day 17. 
Figure 6.1 shows the growth curves of the primary tumors treated with the various 
cytotoxic drugs. Rats treated with CTX, alone or in combination with CDDP (curves 
4,5), showed significantly (p < 0.002) smaller tumors than the saline controls or 
platinum or TNO-6- treated rats (curves 1, 2 and 3) (p < 0.002). Tumor volume was 
not significantly smaller in rats treated with CTX plus CDDP compared with rats 
treated with CTX alone ( ρ < 0.05). Except for one animal, the tumor volumes in the 
combination group did not exceed 10 cm3. No significant difference was noted between 
the inhibitory effect of CDDP and TNO-6 compared to the saline-treated animals 
(curves 1, 2 and 3). 
The same statements are possible for the comparison in tumor volume growth curves up 
to day 24 (only CDDP has not been considered in this comparison). Eight of the 16 
CTX-treated animals showed decreasing tumor growth after initial growth, while one 
of the animals had no tumor growth at all. Of the 16 CTX + CDDP-treated animals 
six animals showed decreasing tumor size after initial growth, and two animals showed 
disappearance of the tumor after initial growth. 
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TABLE 6.1 Effect of chemotherapeutic treatment on survival of animals 
Treatment 
groups 
l.SALINE 
2. CDDP 
3. TNO-6 
4. CTX 
5. CTX + 
CDDP 
Number of 
animals 
15 
16 
16 
16 
16 
Died in 
cage on 
day 
15,17,17 
11 
19,20,22 
22 
21,24,24 
13,14,15 
Sacrificed 
because of 
poor condi-
tion on day 
22,22 
Died due to 
technical 
failure 
on day 
19a 
1 9 b 
Animals surviving 
the experiment 
sacrificed 
on day 
21;23 (N = 5) 
18 (N = 8), 19;20 
20;21 (N =4) 
22;23(N = 11) 
23 (N = 13) 
23 (N = 10) 
Estimated % 
survival 
day 21 
0.73 
0.94 
0.88 
0.94 
0.68 
)a Overdose of ether 
)b Died during blood sampling 
6.3.3. Effect of cytotoxic treatment on metastases 
Lymph node metastases 
Figure 6.2 shows the percentage of lymph node metastases. Sixty animals in which a 
complete survey of the lymphatics was possible were considered. The greatest loss of 
animals for examination of lymphatic material occurred in the saline treated animals. 
When these animals died in cage overnight, mostly of enormous tumor growth, they 
were partially eaten by the other rats. Complete autopsy was therefore not possible. 
Similarly, some loss of animals occurred in the other groups. 
Inguinal lymph node metastases were seen only in the saline and TNO-6- treated 
animals. Ipsilatcral inguinal nodes present in the TNO-6 and saline-treated animals 
were the result of local tumor extension. Significantly fewer axillary lymph node 
metastases were present in the CDDP, CTX and CTX + CDDP-treated animals 
(chi-square test, right axillary ρ = 0.0002 and left axillary ρ = 0.002) compared to the 
saline and the TNO-6 group (table 5.2). 
In the CTX + CDDP group, five of the ten animals (50%) were free of lymph node 
metastases. In the CTX-treated animals four of the fourteen animals were free of lymph 
node lesions. In the CDDP group four of the fourteen animals (29%) were free of 
metastatic lesions in the lymph nodes. In the saline and the TNO-6-treated animals, all 
animals had metastatic tumors in the lymph nodes. 
Median tumor volume 
( c m 3 ) 
Τ™!"™!-™1"Τ^ ™Τ~™Τ™™Γ" I I I T™T—~Ι"T™T™~I~T~~!—"Π""!-Τ 
4 8 12 16 20 24 
Days post tumor inoculation 
1=1.2,3,4,5 1=2 1=1,3,4,5 
Fig 6 1 
Effects of two courses of chemotherapy on MATLyLu tumor growth 'm vivo' compared to a saline-treated 
group; median tumor volumes for the different treatment groups 
Tumors were implanted on day 0 and the two chemotherapy courses were given on days 5 and 19, except 
CDDP, which was given on days 5 and 12 (see text) 
η - number of animals 
administration of cytotoxic drug or saline. 
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Lung metastases 
Figure 6.3 shows the percentage of lung metastases (55 animals). In 24 animals, 
complete lung examination was not possible for reasons noted above. 
Although relatively few lung autopsies were possible in the saline group, all animals 
autopsied had metastatic lesions in the lung. In the TNO-6-treated animals, almost the 
same percentage of spread to the lungs was found. Not only were fewer lung metastases 
found in the CTX + CDDP group and the CTX group, but the lung lesions were much 
smaller than in the other therapy groups. (Figs. 6.4 A-B, 6.5). In the animals treated 
with combination chemotherapy, only 33% had microscopic pleural lesions. No hilar 
lesions were noted. Six of the nine (67%) CTX + CDDP-treated animals had no lung 
lesions at all. Ten of the thirteen animals (77%) treated with CTX had no lung 
metastases. 
Statistical analysis revealed a significant difference in lung metastases between the 
saline and the TNO-6 treated animals on the one hand and the CTX and CTX + 
CDDP-treated animals on the other hand,while the CDDP-treated animals occupy an 
intermediate position (chi-square test, table 5.3). 
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Fig 6.2. 
Effect of cytotoxic treatment on lymph node metastases in the MATLyLu prostatic tumor in the rat. 
For 3 + 1 , four bar graphs are shown, for 2,4 + 5 only three, because in the latter three groups 
(CDDP,CTX and CTX + CDDP) no inguinal metastases were found. 
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Fig. 6.3. 
Effect of cytotoxic treatment on lung metastases in the MATLyLu prostatic tumor in the rat. For groups 
1,2,3 and 4 three bar graphs are shown, for group 5 (CTX + CDDP) only one, because in this group only 
microscopic pleural metastases were found. 
6.3.4. Cure 
Cure was defined as absence of gross or histologic evidence of tumors at autopsy. Both 
in the CTX and in the CTX + CDDP groups one animal was totally cured of its 
anaplastic tumor (1/9 and 1/13 respectively). Both animals were sacrified on day 26 in 
good condition. 
6.3.5. Toxicity 
As expected with the use of cytotoxic drugs, myelosuppression occurred in our 
experiments. We calculated the ratio of blood values obtained just before autopsy to the 
initial blood values prior to chemotherapy (ratio E/S; E = end value, S = start value). 
An overview of peripheral blood counts is shown in tables 6.2 and 6.3. Except for the 
lymphocytes, the difference in initial values between the treatment groups was not 
significant. 
Mild anemia was noted in all groups of animals including the saline-treated animals. 
The decrease of platelets was obvious in the TNO-6 group and mild in the other groups. 
The reduction of leukocytes was marked in the CTX and CTX + CDDP treated 
animals, while relative leukocytosis was present in the other groups, possibly due to 
necrosis in a rapidly growing tumor, since infections were not seen in these animals. 
The differential blood count showed a decrease of neutrophils and lymphocytes in the 
CTX and the CTX + CDDP group. 
In a pilot study, considerable weight loss was noticed in a group of non-tumor-bearing 
Fl rats, treated with the same chemotherapy schedules as used in this study. Drug 
schedules in our experiments, as mentioned earlier, were adapted to this predictable 
weight loss. All animals were able to regain weight after the first dose of chemotherapy, 
minimizing a possible tumor-reductive effect of loss of body weight. As the CDDP-
treated animals did not show significant weight loss, this drug could be administered at 
shorter intervals. 
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Fig.6.4. 
Macroscopic appearance of whole lung. 
A: control inflated lungs 
B: lungs with focally distributed pleural metastases. 
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Fig.6.5. 
Lung with extensive and confluent metastases (terminal stage) 
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TABLE 6.2 Differential blood count in the treatment and control groups 
Group 
l.SALINE 
2. CDDP 
3. TNO-6 
4.CTX 
5. CTX + CDDP 
Kruskal-Wallis test 
(overall comparison^ 
Wilcoxon testsb 
(paired comparison) 
Mean ratio3 
SD 
N 
Mean ratio 
SD 
N 
Mean ratio 
SD 
N 
Mean ratio 
SD 
N 
Mean ratio 
SD 
N 
I 
Leukocytes 
3.67 
1.69 
8 
1.95 
1.24 
15 
3.00 
1.71 
13 
0.18 
0.20 
14 
0.13 
0 09 
10 
p < 0.0001 
5 4 2 3 1 
Neutrophils 
8.26 
4.07 
7 
4.47 
2.62 
15 
9.84 
9.89 
10 
0.22 
0.23 
14 
0.22 
0.22 
10 
p<0.0001 
5 4 2 3 1 
Lymphocytes 
1.63 
0.77 
7 
1.46 
1.21 
15 
0.46 
0.20 
10 
0.13 
0.10 
14 
0.10 
0,08 
10 
p < 0.0001 
5 4 3 2 1 
) a ra l io^ E = blood value prior to autopsy 
S S = initial blood value prior to chemotherapy 
) b Group numbers above the same bar are not significantly different from each other and are ordered 
byincreasing mean rank number 
TABLE 6.3 Peripheral blood count in treatment and control groups 
Group 
l.SALINE 
(N = 8) 
2. CDDP 
( N = 1 5 ) 
3. TNO-6 
(N = 13) 
4. CTX 
(N = 14) 
Mean ratio3 
SD 
Mean ratio 
SD 
Mean ratio 
SD 
Mean ratio 
SD 
5. CTX + CDDP Mean ratio 
(N = 10) SD 
Kruskal-Wallis test 
(overall comparison) 
Wilcoxon testsb 
(paired comparison) 
Erythrocytes 
0.73 
0.23 
0.80 
0.20 
0.58 
0.13 
0.75 
0.09 
0.78 
0.12 
ρ = 0.004 
3 1 4 5 2 
~ " 
Hemoglobin 
0.75 
0.18 
0.82 
0.18 
0.62 
0.13 
0.78 
0.10 
0.80 
0.11 
ρ = 0.008 
3 1 4 5 2 
Hematocrit 
0.78 
0.17 
0.84 
0.16 
0.65 
0.13 
0.79 
0.09 
0.81 
0.10 
ρ=0.006 
3 1 4 5 2 
Platelets 
0.66 
0.20 
0.68 
0.20 
0.48 
0.27 
0.76 
0.30 
0.95 
0.82 
p = 0.13 
) a ratio_£ E = blood value prior to autopsy 
S S = initial blood value prior to chemotherapy 
) b see table 6 2 
6.3.6. Soft agar clonogenic cell culture 
Fifty-three tumors were suitable for Ίη vitro' culturing. The other tumors could not be 
used because of partial destruction and infection. In the CTX and the CTX + CDDP 
group respectively, one and two animals showed no tumor growth at all in soft agar. 
In the group of animals treated with CTX + CDDP, the total number of colonies and 
the median colony diameter per plate were significantly smaller than in the other 
treatment modalities (figures 6.6. and 6.7). On average, the TNO-6 and the 
CTX-treated animals showed fewer colonies in their cultured tumors compared to the 
CDDP and saline groups, but this difference was not statistically significant. On day 15 
there was no significant difference in the median diameters of the colonies between the 
TNO-6, CDDP and CTX groups. Compared with these three groups, the saline group 
had larger colonies on day 15 and the CTX + CDDP group had significantly smaller 
colonies than the other groups. 
Number of colonies per plate 1 
500 
Д00 
300 
200 
100 
0 
8 15 
Days in culture 
5 Д 3 2 1 5 Д 3 2 1 
(p=0.02) (p = 0.004) 
Fig.6.6. 
Effect of chemotherapy on median number of tumor cell colonies per soft agar cultured plate. 
1 = saline, 2= CDDP, 3= TNO-6, 4 = CTX, 5= CDDP. 
Group numbers above the same bar are not significantly different from each other and are ordered by 
increasing mean rank number. 
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* 5 
Diameter of colonies per plate 
300η 
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200-
150-
100-
50 
if/ / 
u/t / 
•V / 
0^-
if' ' 
!" / 
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Hf / 
8 
(p = 0.10) 
15 
Days in culture 
52 U 31 
(p=0.005) 
Fig, 6.7. 
Effect of chemotherapy on median diameter of colonies per soft agar cultured plate. 
1 = saline, 2 = CDDP, 3= TNO-6, 4 = CTX, 5= CTX + CDDP. 
Group numbers above the same bar are not significantly different from each other and are ordered by 
increasing mean rank number. 
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CYTOTOXIC DRUG EFFECTS ON THEMATLyLu 
PROSTATIC TUMOR IN VIVO AND IN VITRO 
% G2M 
MEDIAN DIAMETER 
250-1 CELL COLONIES 
SALINE Ш CYCLOPHOSPHAMIDE 
TNO-6 Ш CYCLOPHOSPHAMIDE • CISPLATIN 
CISPLATIN 
Fig. 6.8. 
Summarizing results of tumor measurements 'in vivo', growth potential of residual tumor 'in vitro' and PCM 
analysis of cytotoxic-treated tumor cells show that the smallest tumor volume, the smallest median diameter 
of colonies in soft agar culture, the lowest percentage of G1 tumor cells and the highest percentage of G2 
tumor cells are seen in the CTX + CDDP-treated animals. 
6.3.7. Flow-cytometric analysis 
Results of our flow-cytometric studies are summarized in table 6.4. As a mean criterion 
for evaluating drug action on changes in DNA synthesis, we used the ratio of percentage 
of tumor cells in the G2M (mitosis) phase of the cell cycle to the percentage of tumor 
cells in the G1 phase of the cell cycle. This ratio was chosen to minimize the effect of 
variable numbers of normal Gl cells in the treated tumors (stroma, capsule). 
Table 6.4 shows the ratio of tumor cell % G2M/% Gl χ 10 in the different treatment 
groups. The ratio showed significant differences between the five treatment groups 
(Kruskal-Wallis test, ρ < 0.0001). On paired comparison (Wilcoxon tests), it appeared 
that there is a significant difference (p< 0.05) between the saline and the TNO-6 group 
compared to the CTX, CDDP and the combination groups. 
In addition, these were significant differences between the CTX, the CDDP and the 
combination groups. 
The saline and the CTX-treated animals showed only a slight difference in the number 
of cells in the S-phase. 
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6.3.8. 'In vivo'- 'in vitro' correlations 
The results of tumor measurements Ίη vivo', cell growth of residual tumor 'in vifro', 
and flow cytometric analysis are summarized in figure 6.8. This figure shows that the 
smallest tumor volume, the smallest median diameter of colonies in culture, and the 
lowest percentage of Gl and the highest percentages of G2M tumor cells were seen in 
the tumors treated with the combination of CTX and CDDP. 
6.4. DISCUSSION 
In the last 30 years prostate cancer in man has been treated with surgery, radiotherapy, 
hormones or combinations of these modalities. Most patients with prostate carcinoma 
in early stages will be curable as is the case with other tumors. 
Whitmore (1973) estimated that 40% or more of patients in whom prostate cancer is 
first diagnosed, have lymphatic and/or hematogenous spread. Thus, attention has been 
directed to both early detection of prostate cancer and improvement of the treatment of 
advanced prostate cancer. Distant metastases can be cured only with chemotherapy. 
Since 1973, cytotoxic drugs in prostate cancer have been systematically studied in 
clinical trials (Murphy 1979). So far, the results of these trials have shown that 
cyclophosphamide has more subjective and objective effects on patients with prostate 
cancer than other drugs (Javadpour 1982). CDDP has been investigated in patients with 
high-stage, high-grade prostatic carcinoma (Beckley et al. 1980, Merrin and Beckley 
1979). However, the absence of well-defined parameters for tumor growth and 
metastatic lesions prevents further progress in the adequate application of chemotherapy 
in prostate cancer in man. 
An ideal animal model for prostatic carcinoma does not yet exist (Handelsman 1977). 
The transplantable DUNNING R 3327 MATLyLu prostatic tumor in the rat is a 
well-defined and suitable model (Isaacs et al. 1981), which, except for the absence of 
bony metastases, reflects the course of anaplastic prostate cancer in man. 
Chemotherapeutic studies in animal models of prostate cancer are scarce. Drago (1980) 
found that CTX produced marked reduction of tumor in the androgen insensitive PR 
A I - II Noble rat. In the same model system, triple drug therapy induced more reduction 
of metastases as well as permitting complete remission in more cases (Drago and Worgul 
1981). Block (1977) tested cytotoxic drugs in the DUNNING R 3327 G tumor, finding 
CTX + ADM to be effective in tumor reduction but at the cost of high toxicity. 
Kadmon (1981) studied different therapy modalities (chemotherapy, surgery, and a 
combination of surgery and chemotherapy) in the MATLyLu tumor model, and found 
that surgery and adjuvant chemotherapy with CTX were most effective in controlling 
local tumor growth and metastatic disease. 
Although Ίη vivo" growth of tumors can be manipulated by cytotoxic drugs, 
measurements by the caliper method give only an impression of tumor reduction. 
Regression of tumor after chemotherapeutic treatment provides no information about 
the viability of residual tumor cells. However, this viability in treated tumors can be 
determined by means of cell culture systems (Herman et al. 1983a,b). In our model 
system, we found analogous results during Ίη vivo1 and Ίη vitro" studies. Significant 
reduction in the number of tumor colonies formed 'in vi'iro' is a condition for viability 
reduction caused by cytotoxic drug action on the tumor. This inhibition of tumor growth 
finds its expression in the colony growth curves (Kirkels et al. 1983). 
The present study on the MATLyLu tumor combines evaluation of 'in vivo' and 'in 
vitro1 parameters to assess chemotherapeutic efficacy. A combination of CTX and 
CDDP was shown to produce the greatest therapeutic benefit. 
In general, this combination in full additive doses produced marked reduction of tumor 
load with the greatest reduction of proliferative potential of the remaining tumor cells, 
as assessed by means of soft agar culturing and fiow-cytometric analysis of post-therapy 
persistent tumors. Overall toxicity of the combination was not significantly greater than 
that of the drugs used alone as judged from survival of the animals, although 
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TABLE 6.4 Flow-cytometric analysis of tumor kinetics in different reatment groups 
compared to a control group (saline). 
Treatment 
l.SALINE 
2. CISPLATIN 
3. TNO-6 
4. CYCLOPHOSPHAMIDE 
5. CYCLOPHOSPHAMIDE 
+ 
CISPLATIN 
Kruskal-Wallis test 
Wilcoxon tests b) 
(paired comparison) 
Ratio %G2M/% Gl 
xlO 
X SD 
1.5 0.3 
2.0 0.3 
1.5 0.2 
4.0 1.4 
8.2 5.6 
p < 0.0001 
1 2 3 4 5 
S-PHASE 
X 
12.9 
14.9 
14.4 
17.0 
15.4 
p= 0.01 
1 2 5 3 4 
SD 
0.8 
1.9 
2.8 
2.1 
2.8 
N 
6 
15 
12 
13 
7 
b)Refer to table 6.2 
significantly more leukopenia was caused by the combination and by CTX alone 
compared with CDDP alone. A less than additive effect was seen when CTX alone was 
compared with CTX + CDDP, except for the reduction in number of soft agar colony 
forming units (synergistic, figure 6.6) and the median diameter of tumor colonies formed 
(approximately additive, figure 6.7). 
As expected, full doses of platinum add virtually no hematologic toxicity to the CTX 
effects (tables 6.2 and 6.3). The reduction of proliferative potential of the tumor may 
be entirely due to the synergistic blockade of tumor cells in the G2M phases of the cell 
cycle. 
Our findings with FCM indicate that combinated chemotherapy is effective in inhibiting 
cell division. In this group, blockade of cells in the G2M phase of the cell cycle with 
consequent accumulation of cells in the G2M phase occurs. Since the S-phase 
percentage is the same in all groups, the increased G2M/G1 ratio indicates a block in 
cell proliferation rather than an increased proliferation rate. 
Extrapolation of the results of this animal model to the human situation is difficult even 
if we consider only timing of administration of chemotherapy. Moreover, most patients 
treated with cytotoxic agents have stage-D disease and have already been treated with 
various other modalities (hormones, radiotherapy). Earlier treatment especially with 
cytotoxic drugs alone or in combination with surgery or hormones has to be considered 
in patients with anaplastic carcinoma of the prostate. 
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Chapter 7 
CYTOTOXIC TREATMENT OF THE MATLyLu PROSTATE 
TUMOR. 
MULTIPARAMETER EVALUATION OF RESIDUAL TUMOR 
CELLS IN A DOUBLE LAYER SOFT AGAR SYSTEM WITH THE 
OMNICON AUTOMATED TUMOR COLONY COUNTER 
7.1. INTRODUCTION 
In addition to a few reliable animal models in prostate cancer (Noble and Hoover 1975, 
Pollard 1973, Dunning 1963), Ίη vitro" systems have a recognized potential value for 
the study of prostate cancer (Merchant 1976). 
The cultivation of prostatic tumor cells was described as early as 1917 by Burrows et al., 
using the hanging drop technique. As with the reliable animal models, no significant 
studies on prostatic cells cultured Ίη vitro' were mentioned until the late sixties (Kaighn 
1980). Despite the potential limitations of short-term culture (Williams 1980), the two 
layer soft agar culture developed by McPherson and Montagnier (1964), and modified 
by Hamburger and Salmon(1977), provides new sources of data to experimental and 
clinical oncology. This short-term culture system has been most extensively used as an 
'in vίtro, system for testing chemotherapeutic sensitivity and resistance of tumor cells 
analogously to the sensitivity testing for antibiotics in patients with bacterial infection 
(Salmon et al. 1978, Selby et al. 1983, Lieber and Kovach 1981, Von Hoffet al. 1981). 
The semisolid agar culture suppresses the growth of most normal cells (McAllister and 
Reed 1968, Montagnier 1971, McPherson and Montagnier 1964). More colonies per 
dish can be grown in agar than in monolayer while seeding of daughter colonies from 
the initial colonies is prevented (Courtenay 1976). 
Hypothetically, colonies in soft agar develop from a sub-population of cells, which have 
been termed colony-forming units (CFU). These 'stem' cells may be the population of 
tumor cells responsible for the expansion and metastatic spread of a malignant tumor 
(Niel et al. 1982), and thus would form the primary target for any cytotoxic therapy of 
cancer (Selby et al. 1983, Stanisic and Buick 1980). 
Measurements of growth parameters and even reliable colony counts Ίη vitro1 depend 
mostly on rather inaccurate and time-consuming manual counting procedures (Herman 
et al. 1983a, Kressner et al. 1980). Shortly after the introduction of the soft agar cloning 
system, an automated tumor colony counter was developed (Kressner et al. 1980), the 
OMNICON system (Bausch and Lomb Inc., Rochester). 
This colony counter provides reproducible information not only on the number of 
colonies but also on the size distribution of colonies. 
The first objective of this study was to establish an Ίη vitro' system for the MATLyLu 
tumor to evaluate residual tumor cell growth after 'in vivo' cytotoxic treatment. This 
post-therapy evaluation of a persistent tumor has also been suggested for clinical 
oncology (Herman et al 1983b). A second objective was to evaluate the reproducibility 
and accuracy of the OMNICON system for this animal model and to establish a 
statistical model for quantification of two parameters (number of colonies, size of 
colonies) of Ίη vitro1 growth. The qualitative characteristics of the MATLyLu tumor 
cells Ίη vitro1 were discussed in chapter 4. 
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7.2. MATERIALS AND METHODS 
Concerning the animals, tumors and the preparation of monodispersed cell suspension, 
the material and methods were described in chapter 6. 
Tumor maintenance, tumor inoculation and the cytotoxic drugs used in the '/я г о' 
experiments were described in chapters 5 and 6. 
The overall Ίη vivo'-'in vitro1 correlations were presented in chapter 6. 
7.2.1. Statistical methods 
Short-term growth of tumor cells in a two layer soft agar system was analyzed one week 
and two weeks after initial seeding of cell samples in culture dishes. At these two time 
points, the OMNICON automated colony counting system was used for evaluating the 
number of colonies and for colony diameter measurements. 
The culture dishes were counted twice in succession. 
A colony of tumor cells is defined as a spherical three-dimensional cellular aggregate 
with smooth borders containing at least 30 cells (Herman et al. 1983a). 
We shall describe the growth process by means of two variables at each time point, the 
number of colonies (N), and the median diameter of the colonies counted (D). 
7.2.2. Omnicon counting process 
The theoretical and operational use of the automated colony counting has been described 
by Kressner et al.(1980). We used the same evaluation as described by Herman et 
al.(1983a). In short, the OMNICON divides a culture dish into 35 counting fields. By 
means of an image analysis system, colonies are recognized and their diameter is 
measured. In some fields, the counting process does not succeed if the total density of a 
field is too high due to contamination or clumps. These fields are noted as rejected fields 
and the number per dish is denoted by D . The diameter measurements of the tumor 
colonies are grouped according to classes of which the class limits can be chosen by the 
user. In this study, we had to deal with class limits used for human tumors. A survey of 
the counting process is given in table 7.1. 
The number of colonies in 35 fields is calculated as: 
Ν = M — ^ 1 — = 1 2 
'
 l 3 5 - n
r e i " ' '
Z 
(M, is the unstandardized and N, the standardized number of colonies growing in a 
culture dish). 
Calculation of the two growth parameters, i.e. number of colonies and median colony 
diameter, is most efficiently done by adding the counting results for the two dishes as is 
illustrated in table 7.1. 
The total number of colonies (N) per 35 Fields (one dish) is calculated as follows: 
N - M ' + M 2 χ35 = 3 5 χ Μ 
( 3 5 - n
r e j l ) + (35-n r e j 2 ) 70-n r e j 
In calculating the median diameter, we were faced with the rather peculiar fact that 
>50% of the colonies were grouped in the highest size class (diameter > 149 μιη ). So, 
only censored observations were available for far more than half of the diameter 
measurements. This forced us to calculate the median diameter within a parametric 
statistical model. Noting that the class limits have an equal distance on a logarithmic 
scale (multiplication factor 1.2, table 7.1) and having available the computer program 
CENSOR (Meeker and Duke 1980), we decided to calculate the median diameter and 
to perform the statistical analysis within each of the three parametric models: the 
distribution of a colony diameter within a dish can be described by (1) a log normal 
distribution, (2) a loglogistic distribution, and (3) a Weibull distribution. Before fitting 
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TABLE 7.1. Description of the OMNICON counting results 
size of diameter number of colonies 
class dishl dish 2 dish 1 + dish 2 
60 - 72 μπι 
72 - 86 μπι 
86- 104 μπι 
104- 124дт 
124- 149 м т 
ml 
т 2 
т З 
т 4 
т 5 
т Ц іП| = mij + т І 2 
т22 пц — т 2 | + т22 
т32 т з = тЗ] + т32 
т42 т4 = т 4 1 + і г ^ 
m52 vn¡ = mSj + m52 
> 149 д т 
TOTAL 
Number of rejected fields 
т б , 
Ml 
" r e j 1 
m62 
M2 
n
r e j2 
m6 = тб, + тб2 
M = Ml + M2 
n
re j = n rej 1 + n rej 2 
Table 7.2. Compilation of the 'in vitro' colony counting (number and median diameter) 
specified for the 'in vivo' tumor treatments 
In vivo treatment 
1 = saline 
2 = CDDP 
3 = TNO-6 
4 = CTX 
5 = CTX + CDDP 
Kruskal-Wallis test 
Wilcoxon tests* 
(paired comparison) 
No.animals 
5 
12 
13 
10 
8 
Number of colonies 
for median animal 
day8 
376 
362 
248 
268 
45 
p=0.02 
5 4 3 2 1 
day 15 
473 
451 
280 
258 
41 
p=0.004 
5 4 3 2 1 
Median diameter 
for median animal** 
day 8 
191 
160 
185 
173 
119 
p=0.12 
day 15 
221 
178 
203 
196 
152 
ρ = 0.008 
5 2 4 3 1 
* Group numbers lying above the same bar are not significantly different from each other and are ordered 
by increasing mean rank number. 
** Weibull model 
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TABLE 7.3. Distribution of the coefficient of variation between two dishes as a pair for 
the number of colonies (N) and the median diameter (D) (pairs of dishes = 89) 
Coefficient of variation cumulative frequency 
Number (N) median diameter (D) 
- 1% 
- 5% 
- 10% 
-20% 
-40% 
-60% 
12.4% 
43.8% 
64.0% 
86.5% 
98.9% 
100 % 
12.4% 
33.7% 
57.3% 
79.8% 
94.4% 
98.0% 
Median coefficient of variation 8 % 6 % 
TABLE 7.4. Occurrence of rejected fields according to the number of colonies 
Number of colonies Number of dishes Mean number of % of dishes 
rejected with N rej>0 
fields 
- 100 40 
100-200 25 
200 - 300 43 
300 - 400 28 
400 - 500 22 
500 - 600 11 
600-700 12 
700 - 800 2 
0.1 
0.04 
0.1 
0.3 
2.2 
1.2 
5.3 
2.5 
5% 
4% 
14% 
25% 
36% 
45% 
75% 
50% 
120 
the model to the data by means of CENSOR (Meeker and Duke 1980), one must 
subtract 60 (the lower value) from the calculated colony diameter. 
Subsequently, the program calculates the median value and then we add 60 to this value 
to arrive at the proper result. 
It turns out that among these three models the Weibull model fits the data in this study 
best (in seven out of eight cases the fitting of the Weibull model was satisfactory). 
Fortunately the result of the calculation of the median diameter was only slightly 
affected by the model used. Besides, for the cases with fewer than 50% of the colonies 
in the highest class, the median diameter calculated with the Weibull model was very 
close to the corresponding median diameter based on the polygonal cumulative sample 
distribution function (standard procedure). 
So the calculation of the median diameter seems to be rather suitable for the model used 
and the results seem quite valid. Consequently, the results of the statistical analyses with 
respect to the comparison of the treatment groups (the ultimate goal of the Ίη vitro" 
study) were the same, independently of the model used. We shall merely present the 
results of the statistical analysis as far as the colony diameter is concerned for the 
Weibull model. 
7.3. RESULTS 
The results of the residual growth capacity of MATLyLu tumor cells in the different 
treatment groups were mentioned in chapter 6. A brief summary will follow here. 
The total number of colonies and the median diameter of colonies in the different 
treatment groups are shown in table 7.2. The five treatment groups are compared by 
means of the Kruskal-Wallis test. If this test shows significant results (p < 0.05), then 
each pair of treatment modalities is compared by means of Wilcoxon tests in order to 
describe more detailed differences between the treatment groups. 
Figures 6.6. and 6.7. show the differences between the 'zw vivo' treatment modalities on 
residual growth capacity 'in vitro1. The two parameters for measurements 'in vitre? are 
the total number of colonies and the median diameters of the colonies. 
The combination therapy CTX + CDDP resulted in the lowest number of colonies on 
both days 8 and 15 of the 'in vitro1 culture. 
With this treatment as well as with the treatment with CTX alone, the number of 
colonies did not increase from day 8 to day 15. 
The treatment with CDDP resulted in only a minor reduction in number of growing 
colonies on days 8 and 15. 
In addition, the diameter of the colonies formed on days 8 and 15 is smallest in the CTX 
+ CDDP-treated group. Note that the increase in diameter from day 8 to day 15 is 
relatively high in this combination group. 
The treatment with CDDP resulted in reduction of the diameter of colonies. 
7.4. STATISTICS (Error discussion) 
Fitting of the Weibull model 
Fitting of the Weibull model is illustrated in figures 7.1 and 7.2 for case no 70 (a 
TNO-6-treated animal). For illustration, the upper limit of the colony diameter is set 
at 400 д т . 
For the 23 cases with less than 50% of the colony diameter in the upper class, the mean 
difference of the median diameter calculated within the Weibull model and the 
distribution-free calculated median value is 1.7 μιη (mean absolute difference). 
The standard deviation of the absolute difference is 1.4 μιη. As the median diameter for 
the cases is generally over 100 μιη, the differences between the estimated median within 
a model or the distribution-free calculated value is less than 5% for the tumor colonies 
in this study. 
3.00 η 
2.50-
2.00-
1.50-
1.00-
0.50-
0.00 
л < J i t ЭІГ 1 U U l Ю П 
Rat :70 
Day : 8 
Number of colonies : Д65 
( P 5 0 = 2 3 6 ) 
x ' ' ~ 
/ 
4 h—' 1 
ц — 
""• · · ^ 
1 — ι 1 1 1 r 'J— l ' I 1 1 1 
5 0 9 0 130 170 210 2 5 0 2 9 0 330 370 
Diameter of c o l o n i e s ( / J ) 
Fig.7.1. 
Weibull distribution for calculation of the median diameters of tumor colonies in soft agar as measured by 
the automated colony counter (OMNICON). More than 50% of the colonies were grouped in the highest size 
class (diameter > 149дт). The censored data in this group were measured with a parametric model. Rat 70 
was treated with TNO-6, total number of colonies counted: 465, median diameter (P50) : 236 μπ\ on day 8. 
W e i b u l l d i s t r i b u t i o n 
3.00 π 
2 . 5 0 -
2 . 0 0 -
1.50 
1.00 
0.50-1 
0.00 
Rat : 70 
Day : 15 
N u m b e r of colonies : ¿,99 
( P 5 0 = 191) 
ι Γ Ί Ì I I I I I I I I I I I I I г 
50 9 0 130 170 210 2 5 0 2 9 0 330 370 
D i a m e t e r of c o l o n i e s (/J ) 
Fig.7.2. 
Weibull distribution for calculation of the median diameter of tumor colonies in soft agar as measured by the 
automated colony counter (OMNICON). 
Same calculations as in fig. 7.1. now for day 15. 
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Coefficient of variation between the two paired dishes 
The variation between the two dishes counted on the scheduled days with respect to the 
number (N) and the median diameter (D) of the colonies is expressed in the coefficient 
of variation. The distribution of this coefficient of variation over the two successively 
counted dishes is presented in table 7.3. 
One might expect that these calculated coefficients of variation depend on the number 
of rejected fields within a pair of dishes. However, there was no indication of such a 
relationship. 
Rejected field and number of counted colonies 
The number of rejected fields in a dish-counting procedure was always less than 20, and 
only occasionally were more than five rejected fields noted. 
We grouped the dishes according to their number of colonies (N) and calculated in each 
class the mean number of rejected fields (n
r e
 ) and the percentage of dishes in which at 
least one rejected field occurred (n
r e j > 0). 
It could be shown that with an increasing number of colonies the chance of at least one 
rejected field occurring increased. This might imply that, in dishes with a larger number 
of colonies, both number of colonies and median diameter of colonies may be 
underestimated (table 7.4). 
7.5. DISCUSSION 
The use of the OMNICON automated colony counter in the 'in vitro1 culture system 
with the MATLyLu tumor indicates that significantly more information can be derived 
from the system than is possible with manual counting. In addition, the reproducibility 
of this system has been shown to be higher than that of manual colony counting 
(Herman et al. 1983a). 
The median coefficient of variation (C V) for paired counts of dishes plated with 
MATLyLu tumor cells is 6% for the number of colonies and 8% for the median diameter 
of colonies. 
These figures are slightly better than the findings in human cultures but they fully 
confirm these data (Herman et al. 1983a). 
The finding that the coefficient of variation does not change markedly with the number 
of rejected fields within the paired dishes underlines the accuracy of the interpretation 
of colony formation. 
Contrary to the colony counting and size distribution in human cell cultures, more than 
50% of the tumor cell colonies of MATLyLu tumors are counted in the last category 
( > 149 μιη). The overall median diameter was therefore estimated with a parametric 
model. This is the first time that a statistical model described in the literature is now 
suitable for experimental models with sufficient growth capacity in two layer soft agar 
in relation to the diameter of colonies. 
Solid malignancies are built up of structurally and functionally heterogeneous 
populations of cells (Stanisic and Buick 1980). 
Only a small sub-population of tumor cells ('stem' cells) with self-replication ability is 
responsible for tumor growth 'in vivo'. This cell population forms colonies (i.e. is 
clonogenic) in a semisolid culture medium (McKillop et al. 1983, Park et al. 1971, Steel 
1977). For the evaluation of the soft agar culture results, it is essential to make some 
critical remarks concerning the interpretation of the cells that are growing and of the 
possible influence of a diversity of factors on the growth pattern of cells. 
1. Disaggregation techniques vary in producing single (viable) cell preparations from 
one experimental tumor system to another (Waymouth 1974). In our system we used 
only collagenase and retained sufficient numbers of cells with a plating efficiency of 
nearly 7%-8% (350-400 colonies after plating of 5,000 cells). 
Clumps of tumor cells were rarely seen. This is an ideal situation, commonly seen in 
experimental models and tumor cell lines. Enzymatic disaggregation in place of 
mechanical procedures has also been suggested for use in human tumors (Hamburger 
et al. 1982, Pavelic et al. 1980). The plating efficiency is often much lower in human 
tumors than in experimental ones: 0.005-0.1% (Buick et al. 1979, Hamburger and 
Salmon 1977,Selby et al. 1983). 
Furthermore, we have to consider that disaggregation causes damage to the cells as a 
second 'cytotoxic' treatment (Selby et al. 1983, Rasey and Nelson 1980). This 
interaction could be specific for the drug used, but little is known about this 
phenomenon. Fragile tumor cells, too, are probably excluded from growth when the 
disaggregation technique is used as is suggested for the microscopic defined 'large' cells 
of the MATLyLu tumor (chapter 4). 
2. The diversity of culture media points to the fact that extensive work has to be done 
to define the specific optimal medium with additives for a specific (group of) tumor(s) 
(Hamburger 1981). 
3. Clonogenic cells with a doubling time of a few weeks would not be recognizable as 
colonics in the culture dish (Lieber and Kovach 1981). 
4. It is essential to distinguish between the denotation stem cells 'in vivo' and clonogenic 
cells 'in vitro' (Buick et al. 1980). Hypothetically, the capacity of cells to form colonies 
'in vitro' could indicate that these cells are 'stem' cells, the most important cells within 
a tumor (Bruce et al. 1966, Park et al. 1971, Steel 1977). 
In tumor biology, stem cells are cells with a capacity for self-renewal on the one hand 
and for initiation of the growth of a large number of descendant transitional cells and 
end cells on the other hand. Some stem cells will proliferate only under specific 
environmental conditions (Buick et al. 1979, Selby et al. 1983), (figure 7.3). 
Discrimination between colonies produced by stem cells and small abortive colonies is 
obvious (Selby et al. 1983). These small colonies are probably built up from transitional 
cells. Transitional cells develop out of stem cells and are non-renewable cells (McKillop 
et al. 1983). Plating efficiency could be overestimated. 
In our studies with the MATLyLu tumor, we found evidence that a selected 
('intermediate') type of cell remained in both the end stage of solid tumor growth and 
'in vitro' (chapter 4). 
However, the probably more fragile clonogenic cells ('large-sized') may not only be 
vulnerable to disaggregation procedures but may also require a more sophisticated 
culture medium and, therefore, will not be recognized as stem cells 'in vitro'. 
We described in chapter 4 that three types of cells are initially present in the MATLyLu 
tumor. It could not yet be confirmed whether these described types of cells are 
descendants of 1) three types of'stem' cells 2) one 'stem' cell or 3) represent various 
differentiation stages. If three types of stem cells exist, the number of clonogenic cells 
developing 'in vitro' from different stem cells could be underestimated, if not all stem 
cells produce clones 'in vitro'. 
To determine real clonogenic cell activity in culture, it is necessary to measure more 
parameters than only the total number of colonies. 
The automated colony counting system (OMNICON) permits measurements of both 
the number and the diameter of the colonies (Kressner et al. 1980, Herman et al. 1983a). 
The size of a colony may be directly related to the proliferative potential of the cell of 
origin. 'Stem' cells might give rise to larger colonies (Selby et al. 1983). 
The Dunning tumor system has not been the subject of extensive investigation in soft 
agar culture. Rao et al.(1978) reported on a non-agar 'in vitro' clonogenic assay for the 
R3327 AT tumor. Dibner and Nakeff (1983a,b) studied the proliferative potential of 
three Dunning sublines in liquid culture, plasma clot, and agar culture (R3327 AT, 
R3327 A and the R3327). Sestili et al. (1983) used agar culture in subcloning studies 
of the R3327 tumor. 
No studies to date have described the proliferation of clonogenic cells after 'in vivo' 
treatment of the Dunning tumors. The results of our investigations are described in 
chapters 6 and 7. In summary, the total number of colonies and the median diameter of 
colonies are markedly decreased when the MATLyLu tumor is treated 'in vivo' with a 
combination of cyclophosphamide and cisplatin. 
Despite the critical remarks on the short-term culture system, this study provides insight 
into basic cell biologic features of clonogenic cells (Durie and Salmon 1980). Much more 
can be learned about the subclones 'in vivo' and 'in vitro', subclones which may be the 
primary target cells in the therapy of cancer? (Selby et al. 1983, Park et al. 1971). 
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STEM CELL DIFFERENTIATION 
TRANSITIONAL END 
CELLS CELLS 
Fig. 7.3. 
Presentation of the stem cell hypothesis. The stem cell is proposed to be central in renewing the tumor cell 
population: 1. self-renewal; 2. growth of large numbers of cells with the same characteristics (clones) with 
proliferating non-renewing transitional cells and non-proliferating non-renewing end cells; 3. non-proliferating 
'dormant' stem cells in G0 phase of cell cycle. The stem cell is the ultimate target for cytotoxic drug treatment. 
The 'dormant' stem cells are thought to be responsible for renewed tumor growth after apparent cure. If 
transitional cells provide limited colony-forming ability, this probably causes discrepancy between 'in vitro' 
cytotoxic test results and 'in vivo' survival (see text). 
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Even the mechanism of developing resistance after cytotoxic treatment Ίη vivo'1 or the 
residual capacity of cell growth after cytotoxic agents, hormones, or radiation can be 
studied. 
The system is not perfect and especially two features contribute to this: the 
disaggregation techniques and the appropriate culture medium and additives. 
The automated colony counter (OMNICON) as used in our culture system is capable 
of estimating quantitative properties of cultured cells in an accurate, reproducible and 
time-saving way. 
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SUMMARY 
Chapter 1 
Initially, anaplastic or disseminated prostatic cancer is treated by a variety of tumor 
modalities. Cure with standard endocrine therapy is not attainable. The aim of this 
thesis was to develop a model system in which new non-hormonal (cytotoxic) drugs could 
be tested Ίη vivo' on both local and metastatic tumor growth. A further object of this 
study was to evaluate the basic biologic properties of the model Ίη vivo' as well as Ίη 
vitro' in relation to other Dunning models. 
Chapter 2 
A review of model systems in prostate cancer is given in this chapter. Ideal properties 
for an animal model are summarized. An overview of spontaneously occurring tumors, 
spontaneously transplantable tumors, and inducible tumors (chemically, hormonally) 
is given. The Dunning system is reviewed at length in view of the background of the 
thesis. Ίη vitro' models for mainly human tumors are briefly described as well as 
xenografting in the nude mouse model. 
Chapter 3 
Characterization is the basic procedure for every model system before results obtained 
in that model system are published. This characterization has to be repeated within a 
certain period of time with a view to the stability of a tumor and to be sure that no 
'biologic drift' has taken place. 
Multiparameter studies were done to prove the origin and stability of the MATLyLu 
tumor. The tumor was shown to be primarily of lymphogenic metastatic potential. 
Electron microscopy and immunohistochemical analyses proved the epithelial nature 
of the anaplastic tumor. In karyotyping the MATLyLu tumor no HeLa markers were 
found. Light-microscopic analysis rarely revealed formation of tubuli. 
The tumor showed prostatic acid phosphatase inhibitable granules. All these findings 
confirm the rat (epithelial) prostatic origin of the tumor. 
Flow-cytometric analyses furthermore demonstrated a constant pattern of DNA-index 
within a year. Even in monolayer culture, a constant pattern of (hyperploid) DNA was 
noted. 
Chapter 4 
This chapter deals with the biologic description of the tumor in general and of the 
MATLyLu tumor in particular. 
Heterogeneity was confirmed in this anaplastic tumor especially in EM and flow 
cytometry with cell sorting. 
The hypothesis of selection of tumor cells Ίη vivo' and Ίη vitro' under environmental 
pressure (cytotoxic agents, hormonal changes, culture media) on the one hand, and of 
genetic instability on the other hand was suggested in the Dunning system and was 
evaluated especially in the MATLyLu tumor. 
In the final stage of the MATLyLu tumor, one intermediate cell type generally 
remained. The same cell type dominated in the soft agar culture and in metastatic 
lesions in the lymph nodes and the lung. This could point to the final stage of a selective 
process. Under the special conditions in this tumor model in hybrids, this selective 
progress probably calls for individual approach to the treatment of specific (groups of) 
tumors. This may account for the failure of overall therapy in human cancers. 
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Chapter 5 
Several therapeutic agents, including the newly developed chemotherapeutic TNO-6, 
were tested in the MATLyLu tumor. Although there was no difference in survival, CTX 
was the only effective drug in reducing both lymph nodes and lung metastases. In terms 
of erythrocytopoiesis and thrombocytopoiesis, CTX was not significantly different in 
marrow toxicity from CDDP whereas it was slightly (though not statistically 
significant) less toxic than TNO-6. However, myelopoietic toxicity was severe as was 
lymphocytotoxicity, which may have been responsible for losing the survival advantage 
gained by reducing tumor growth. Administration of CTX together with CDDP 
provided hardly any additional tumor reduction or toxic effects. 
Extrapolation of findings in animal models to the human situation should be done with 
care due to physiologic and anatomic differences. But when a drug has shown effective 
reduction of tumor load in animals, it is worth while to consider such drugs against an 
increasing mutant subpopulation in a human solid anaplastic prostatic tumor. 
Chapter 6 
In this chapter, the extension to the Ίη vitro1 correlation after cytotoxic treatment 4n 
vivó' is proposed. With these 'ш vitro soft agar techniques, a relative advantage in 
combining CTX and CDDP was seen, which was not noted in the Ίη vivó" study. 
Furthermore, fiow-cytometric analysis of cell suspensions of tumors tested Ίη vivo' 
showed a striking correlation. Combination therapy produced blockade of cells in the 
G2M phase of the cell cycle. 
Chapter 7 
The automated colony counter was used for the MATLyLu tumor. It became apparent 
that the automated counter provides a major gain in the efficiency and accuracy of 
counting a sufficient number of cultured plates in a relatively short time. Additionally 
the median diameter was measured as a parameter, which is not possible when the 
manual counting procedure is employed. 
In contrast to human tumors, the upper limit of 149 μτη was exceeded by more than 50% 
of the MATLyLu tumor colony diameters. A statistical model was designed to evaluate 
these data with the aid of the Censor computer program. 
There are still some critical remarks on the disaggregation techniques (cytotoxic 
effect?), on the diversity of culture media and their contents, and on the exact nature 
of the cell growing in the culture media. The only partial success in revealing tumor 
reduction and residual cell growth Ίη vitro' in the CTX + CDDP group could suggest 
selection of a mutant through genetic instability or the possibility that the real stem cell 
is not amenable to therapy. 
In conclusion, this thesis has not been prepared with an eye to finding a solution to the 
diverse questions still remaining and emerging in cancer of the prostate. 
A model was developed that could be used to investigate mainly new cytotoxic drugs 
that could play a role as initial or adjuvant therapy of anaplastic or disseminated 
prostate cancer. 
A multiparameter approach was used in an attempt to develop new diagnostic tools 
probably fitting into the clinical situation. Above all, this model system could be used 
to study basic principles of the unresponsive cancer cell that will ultimately metastasize 
and is responsible for host killing. 
Heterogeneity and instability of tumors could lead to a more individual approach to the 
treatment of malignancies in general and prostatic carcinomas in particular. 
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SAMENVATTING 
Hoofdstuk 1 
Patiënten met een anaplastisch en/of gemetastaseerde prostaattumor worden op 
verschillende manieren behandeld. 
Genezing met gebruikelijke endocriene therapie is niet mogelijk. 
Het doel van dit proefschrift is een modelsysteem te ontwikkelen waarin nieuwe 
niet-hormonale (cytotoxische) geneesmiddelen 'in vivo' kunnen worden getest op zowel 
locale als metastatische tumorgroei. 
Een verder doel van de studie was de biologische basisprincipes van het model 'in vivo' 
en 'in vitro' te evalueren in relatie tot andere Dunning modellen. 
Hoofdstuk 2 
In dit hoofdstuk wordt een overzicht gegeven van modelsystemen voor 
prostaatcarcinomen. Na een korte bespreking van de ideale eigenschappen, die een 
diermodel moet hebben wordt ingegaan op spontane tumoren, spontaan transplantabele 
tumoren en induceerbare (chemisch, hormonaal) tumoren. Het Dunning-model is 
uitvoerig beschreven in het kader van dit proefschrift. 
Tenslotte volgt een korte beschrijving van 'm vitro' modellen, hoofdzakelijk voor 
humane tumoren en van de heterotransplantatie van tumoren naar de naakte muis. 
Hoofdstuk 3 
Typering van elk tumormodel moet geschieden voordat resultaten, verkregen met dit 
model, worden gepubliceerd. 
Deze typering dient herhaald te worden binnen bepaalde tijd met het oog op de 
stabiliteit van de tumor en om er zeker van te zijn dat er geen biologische 'ontsporing' 
plaatsgevonden heeft. 
Om de herkomst en de stabiliteit van de MATLyLu tumor te onderzoeken werden 
multiparameter-studies verricht. Het bleek dat de MATLyLu tumor met name 
lymphogeen metastaseert. 
Electronenmicroscopisch en immunohistochemisch onderzoek bewijzen de epitheliale 
oorsprong van de tumor. 
Bij genetisch onderzoek (Karyotypering) van de MATLyLu tumor werden geen HeLa 
kenmerken aangetroffen. 
Lichtmicroscopisch onderzoek toont enkele malen buisvorming in de tumor, naast 
prostaat sensitieve zure fosfatase activiteit. 
Deze bevindingen zijn een bevestiging van de (epitheliale) prostaatherkomst van de 
tumor in de rat. 
Flowcytometrisch onderzoek van de tumor geeft een constante DNA-index te zien 
gedurende een jaar. Zelfs in monolayer-kweek wordt een constant patroon van 
(hyperploid) DNA gezien. 
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Hoofdstuk 4 
Dit hoofdstuk behandelt de biologische beschrijving van tumoren in het algemeen en 
van de MATLyLu tumor in het bijzonder. 
Deze anaplastische tumor blijkt heterogeen te zijn. Dit wordt vooral bevestigd door 
electronenmicroscopisch en flowcytometrisch onderzoek met celsorteringstechnieken. 
Selectie van tumorcellen 'in v/vo' en Ίη vitro' onder druk van omgeving (cytostatica, 
hormonale veranderingen, kweekmedia) enerzijds en genetische instabiliteit anderzijds 
als hypothese, wordt verondersteld in het Dunning-model systeem en wordt geëvalueerd 
in de MATLyLu tumor. 
In het eindstadium van de MATLyLu-tumorgroei blijft vooral een intermediair celtype 
over. Dit zelfde type cel overheerst in de soft agar kweek en in lymphklier- en 
longmetastasen. Wijst dit op een eindstadium van een selectief proces? 
Voorzichtigheidshalve kan gesteld worden, dat op grond van dit selectief proces in het 
MATLyLu-tumormodel in hybriden een individuele benadering voor de behandeling 
van een specifieke (groep van) tumor(en) aangewezen lijkt. Mogelijk is een dergelijk 
selectief proces de reden voor het falen van een algemene therapie voor humane 
tumoren. 
Hoofdstuk 5 
In het MATLyLu model systeem worden verschillende cytostatica getest, waaronder 
TNO-6, een nieuw ontwikkeld chemotherapeutisch agens. 
Cyclophosphamide was het enige effectieve middel ten aanzien van het reduceren of 
voorkomen van zowel lymphklier- als longmetastasen. Verschil in overleving is er echter 
niet in de verschillende behandelingsgroepen. 
Cyclophosphamide geeft geen significant verschil in beenmergtoxiciteit ( erythropoëse 
en thrombocytopoëse) ten opzichte van cisplatinum, en is minder toxisch dan TNO-6 
(hoewel statistisch niet significant). 
De myelopoëtische toxiciteit en de lymphocytotoxiciteit is ernstig in de 
cyclophosphamidegroep. Deze toxiciteit is wellicht verantwoordelijk voor de afname van 
de overleving ondanks de reductie van tumorgroei. 
De toediening van cyclophosphamide samen met cisplatinum geeft noch additionele 
toename, noch een toename van de toxische effecten. 
Extrapolatie van bevindingen in diermodellen naar de humane situatie moet omzichtig 
gebeuren vanwege fysiologische en anatomische verschillen. 
Maar als een cytostaticum effectieve afname geeft van tumoren in het diermodel, dan 
moeten we overwegen om dit middel tegen een mutante subpopulatie van een humane, 
solide, anaplastische tumor te gebruiken. 
Hoofdstuk 6 
Een correlatie tussen de resultaten in de diverse behandelingsgroepen van de 
MATLyLu-tumor Ίη v/vo' en de restactiviteit Ίη vitro' wordt verondersteld. Met 
gebruik van de Ίη vitro' soft agar techniek, zien we een relatief voordeel van de 
combinatie van cyclophosphamide en cisplatinum. Dit voordeel wordt niet gezien in de 
Ίη vivo' studie. Flowcytometrisch onderzoek van de tumor celsuspensies van 'in vivo' 
behandelde tumoren geven een opvallende correlatie. De combinatie-therapie geeft een 
blokkade van de cellen in de GjM-fase van de cel-cyclus te zien. 
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Hoofdstuk 7 
Het gebruik van de geautomatiseerde kolonieteller (OMNICON) in het MATLyLu-
tumormodel wordt in dit hoofdstuk beschreven. 
Duidelijk komt naar voren, dat de geautomatiseerde teller een belangrijke aanwinst is 
ten aanzien van de efficiëntie en de nauwkeurigheid in het tellen van een voldoende 
aantal kweekschalen in een relatief korte tijd. Bovendien wordt de mediane diameter 
van een kolonie gemeten, een parameter die bij de manuele telling van kolonies niet 
gebruikt kan worden. 
In tegenstelling tot de humane celkweken, wordt de maximale diametergrens van 
149 μπι in meer dan 50% van de gevallen overschreden door de MATLyLu celkolonies. 
Om deze data toch te verwerken wordt een statistisch model ontworpen met behulp van 
het censor computerprogramma. 
Er kunnen ten aanzien van de celkweekmethoden nog steeds enige kritische 
kanttekeningen geplaatst worden wat betreft de disaggregatietechnieken (cytotoxisch 
effect), de diversiteit aan kweekmedia en de inhoud ervan, en ten aanzien van de juiste 
aard van de cellen die in een kweekmedium groeien. 
De slechts gedeeltelijk succesvolle tumorafname 'in vivo' en restgroei Ίη vitro' in de 
combinatiegroep, zouden kunnen wijzen op selectie van een mutant door genetische 
instabiliteit, of op de mogelijkheid dat de echte stamcel niet bereikbaar is voor therapie. 
Concluderend kan gesteld worden, dat dit proefschrift niet geschreven is om een 
oplossing te geven voor de diverse vragen die blijven op het gebied van prostaattumoren. 
Er wordt een model ontwikkeld om met name nieuwe cytostatica uit te testen, die een 
rol kunnen spelen als initiële of adjuvante therapie van anaplastische of gemetastaseerde 
prostaattumoren. 
Een 'multiparameter' benadering wordt aangewend om nieuwe diagnostische middelen 
te ontwikkelen, die wellicht ook in de kliniek van pas komen. 
Dit tumor-modelsysteem kan echter met name gebruikt worden om basisprincipes van 
de ongevoelige tumor-cel te bestuderen. Het is deze tumorcel die uiteindelijk 
metastaseert en verantwoordelijk is voor de dood van de gastheer. 
Heterogeniteit en instabiliteit van tumoren kan leiden tot een meer individuele 
benadering van de behandeling van maligniteiten in het algemeen en van 
prostaattumoren in het bijzonder. 
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STELLINGEN 
behorend bij het proefschrift van J.B.J. Boerema, Experimental Prostatic Tumors. 
A study of the R3327 MATLyLu prostatic tumor model in the rat, a multidisciplinary approach. 
I. Especially in case of fast-growing tumours, it is essential to 
monitor histology, growth rate, chromosomal analysis, flow 
cytometry and immunohistochemistry in order to standardize 
the subline used. 
II. Heterogeneity of tumours clearly has consequences for therapy 
and call for a more tumour-specific therapy compared to the 
conventional 'over all' therapy. 
III. Cyclophosphamide alone was as efficacious in inhibiting tumour 
growth and in preventing massive metastases to lymph nodes 
and lungs, as was the combination therapy (cyclophosphamide 
+ cisplatin). Systemic drug toxicity however is invariably 
associated with survival. This is a problem in the clinical setting 
too. 
IV. In general this combination therapy (cyclophosphamide + 
cisplatin) produces marked reduction of tumour load with the 
greatest reduction of proliferative potential of the remaining 
tumour cells as assessed by means of soft agar culturing and 
flow-cytometric analysis of post therapy persistent tumours. 
V. It should not be concluded that all species are identical, however 
the similarities are more common than the differences. 
John T. Isaacs, Cancer of Prostate (1982). 
VI. ' Na hysterosalpingografische en/of laparoscopische ingrepen 
komen vitale endometriumcellen in de buikholte terecht die in 
de weefselkweek nog goed prolifereren. 
VII. Bij de introductie van een antibioticumbeleid dient een feedback 
methode aanwezig te zijn om de gegevens van de patient 
gekoppeld aan het geneesmiddelengebruik, de resultaten van de 
behandeling en de ontwikkeling van resistentie, periodiek te 
evalueren. 
VIII. Tumour cells are similar to members of other societies. 
The way in which they interact depend upon their potential and 
circumstances in which they find themselves. 
Gloria H. Heppener, Cancer Research 
44, 2259-2265 (June 1984) 
IX. Bij in principe curatieve chemotherapie is het een kunstfout de 
'patient compliance' te verspelen door inadequate anti-emetische 
behandeling, of door het nalaten ervan. 
X. Wetenschappelijke fraude, gepleegd door onderzoekers in het 
gevecht om onderzoeksgelden, zal sterk worden gereduceerd 
indien universiteiten en projectleiders (senior onderzoekers) 
financieel aansprakelijk worden gesteld voor de gevolgen ervan. 
(KRISTEIN, M.M. Quarterly Review of Biology) 
59,295-297(1984) 
XI. Er wordt in Nederland, veel zogenaamd onderzoek gedaan door 
huisartsen voor de farmaceutische industrie, maar daar is niets 
bij wat de naam 'onderzoek' verdient, op een enkele uitzondering 
na. Mijn gedachten gaan uit naar een onafhankelijk instituut 
via welk al het geneesmiddelenonderzoek in de huisartsenpraktijk 
(en in de kliniek) gaat lopen. 
E. v.d. Does, 
TGO (Tijdschrift voor Geneesmiddelen Onderzoek, december 
1981, speciale uitgave). 
XII. 'Antibiotics are not intended to make the treatment easier for 
the surgeon, but the results better for the patient'. 
T.G. Lowden. 



